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Introduction  
 
P. Biginelli reported the synthesis of functionalized 3,4-dihydropyrimidin-2(1H)-ones 
(DHPMs) via three-component condensation reaction of an aromatic aldehyde, urea, and 
ethyl acetoacetate. In the past decade, this multicomponent reaction has experienced a 
remarkable revival, mainly due to the interesting pharmacological properties associated 
with this dihydropyrimidine scaffold.  
 
 
 
 
 
 
 
 
The classical three-component Biginelli condensation is usually carried out in alcoholic 
solution containing a few drops of concentrated hydrochloric or sulfuric acid as catalyst, 
although other systems such as THF/HCl, dioxane/HCl, or acetic acid/HCl have also been 
employed. Multicomponent reactions (MCRs) occupy an outstanding position in organic 
and medicinal chemistry for their high degree of atom economy, applications in 
combinatorial chemistry, and diversity-oriented synthesis.[1] The classical Biginelli 
reaction, one pot cyclocondensation of aldehyde, 1,3-ketoester, and urea or thiourea, is 
inarguably one of the most useful MCRs.[2] Polyfunctionalized dihydropyrimidines 
(DHPMs) represent a heterocyclic system of remarkable pharmacological activity. 
4-Aryl-1,4-dihydropyridines of the nifedipine type are the most studied class of organic 
calcium channel modulators and, since their introduction into clinical medicine in 1975 
have become almost indispensable for the treatment of cardiovascular diseases such as 
hypertension, cardiac arrythamias, or angina. In recent years research interest has also 
focused on aza-analogs such as Dihydropyrimidines which shows similar 
pharmacological profile to this type of classical dihydropyridines calcium channel 
modulators. [3] 
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Mechanistic Studies  
 
The mechanism of the Biginelli reaction has been the subject of some debate over the past 
decades. Early work by Folkers and Johnson suggested that bisureide i.e., the primary 
bimolecular condensation product of benzaldehyde and urea is the first intermediate in 
this reaction.[4] In 1973, Sweet and Fissekis proposed that a carbenium ion, produced by 
an acid-catalyzed aldol reaction of benzaldehyde with ethyl acetoacetate, is the key 
intermediate and is formed in the first and limiting step of the Biginelli reaction [5]. 
Oliver Kappe et al reinvestigated the mechanism in 1997 using 1H and 13C NMR 
spectroscopy (CD3OH/HCl) and have established that the first step in this reaction 
involves the acid-catalyzed formation of an N-acyliminium ion intermediate from the 
aldehyde and urea component. Interception of the iminium ion  by ethyl acetoacetate, 
possibly through its enol tautomer, produces an open-chain ureide  which subsequently 
cyclize to dihydropyrimidine. Although the highly reactive N-acyliminium ion species 
could not be isolated or directly observed, further evidence for the proposed mechanism 
was obtained by isolation of intermediates, employing sterically bulky[6] or electron-
deficient acetoacetates,[7] respectively. The relative stereochemistry in 
hexahydropyrimidine  was established by an X-ray analysis.  
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Atwal alternative synthetic route 
Apart from the traditional Biginelli condensation, there are only few other synthetic 
methods available that lead to DHPMs. Since most of these protocols lack the 
experimental and conceptual simplicity of the Biginelli one-pot, one-step procedure, none 
of these have any significance today or can compete with the original Biginelli MCR 
approach. One noticeable exception is the so-called “Atwal modification” of the Biginelli 
reaction. [8] Here, arylidene is first condensed with a suitable protected urea or thiourea 
derivative under almost neutral conditions. Deprotection of the resulting 1,4-
dihydropyrimidine with HCl or TFA/EtSH leads to the desired DHPMs. Although this 
method requires prior synthesis of enones (Arylidenes), its reliability and broad 
applicability make it an attractive alternative to the traditional one step Biginelli 
condensation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Another novel approach to DHPMs has been described by Shutalev et al. and is outlined 
below. [9] This synthesis is based on the condensation of readily available R-tosyl-
substituted (thio)ureas with the (in situ prepared) enolates of acetoacetates or 1,3-
dicarbonyl compounds. The resulting hexahydropyrimidines need not to be isolated and 
can be converted directly into DHPMs. This method works particularly well for aliphatic 
aldehydes and thioureas and produces high overall yields of the desired target 
compounds. 
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Pharmacological Profile 
 
The interest in synthesis of dihydropyrimidines - Biginelli compounds stems from their 
close structural relationship [10] to clinically important 1,4-dihydropyridine calcium 
channel modulators of the type nifedipine etc. and also because of interesting biological 
properties of several marine alkaloids [11-13] based upon dihydropyrimidine viz. 
crambine, batzelladine (potent HIV gp-120-CD4 inhibitor) and ptilomycelin A.  
Derivatization of the dihydropyrimidines especially [14] at C-4 has led to the recoginition 
of several lead compounds that show a very similar pharmacological profile[15-17] to 
1,4-dihydropyridine based drugs. 
C. crambe is a bright red marine sponge, that is the most wide spread in the northwestern 
meditettanean [18]. Extract of C. crambe have been known to be ichthyotoxic and shown 
various pharmacological activies. A variety of structurally intricate guanidine alkaloids 
are present in marine sources.  [19] Diverse biological activities are associated with many 
of these alkaloids, likely reflecting the multiples ways that a guanidinium cation can 
participate in noncovalent interactions. Among the most notable marine alkaloids of these 
are the crambescidin [20] and batzelladine [21] alkaloids, which have been isolated 
primarily from sponges belonging to the orders Poecilosclerida and Axinellida.  Diverse 
biological activities have been reported for these secondary metabolites, including 
cytotoxicity toward several cancer cell lines, antifungal and antiviral activities, and 
inhibition of HIV-1 fusion. The novel structures of these marine alkaloids have inspired 
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the development of many strategies for assembling polycyclic guanidines that contain the 
octahydro-5,6,6a-triazaacenaphthalene and hexahydro-5,6,6a-triazaacenaphthalene  
moieties common to the crambescidin and batzelladine alkaloids.[22, 23] 
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More recently, appropriately functionalized DHPMs have emerged as, e.g., orally active 
antihypertensive agents [24-26] or α1a adrenoceptor-selective antagonists [27] 
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                                    α1a adrenoceptor-selective antagonists 
 
Simple DHPM monastrol as a novel cell-permeable molecule that blocks normal bipolar 
spindle assembly in mammalian cells and therefore causes cell cycle arrest.[28] 
 
 
 
 
 
 
Kappe et al reported N-substituted 3,4-dihydropyrimidinones entities shows very good 
activity as a calcium channel blockers[29] 
DHPM calcium channel blockers and biological active DHPM lead compounds 
 
 
 
 
 
 
Keith Demarest et al reported that calcitonin, a 32 amino acid polypeptide hormone 
secreted by the thyroid and thymus glands, plays an important role in inhibiting bone 
resorption through the mediation of osteoclasts. By inhibiting bone resorption and 
promoting renal calcium excretion, calcitonin has therapeutic applications in a variety of 
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clinical disorders, including hypercalcemia associated with Paget’s disease [30] and 
osteoporosis.[31-32] 
A multiplex mimetic cell based assay was designed for high-throughput screening. In an 
effort to differentiate activity amongst similar G-protein coupled receptors, 6 cell lines-
calcitonin receptor-2 (CTR-2; clone #33), glucogen-like peptide 1 (GLP1-7; clone #7), 
gastric inhibitory polypeptide (GIP-1; clone #1), parathyroid hormone receptor 1 (EPTH-
1-1; clone #1) and calcitonin gene related peptide-1 (CGRP1-7; cone 7) were cloned onto 
the human embryonic kidney (HEK 293) cell line and plated together in one assay well. 
The following compounds are examples of an active series of 1,4-dihydropyrimidines that 
stimulated cAMP accumulation in HEK 293 cells expressing the CTR-2 ligand.[33] 
 
 
 
 
 
 
 
 
 
 
 
 
Research interest in multifunctionalized DHPMs of privileged heterocyclic core 
associated with several pharmacological properties. Small molecules targeting the mitotic 
machinery.[34] Notably, 4-aryldihydropyrimidinone heterocycles attached to an 
aminopropyl-4-piperidine moiety via a C5 amide linkage have proven to be excellent 
templates for selective α1a receptor subtype antagonists to warrant further consideration 
for the treatment of Benign Prostatic Hyperplasia (BPH). [35] In the synthesis of these 
DHPM-5-carboxamides, amide bond formation between the requisite amines and the 
corresponding DHPM acids was performed using standard solution phase amide coupling 
chemistry involving carbodiimide coupling reagents [35-36] 
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                    Fragment based Approach     
      
 Some dihydropyrimidines (V), (III), and (IV) were weaker in blocking atrioventricular 
conduction in anesthetized open-chest dogs and less toxic than the dihydropyridines.[37] 
 
 
 
 
 
 
 
 
 
 
 
  
 
Christopher Blackburn et al synthesized 3,4-dihydropyrimidinone analogues   as a fatty 
acid transporter FATP4. Among these some of the compounds hit by high through put 
screening and optimized FATP4 inhibitors. Blocking the absorption of fats (triglycerides) 
by administration of an anti-absorptive agent is of interest for the treatment of 
obesity.[38]  
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Ingested dietary triglycerides are hydrolyzed by gastric and pancreatic lipases, and the 
resulting fatty acids are taken up by enterocytes lining the small intestine where they are 
re-esterified to triglycerides and then transported into the blood. The lipase inhibitor 
orlistat (XenicalTM) blocks fat absorption by inhibiting the hydrolysis of dietary fat to 
fatty acids [39] with administration leading to a concomitant decrease in body weight and 
improvement of blood lipid profiles. A family of proteins, termed fatty acid transport 
proteins (FATPs), that mediate the uptake of fatty acids into cells has been described.[40, 
41] earlier studies[42-45] provided evidence that fatty acid transport protein 4 (FATP4) 
mediates the transport of fatty acids from the gut into enterocytes both in vitro and in 
vivo. We therefore reasoned that inhibitors of FATP4 might be expected to have benefits 
similar to orlistat. Since FATP4 inhibition would result in the accumulation of free fatty 
acids rather than triglycerides, we would also expect a different, possibly improved, side-
effect profile compared to orlistat. The FATP family of proteins is most closely related in 
sequence to the ATP-utilizing acyl-CoA synthetase enzymes. [46-49] 
 
Moreover, Merck and Co. developed a compounds which is very active as non- 
nucleoside inhibitors of human hepatitis B virus (IC 50=53 nM) for reduction of HBV 
DNA in human hepatoma HepG2.2.15 cells) with low cytotoxicity in uninfected cells 
(CC50 = 7 mcM). This compound inhibited both viral DNA and viral cores in Hep 
G2.2.15 cells and HBV- transfected cell lines, whereas it did not affect the activity of 
endopolymerase and had no effect on other DNA and RNA viruses. In vivo, in a 
transgenic mouse model, oral doses of 3-100 mg/kg  b.i.d or t.i.d for 28 days dose.[50] 
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Synthetic Approaches 
 
Utilization of 1,3-Dicarbonyl Derivatives in Multicomponent Reactions 
 
[a] Hantzsch’s Heterocyclic Syntheses 
 
H O
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A. Hantzsch, Justus Liebigs Ann. Chem. 1882, 215, 1. 
 
[b] Biginelli Dihydropyrimidine Syntheses 
   
 
 
 
P. Biginelli, Gazz. Chim. Ital. 1893, 23, 360-413. 
 
[c] The Mannich Reaction 
  
 
 
  
C. Mannich, Arch. Pharm. Berl. 1934, 272, 323_359. 
 
[d] The Knoevenagel Reaction 
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L. F. Tietze, U. Beifuss, in Comprehensive Organic Synthesis (Ed.: B. M. Trost), Pergamon 
Press, Oxford, 1991, vol. 2, 341-394 
 
[e] The Robinson Schöpf Reaction 
 
 
 
 
R. Robinson, J. Chem. Soc. 1917, 111, 762. 
C. Schöpf, Angew. Chem. 1937, 50, 779. 
C. Schöpf, Angew. Chem. 1937, 50, 797. 
 
[f] The Domino-Knoevenagel Hetero-Diels_Alder Reaction 
 
 
 
 
L. F. Tietze, J. Het. Chem. 1990, 27, 47. 
L. F. Tietze, U. Beifuss, Angew. Chem. Int. Ed. Engl. 1993, 32, 131-163. 
L. F. Tietze, A. Modi, Med. Res. Rev. 2000, 20, 304-322.  
[g] Knorr-Pyrrole synthesis 
 
 
  
V. F. Ferreira, M. C. B. V. De Souza, A. C. Cunha, L. O. R. Pereira, M. L. G. Ferreira, Org. 
Prep. Proc. Int. 2001, 33, 411-454 
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Catalysts  
 
Previous reported protocols normally required prolonged reaction times and high 
temperature with moderate yields, so there has been considerable interest to explore mild, 
rapid, and higher yielding protocol. The toxicity and volatile nature of many organic 
solvents, particularly chlorinated hydrocarbons that are widely used in huge amounts for 
organic reactions have posed a serious threat to the environment. Thus, so many 
improved protocols have been designed for preparing these types of entities have been 
developed to improve and modify this reaction by several catalysts. Catalytic reaction has 
received tremendous attention in recent times in the area of green synthesis. However, it 
has been observed that the solvent and Lewis acids employed are not always ecofriendly, 
and because of this severe environmental pollution often results during the process of 
waste disposal. This prompted us to initiate a systematic investigation to look into the 
feasibility of a reaction under modified experimental conditions towards development of 
real green methodology for useful molecules. 
Different catalysts have been employed for these types of reaction are listed below. 
 
FeCl3/ tetracthyl orthosilicate[51] 
Triflates [52,53] 
Metal bromide[54, 55] 
Polyoxometalate [56] 
Strontium(II) nitrate[57] 
Cerium(III)chloride [58] 
Li (OTf) [59], Ln(OTf) 3 [60] 
Heteropolyacids [61-65] 
Ion exchange resins, Polymer based solid acid [66, 67] 
L-Proline [68, 69] 
Chiral phosphoric acid [70] 
TMSCl [71] 
ZrCl4 [72]  
Dowex [73] 
BF3. Etharate [74] 
BF3. Etharate/ CuCl [74] 
 
 
Review on literature………. 13
VCl3[75] 
LiClO4[76] 
Numerous modifications on Lewis acid adsorbed on mineral inorganic solid supports, 
silica, different clays are also reported and discloses a simple modification of the Biginelli 
DHPM synthesis. Excellent yields enhanced reaction rates, compatibility with various 
functional groups, environmentally friendly procedure, timesaving process, low cost and 
easy availability of the catalyst are some of the salient features of this reaction. This 
procedure will offer an easy access to substituted dihydropyrimidin-2(1H)-ones and 
thiones with different substitution patterns in high to excellent yields. 
 
Ionic Liquids 
Liu Zuliang and coworkers used cheap and reusable task-specific ionic liquids that bear 
an alkanesulfonic acid group in an acyclic trialkylammonium cation were found to be 
effective catalysts for synthesizing 3,4-dihydropyrimidine-2-(1H)-ones via the one-pot 
three-component Biginelli reaction. The satisfactory results were obtained with good 
yields, short reaction time and simplicity in the experimental procedure. The catalysts 
could be recycled and reused six times without noticeably decrease in the catalytic 
activity. [77] 
 
 
Jean Pierre Bazureau and coworkers reported new N-3 functionalized 3,4-
dihydropyrimidine-2(1H)-ones with 1,2,4-oxadiazole group as amide isostere were 
synthesized in six steps by ionic liquid-phase organic synthesis (IoLiPOS) methodology 
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from ILP bound acetoacetate. The 3,4-dihydropyrimidine- 2(1H)-one (3,4-DHPM) core 
was prepared in the first step by one-pot three-component Biginelli condensation 
followed by N-alkylation with chloroacetonitrile. Then the nitrile group appended on the 
3,4-DHPM heterocycle was quantitatively transformed into amidoxime. Addition of 
aliphatic carboxylic anhydride or aromatic carboxylic acid to the amidoxime produced the 
expected 1,2,4-oxadiazole via the O-acylamidoxime intermediate grafted on the ILP 
bound 3,4-DHPM using two convergent methods. After cleavage by transesterification 
under mild conditions, the target compounds were obtained in good overall yields. The 
structures and the purities of the reaction intermediates in each step were verified easily 
by routine spectroscopic analysis. [78] 
 
Preparation of ionic liquid-phases bound 3,4-dihydropyrimidine-2(1H)-ones. 
Reagents and reaction conditions: (i) chloroethanol (1 equiv), mw, 180 0C, 60 W, 10 min; 
(ii) KPF6 (1 equiv), MeCN, 25 0C, 18 h; (iii) tert-butyl acetoacetate (2.6 equiv), µω, 170 
0C, 150 W, 10 min; (iv) 100 0C, HCl cat., 60 min 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Preparation of N-3 functionalized 3,4-dihydropyrimidine-2(1H)-ones  
Reagents and reaction conditions: (i) NaH (2 equiv), 0oC, MeCN, 18 h; (ii) KOH (1.7 
equiv), NH2OH, HCl (1.6 equiv), EtOH, 0oC, 1 h then reflux, 18 h; (iii) Method A: a. 
(RCO)2O (20 equiv), 25oC , 18 h; b. H2O, reflux, 18 h.; Method B: a. RCO2H (1.09 
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equiv), DCC (1.02 equiv), DMAP 5%, MeCN, 25oC , 48 h; b. H2O, reflux, 36 h; (iv) 
MeONa (1 equiv), MeOH, reflux, 18 h. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Zlotin, S.G. et al reported  the synthesis of dihydropyrimidinones  by condensation of 
aromatic (heteroaromatic) aldehydes with 1,3-dicarbonyl compounds under the 1-butyl-3-
methylimidazolium tetrafluoroborate ([Bmim][BF4]) ionic liquid-piperidinium acetate 
catalytic system (0.2 equiv. of each component) in the absence of a solvent affords, 
depending on the structures of the reagents, 2-arylidene derivatives of methyl acetoacetate 
and acetylacetone, diethyl 2,4-bis(trifluoroacetyl)-3-phenylpentanedioate, or dimethyl 2-
aryl-4-hydroxy-6-oxocyclohexane-1,3-dicarboxylates. The reactions of the resulting 2-
arylidene derivatives with O-methylisourea in the [Bmim][BF4] ionic liquid produced 
methyl 2-methoxy-4-methyl-6-aryldihydropyrimidine-5-carboxylates and 1-(2-methoxy-
4-methyl-6-phenyldihydropyrimidin-5-yl)ethanone (mixtures of 3,6- and 1,6-dihydro 
isomers), which were transformed into the corresponding 3,4-dihydropyrimidin-2(1H)-
one derivatives. [79] 
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Jingxing Du et al used novel ionic liquid, 3-carboxymethyl-1-methylimidazolium 
bisulfate (CMImHSO4) as a recyclable catalyst for the Biginelli reaction under solvent-
free conditions. [80] Jean Pierre Bazureau  et al  reported ionic liquid phase bound 
acetoacetate  for  the synthesis of 3,4-dihydropyrimidine-2(1H)-ones [81] These 
compounds can also be synthesised in high yields in the presence of catalytic amounts of 
room temperature ionic liquids such as 1-n-butyl-3-methylimidazolium tetrafluoroborate 
(BMImBF4) orhexafluorophosphate (BMImPF6) [82] It has been also reported that not 
only trialkylammonium halides [83] but also very inexpensive and easily available 
ammonium chloride [84] Gholap et al reported the synthesis of DHPMs by using N-
Butylimidazolium tetrafluoroborate ([Hbim]BF4) [85]. Jain et al used [bmim]BF4 
immobilized Cu (II) as a catalyst in synthesis of DHPMs [86]   Hua-Zheng  and 
cowerkers reported non-toxic room temperature ionic liquid l-n-butyl-3-
methylimidazolium saccharinate (BMImSac). [87]  
Recent years, task-specific room-temperature ionic liquids (TSILs) have emerged as a 
powerful alternative to conventional molecular organic solvents or catalysts due to their 
particular properties, such as undetectable vapour pressure, wide liquid range, as well as 
the ease of recovery and reuse The TSILs have also been used as catalysts for Biginelli 
reaction. [88-97]  
However, TSILs with imidazole as the cation are relatively expensive, which hinders their 
industrial applications. Furthermore, typical ionic liquids consist of halogen containing 
anions (such as [PF6]−, [BF4]−, [CF3SO3]− and [(CF3SO2)2N]−) which in some regard 
limit their “greenness” [98-100]. Therefore, it is necessary to synthesize less expensive 
and halogen-free TSILs. 
Shaabani and Rahmati [101] used room-temperature ionic liquid 1,1,3,3-
tetramethylguanidinium trifluoroacetate as catalyst. 
 
Building Blocks and Diversity 
 
Out of the three building blocks in the Biginelli reaction it is the aldehyde component, 
which can be varied to the largest extent. In general, the reaction works best with 
aromatic aldehydes. These can be substituted in the o-, m- or –p- position with either 
electron-withdrawing or –donating groups. Good yields are usually obtained with m- or 
p-substituted aromatic aldehydes carrying electron-withdrawing substituents. For o-
 
 
Review on literature………. 17
substituted benzaldehydes having bulky substituents, yields can be significantly lower. 
Heterocyclic aldehydes derived from furan, thiophene, and pyridine rings also generally 
furnish acceptable yields of DHPM products [102].Aliphatic aldehydes typically provide 
only moderate yields in the Biginelli reaction unless special reaction conditions are 
employed, i.e. Lewis acid catalysts/solvent free methods, or using the aldehydes in 
protected form [103]. The C4 unsubstituted DHPM can be prepared in a similar manner 
employing suitable formaldehyde synthons [103]. Of particular interest are reactions 
where the aldehyde component is derived from a carbohydrate. In such transformations, 
DHPMs having a sugar-like moiety in position 4 (C-nucleoside analogs) are obtained 
[104]. In a few cases, bisaldehydes have been used as synthons in Biginelli reactions 
[105]. Traditionally, simple alkyl acetoacetates are employed as CH-acidic carbonyl 
building blocks, but other types of 3- oxoalkanoic esters or thioesters can also be used 
successfully. With methyl 4-chloroacetoacetate, for example, the corresponding 6-
chloromethyl-substituted DHPMs which can serve as valuable templates for further 
synthetic transformations are obtained [106]. Benzoylacetic esters react analogously, but 
yields are usually significantly lower and the overall condensation process is more 
sluggish [102]. Primary, secondary, and tertiary acetoacetamides can be used in place of 
esters to produce pyrimidine-5-carboxamide [102]. In addition, β-diketones serve as 
viable substrates in Biginelli reactions. Condensations can also be achieved employing 
cyclic β-diketones such as cyclohexane-1,3-dione [107], and other cyclic β-dicarbonyl 
compounds [108]. 
If a C6-unsubstituted DHPM derivative needs to be synthesized, the corresponding 3-
oxopropanoic ester derivative in which the aldehyde function is masked as an acetal can 
be employed [109]. Apart from ester-derived CH-acidic carbonyl compounds, 
nitroacetone also serves as a good building block, leading to 5-nitro-substituted DHPM 
derivatives in generally high yields [110]. The urea is the component in the Biginelli 
reaction that faces the most restrictions in terms of allowed structural diversity [111]. 
Therefore, most of the published examples involve urea itself as building block. 
However, simple monosubstituted alkyl ureas generally react equally well, in a 
regiospecific manner, to provide good yields of N1- substituted DHPMs. Thiourea and 
substituted thioureas follow the same general rules as ureas, although longer reaction 
times are required to achieve good conversions. Yields are typically lower when 
compared to the corresponding urea derivatives. In some instances, it is also possible to 
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react protected urea or thioureas (isoureas), or guandidines under weak basic conditions 
with the aldehyde and CH-acidic carbonyl component (or with a precondensed 
Knoevenageltype enone) to yield the corresponding protected DHPMs [112, 113]. 
Aldehyde and protected aldehyde building blocks used in the Biginelli reaction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This latter method, using precondensed enones of type 5 has been frequently referred to 
as the “Atwal modification” of the Biginelli reaction [102, 103, 113]. Given the diversity 
in building block selection that is tolerated in the Biginelli reaction it is evident that a 
large number of DHPM derivatives of the general structure can be synthesized by 
combination of a relatively small number of (commercially available or proprietary) 
individual building blocks. 
 
CH-Acidic carbonyl building blocks used in the Biginelli reaction 
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 Employing different  aldehydes (point of diversity at C4 position), different CH-acidic 
carbonyl derivatives (points of diversity at 5 and 6 position) and thiourea analogs (points 
of diversity at 2 position) in a Biginelli- or Atwal type condensation would lead to a 
library of 1.000 DHPM compounds, with a total of five diversity points around the 
dihydropyrimidine core [114]. It is therefore not surprising that a literature search for the 
general DHPM structure in the Chemical Abstracts Registry database led to well over 
10.000 hits [114]. It is interesting to note however, that only a small fraction of these 
compounds has been published in the chemical literature (<1.000) [114]. On the other 
hand, more than half the 10,000 structures of type are commercially available, typically 
from companies specializing in chemical library generation. 
Urea-type building blocks used in the Biginelli reaction 
 
 
 
 
 
 
 
 
 
 
M. Kidwai and co-workers have proposed an ecologically benign method for the 
synthesis of benzopyranopyrimidines by reactions of 4-hydroxycoumarin (instead of 1,3 
diketones or β-ketoesters ) with aldehydes and urea and thiourea  in the absence of 
solvent under microwave irradiation.[115] 
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Solid Phase Synthesis  
The generation of combinatorial libraries of heterocyclic compounds by solid phase 
synthesis is of great interest for accelerating lead discovery and lead optimization in 
pharmaceutical research. Multicomponent reactions (MCRs) leading to heterocycles are 
particularly useful for the creation of diverse chemical libraries, since the combination of 
n ≥3 small molecular weight building blocks in a single operation leads to high 
combinatorial efficacy. Therefore, solid phase modifications of MCRs are rapidly 
becoming the cornerstone of combinatorial synthesis of small-molecule libraries.One 
such MCR that has attracted considerable attention in recent years is the Biginelli 
reaction, which involves the one-pot cyclocondensation of a β-ketoester with an aryl 
aldehyde and an urea derivative.The resulting 4-aryl-3,4-dihydropyrimidin-2(1H)-ones. 
O.Kappe and coworkers reported the 4-aryl-3,4-dihydropyrimidines using Resin-Bound  
Isothiourea Building Blocks and Multidirectional Resin Cleavages. Solid phase organic 
synthesis remains one of the cornerstones of combinatorial chemistry, since this technique 
allows the chemist to take full advantage of the powerful principles (i.e. split-and-mix 
synthesis) offered by combinatorial technologies. For a multicomponent reaction such as 
the Biginelli condensation, various solid-phase strategies can be envisaged and in fact a 
number of different approaches have been disclosed in recent years, utilizing different 
resin-bound building blocks and linker combinations. Given the regioselectivity 
encountered in using N-substituted urea building blocks in the Biginelli condensation, a 
solid phase modification where the urea component is linked to the solid support via the 
amide nitrogen is an obvious choice. 
The first actual solid-phase modification of the Biginelli condensation was reported by 
Wipf and Cunningham in1995. [116] In this sequence, γ-aminobutyric acid-derived urea 
was attached to Wang resin using standard procedures. The resulting polymer-bound urea 
was condensed with excess β-ketoesters and aromatic aldehydes in THF at 55°C in the 
presence of a catalytic amount of HCl to afford the corresponding immobilized DHPMs. 
 
 
 
 
In an interesting variation of this protocol, the Biginelli reaction was also adapted to 
fluorous-phase conditions by the Wipf and Curran groups.[116, 117] In fluorous 
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synthesis, an organic molecule is rendered soluble in fluorocarbon solvents by attachment 
of a suitable fluorocarbon group (“fluorous tag”). Fluorocarbon solvents are usually 
immiscible with organic solutions, and fluorous molecules partition out of an organic 
phase and into a fluorous phase by standard liquid-liquid extraction. At the desired stage 
of the synthesis, the fluorous label is cleaved and the product is rendered “organic” 
again.[118] In the fluorous Biginelli reaction, the fluorous urea derivative  was prepared 
by attachment of a suitable fluorous tag to hydroxyethylurea. The fluorous urea  was then 
condensed with 10 equiv each of the corresponding acetoacetates and aldehydes in THF-
benzotrifluoride (BTF) containing HCl. After extraction of the fluorous DHPMs with 
fluorous solvent (perfluorohexanes, FC-72), desilylation with tetrabutylammonium 
fluoride (TBAF) followed by extractive purification provided the “organic” Biginelli 
products DHPMs in good overall yields. Considering the simple experimental techniques 
used in this fluorous chemistry, automation should be feasible, thus allowing the 
preparation of DHPM libraries.[118] 
 
 
 
 
 
 
O. Kappe and co-workers reported the procedure in which urea component is linked to 
the solid (or fluorous) support via the amide nitrogen, which invariably leads to the 
formation of N1-functionalized, so far pharmacologically active, DHPMs. 
 
 
 
 
 
 
 
O. Kappe and co-workers have developed an alternative protocol, where the acetoacetate 
building block is linked to the solid support. Thus, Biginelli condensation of Wang-bound 
acetoacetate with excess aldehydes and ureas/thioureas in NMP(N-methyl 
N
NH
O
EtO2C
OH
O
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pyrollidine/HCl provided the desired DHPMs on solid support. Subsequent cleavage with 
50% TFA (Trifluoro Acetic acid) furnished the free carboxylic acids in high overall yield. 
 
 
 
 
In addition to solid-phase adaptions of the traditional three-component Biginelli 
condensation, solid-phase variations of the “Atwal modification” of the Biginelli reaction 
(see above) have also been reported. Robinett et al have disclosed the synthesis of a 648-
member combinatorial library of 1,4-dihydropyrimidines. Toward this end, polymer-
bound acetoacetate was subjected to Knoevenagel condensation with aromatic aldehydes, 
followed by condensation with isothioureas. The resulting polymer-bound 1,4-
dihydropyrimidines  were cleaved from the resin with 50% TFA to produce carboxylic 
acid.[119] 
 
 
 
 
 
 
 
 
In an effort to increase the molecular diversity in solid phase syntheses of DHPM 
scaffolds, a novel and versatile solid-phase approach was adopted where an isourea 
building block is attached to the solid support.[120] 
In the key step, polymer-bound (Wang) isothiourea B is condensed with enones  in N-
methylpyrrolidone (NMP) in the presence of base. Thepolymer-bound dihydropyrimidine 
can then be directly cleaved from the resin (C→E) by employing different cleavage 
strategies. Therefore, three types of DHPMs E (X =O, S, and NH) can be obtained by 
applying the appropriate cleaving conditions A, B, or C. On the other hand, an additional 
element of diversity can be introduced onto the pyrimidine nucleus by regioselective N3-
acylation of the polymer-bound intermediate C with suitable electrophiles (e.g., acyl 
chlorides, R3COCl). By applying different cleaving strategies to D, the corresponding N3-
functionalized DHPMs F were obtained in moderate to high overall yields. This solid-
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phase approach is therefore particularly attractive for the preparation of 
pharmacologically active N3-acylated analogues such as DHPMs and should be useful for 
the generation of targeted libraries of this heterocyclic scaffold. 
Diversity in solid phase DHPM synthesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Weiwei Li and Yulin Lam had developed Solid-Phase Synthesis of DHMPs Using 
Sodium Benzenesulfinate as a Traceless Linker. [121]  
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Andreas Schober developed synthetic protocol based on Immobilized β-Ketoamides to 
increase the diversity of DHPM derivatives by varying the substituents in position 4 in a 
simple manner. Depending on the building blocks for the three-component reaction, the 
immobilization strategies were chosen. At least three different strategies for the 
preparation of DHPM derivatives on solid support were described in recent literature. The 
first one makes use of immobilized urea or thiourea moieties . The second uses an 
immobilized β-ketoester, and the third one uses an S-linked isothiouronium salt, Biginelli 
protocols depending on immobilized aldehydes were not found. [122] 
DHPM Synthesis with Immobilized -Ketoesters 
 
 
 
 
 
 
DHPM Synthesis with Immobilized β- Ketoamides Using Atwal’s Route 
  
 
 
 
 
 
N-Acyliminium Ion, the Essential Reaction Intermediate 
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Thus by employing any of the solid-phase synthesis methods described above, libraries of 
DHPMs can be generated in a relatively straightforward fashion. Biginelli products are 
therefore contained in many commercially available small molecule libraries or 
compound collections and have undoubtely been subjected to many high-throughput 
screening (HTS) processes. However, all of these products would still be racemic, and 
therefore screening will not address possible enantioselective effects on molecular 
activity. 
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Reaction Scheme 
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Reaction Mechanism 
 
Step 1 
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Step-II 
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Route-II 
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Experimental 
 
Step-1 
Preparation of 4,4,4-Trifluoro-1-(4-methoxyphenyl) Butane-1,3 
-dione 
 
In freshly prepared Sodium Methoxide (1.7equivalent) in methanol, 4-methoxy 
acetophenone was added into it at 15-20 0C. It was stirred for 30 minutes at 20 0C. 1.2 
equivalent of trifluoroethyl acetate was added into it by dropping funnel within 30 
minutes at 20 0C,stirred for 12 hrs at 60 0C. TLC was checked for completion of reaction. 
Reaction mixture was poured in to 10%HCl solution & stirred for 15 minutes. Product 
was precipitated; it was filtered and washed twice successively with 100 ml water. 
Product was recrystallized in methanol: water (80:20) 
Note: - The entire reaction was carried out under nitrogen atmosphere 
It was dried in vacuum at 30-40 0C  
Yield: 78%   MP: - 68 0C 
TLC System: (Hexane: Ethyl acetate) 
                                9    :        1 
Step-2 
Preparation of 4-Hydroxy-5-(4-methoxybenzoyl)-6-substituted-
phenyl-4-(trifluoromethyl)tetrahydropyrimidin-2(1H)-ones 
(General Method) 
 
1.5 equivalent of Urea was dissolved in to 15 ml methanol until clear solution was 
observed. 1.0 equivalent of each of 1,3 diketone and Substituted benzaldehyde was added 
into stirred well, clear solution was observed. 2-3 drops of Conc.HCl was added into it, 
stirred for 5-6 hours according to the reactivity of the substituted benzaldehyde. Reaction 
mixture was cooled at room temperature. TLC was checked for completion of reaction. 
Reaction mixture was poured in crushed ice & extracted with ethyl acetate. Ethyl acetate 
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layer was collected, washed with twice 15 ml of water and 20 ml brine. It was dried over 
anh. Na2SO4. Solvent was evaporated by using vacuum rotavapor at 40 0C. Solid product 
was observed. It was purified by methanol 
Yield: 65-70% 
TLC System: (Chloroform: Methanol) 
                                7            :        3 
 
The physical data are given as separate table No. 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Physical data of 4-hydroxy-5-(4-methoxybenzoyl)-6-substituted-phenyl-4-
(trifluoromethyl)tetrahydropyrimidin-2(1H)-ones 
 
 
 
 
 
 
 
 
Table No: - 1 
 
 
C, H , N Analysis 
 Sr. No Code.No 
 
Substitution 
R 
M.F M.W M.P 
C H N 
1 RK-1001 2-Cl C19H16ClF3N2O4 428.79 218-219 53.22 (53.19) 
3.76 
(3.74) 
6.53 
(6.48) 
2 RK-1002 3-NO2 C19H16F3N3O6  439.34 187-189 
51.94 
(51.90) 
3.67 
(3.66) 
9.56 
(9.58) 
3 RK-1003 4-OCH3 C20H19F3N2O5  424.37 185-187 
56.60 
(56.57) 
4.51 
(4.48) 
6.60 
(6.57) 
4 RK-1004 2-OH C19H17F3N2O5  410.34 212-213 
55.61 
(55.56) 
4.18 
(4.22) 
6.83 
(6.85) 
5 RK-1005 4-F C19H16F4N2O4  412.33 216-217 
55.34 
(55.32) 
3.91 
(3.89) 
6.79 
(6.82) 
6 RK-1006 2-OCH3 C20H19F3N2O5  424.37 195-197 
56.60 
(56.67) 
4.51 
(4.48) 
6.60 
(6.56) 
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Table No: - 1 
 
C, H , N Analysis 
 Sr. No Code.No 
 
Substitution 
R 
M.F M.W M.P 
C H N 
7 RK-1007 4-Cl C19H16ClF3N2O4 428.79 220-222 53.22 (53.18) 
3.76 
(3.78) 
6.53 
(6.48) 
8 RK-1008 3-OH C19H17F3N2O5  410.34 234-236 
55.61 
(55.56) 
4.18 
(4.22) 
6.83 
(6.85) 
9 RK-1009 3,4-di OCH3 C21H21F3N2O6  454.4 220-221 
55.51 
(55.47) 
4.66 
(4.68) 
6.16 
(6.19) 
10 RK-1010 4-SCH3 C20H19F3N2O4S  440.44 198-200 
54.54 
(54.50) 
4.35 
(4.38) 
6.36 
(6.32) 
11 RK-1011 H C19H17F3N2O4  394.34 187-189 
57.87 
(55.76) 
4.35 
(4.39) 
7.10 
(7.05) 
12 RK-1012 3-OCH3 C20H19F3N2O5  424.37 192-194 
56.60 
(56.62) 
4.51 
(4.54) 
6.60 
(6.62) 
13 RK-1013 4-NO2 C19H16F3N3O6  439.34 178-179 
51.94 
(51.87) 
3.67 
(3.70) 
9.56 
(9.60) 
14 RK-1014 2-NO2 C19H16F3N3O6  439.34 182-183 
51.94 
(51.89) 
3.67 
(3.63) 
9.56 
(9.62) 
15 RK-1015 3-Cl C19H16ClF3N2O4 428.79 195-197 53.22 (53.19) 
3.76 
(3.69) 
6.53 
(6.52) 
16 RK-1016 3-Br C19H16BrF3N2O4 473.24 213-215 48.22 (48.20) 
3.41 
(3.43) 
5.92 
(5.89) 
17 RK-1017 3-OPh C25H21F3N2O5  486.44 201-203 
61.73 
(61.70) 
4.35 
(4.38) 
5.76 
(5.70) 
18 RK-1018 3,4,5-tri OCH3 C22H23F3N2O7  484.42 207-209 
54.55 
(54.52) 
4.79 
(4.80) 
5.78 
(5.75) 
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Spectral Discussion 
 
PMR spectral study 
1HNMR of the synthesized 4-Hydroxy-5-(4-methoxybenzoyl)-6-substituted-phenyl-4- 
(trifluoromethyl)tetrahydropyrimidin-2(1H)-ones were recorded on DPX-300MHz FT-
NMR spectrophotometer (Bruker) instrument using TMS (Tetramethyl silane) as an 
internal reference standard in DMSO-D6 solvent. The singlet observed for methoxy (-
OCH3) of 4-methoxy phenyl in the range of δ 3.7-3.9. Methine (-CH) attached with –NH 
and substituted phenyl ring gives typical doublet at δ 4.2-4.6 with J Value 11.4 Hz and 
methine (-CH) group attached with carbonyl shows clear doublet at δ 4.7-5.0 with J Value 
11.3 Hz. Hydroxyl group (-OH) attached to quaternary carbon and two different -NH 
protons of the cyclic ring appears at δ 7.0 -8.5. Proton of the aromatic ring attached to the 
carbonyl group appeared at δ 6.6-7.5. The pattern of the 1HNMR spectra between δ 6.8-
8.0 clearly indicated that the benzene ring attached to the unsymmetrical carbon atom is 
meta or para substituted. 
Individual 1HNMR data of synthesized compounds are mentioned in Spectral data details. 
 
13C NMR Spectral study 
4-Hydroxy-5-(4-methoxybenzoyl)-6-substituted-phenyl-4-(trifluoromethyl)tetrahyd- 
ropyrimidin-2(1H)-ones  
13C NMR spectra were recorded on Bruker 400MHz instruments using DMSO and CHCl3 
as the solvents with tetramethylsilane (TMS) as the respective internal standard. . In the 
spectrum, a doublet or quartet for the carbon atom connected with the trifluoromethyl 
substituent is located at 79-81 ppm (3J(C-F) =31-33 Hz) which is typical for a quaternary 
carbon rather than a carbonyl carbon atom. Methoxy group attached to phenyl ring is 
located at 54-56 ppm. The –CH (asymmetric) group attached with different substituent    
is appeared at 46-47 ppm and –CH (asymmetric) group attached with carbonyl is located 
at 54-56 ppm. The carbonyl carbon attached with phenyl ring and –CH group is located at 
191-196 ppm and carbonyl carbon attached with –NH group  is 160-165 ppm. The pattern 
of phenyl ring depends up on the substitution it is appeared between 110-160 ppm. 
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IR spectral study 
The infrared spectra of all compounds of this chapter were recorded on Shimadzu 8400 
FT-IR spectrophotometer by KBr pellet method. 
The different frequencies of infrared spectrum of 4-hydroxy-5-(4-methoxybenzoyl)-6-
substituted-phenyl-4-(trifluoromethyl)tetrahydropyrimidin-2(1H)-ones are discussed here. 
The Hydroxy group (-OH) appeared in the range of (3350-3400cm-1), typical carbonyl 
frequencies appeared for this cyclic urea in the range of (1620-1660cm-1). The carbonyl 
group attached with 4-methoxyphenyl appeared at (1670-1699cm-1). The secondary –NH 
frequencies appeared in all the compounds in the range of 3160-35400cm-1.The –OCH3 
functional group frequencies are also observed like 1205-1215cm-1 for Ar-O-C stretching. 
The trifluoromethyl group stretching vibrations observed at 1000-1380cm-1 
 
Mass spectral Study 
The mass spectrums of the 4-hydroxy-5-(4-methoxybenzoyl)-6-substituted-phenyl-4-
(trifluoromethyl)tetrahydropyrimidin-2(1H)-ones were recorded by GCMS-QP2010 
spectrometer (EI method). The molecular ion peak (M+) values are in superior match with 
molecular formula for synthesized compounds. In some cases, molecular ion peak (M+) 
peak does not appear due to the loss of H2O from the synthesized compounds, so it 
exhibit M-18 peak. Probable mass fragmentation of 4-hydroxy-5-(4-methoxybenzoyl)-6-
substituted-phenyl-4-(trifluoromethyl)tetrahydropyrimidin-2(1H)-ones is given in spectral 
data of each compounds separately. 
 
Elemental Analysis 
Elemental analysis of the compounds was carried out on Elementar Vario EL III Carlo 
Erba 1108 model at CDRI, Lucknow and the results are in agreement with the structures 
assigned.   
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Spectral Data 
4-Hydroxy-5-(4-methoxybenzoyl)-6-(2-chlorophenyl)-4-(trifluoromethyl)tetra       
hydropyrimidin-2(1H)-one (RK-1001) 
IR (KBr Pellet): 3435cm-1(-OH), 3320cm-1(-NH), 2976.26(C-H), 1670 cm-1(-C=O) 1659 
cm-1(-CO-NH), 1599 cm-1 (-NH Bend), 1223-1275 cm-1 (C-O-C),  1170 cm-1 (C-F),  750 
cm-1 (C-Cl) 
 
4-Hydroxy-5-(4-methoxybenzoyl)-6-(3-nitrophenyl)-4-(trifluoromethyl)tetra          
hydropyrimidin-2(1H)-one(RK-1002) 
1H-NMR (300 MHz, DMSO-d6): δ 3.74 (s, 3H),  4.53 (d, 1H, J=11.09 Hz), 5.10 (d, 1H, 
J=11.06 Hz), 6.81 (d, 2H, J=8.77 Hz), 7.16 (s, 1H), 7.44 (t, 2H, J=8.21Hz) 7.74 (d, 2H, 
J=8.80Hz), 7.83 (d, 2H, J=8.52 Hz), 7.97 (d, 1H, J=8.08 Hz), 8.28 (s, 1H) 
13C NMR (CDCl3): δ 195.53, 163.76, 154.22, 147.39, 139.69, 133.73, 130.13, 129.10, 
129.04, 122.81, 122.23, 113.38, 81.30, 55.02, 54.69, 46.59 
IR (KBr Pellet): 3470cm-1(-OH), 3340cm-1(-NH), 2954(C-H), 1690 cm-1(-C=O) 1659 
cm-1(-CO-NH), 1576 cm-1 (-NH Bend), 1570 cm-1 (-C-NO2), 1243 cm-1 (C-O-C),  1140 
cm-1 (C-F) 
 
4-Hydroxy-5-(4-methoxybenzoyl)-6-(4-methoxyphenyl)-4-(trifluoromethyl)tetra 
hydropyrimidin-2(1H)-one (RK-1003) 
1H-NMR (300 MHz, DMSO-d6): δ 3.60 (s, 3H), 3.76 (s, 3H),  4.32 (d, 1H, J=11.13 Hz), 
4.87 (d, 1H, J=11.06 Hz), 6.70 (d, 2H, J=8.52 Hz), 6.84 (d, 2H, J=8.75 Hz), 7.01 (s, 1H), 
7.75 (s, 1H), 7.28 (d, 2H, J=8.51 Hz) 7.68 (t, 2H, 8.78 Hz) 
13C NMR (CDCl3): δ 196.34, 163.47, 158.90, 154.14, 130.12, 129.31, 129.13, 128.38, 
113.30, 113.24, 81.22, 55.00, 54.58, 46.84 
IR (KBr Pellet): 3466cm-1 (-OH), 3321cm-1 (-NH), 2920-2959cm-1(C-H), 1690 cm-1 
(-C=O) 1662.69 cm-1(-CO-NH), 1576 cm-1 (-NH Bend), 1271 cm-1 (C-O-C), 1190 cm-1 
(C-F) 
4-Hydroxy-5-(4-methoxybenzoyl)-6-(2-hydroxyphenyl)-4-(trifluoromethyl)tetra 
hydropyrimidin-2(1H)-one (RK-1004) 
IR (KBr Pellet): 3520cm-1(-OH), 3440cm-1(-OH), 3399.29cm-1(-NH), 2910-2949cm-1(C-
H), 1700.12 cm-1(-C=O) 1645.54 cm-1(-CO-NH), 1578 cm-1 (-NH Bend), 1229.54 cm-1 
(C-O-C), 1140-1170 cm-1 (C-F) 
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4-Hydroxy-5-(4-methoxybenzoyl)-6-(4-fluorophenyl)-4-(trifluoromethyl)tetra 
hydropyrimidin-2(1H)-one (RK-1005) 
1H-NMR (300 MHz, DMSO-d6): δ 3.76 (s, 3H), 4.36 (d, 1H, J=11.09 Hz), 4.93 (d, 1H, 
J=11.06 Hz), 6.84 (d, 2H, J=8.73 Hz), 6.97 (t, 2H, J=8.58 Hz), 7.06 (s, 1H), 7.22 (s, 1H),  
7.41 (m, 2H, J=5.64 Hz), 7.70 (d, 3H, J=8.30 Hz) 
13C NMR (CDCl3): δ 195.77, 163.49, 162.85, 160.40, 154.02, 133.48, 130.07, 129.27, 
129.19, 114.81, 114.60, 113.28, 81.21, 55.01, 54.44, 46.87 
IR (KBr Pellet): 3471.47cm-1(-OH), 3345cm-1(-NH),  2954cm-1 (C-H), 1699.98 cm-1        
(-C=O) 1659 cm-1(-CO-NH), 1498-1529 cm-1 (-NH Bend), 1243 cm-1 (C-O-C),  1140-
1210 cm-1 (CF3 & C-F) 
 
4-Hydroxy-5-(4-methoxybenzoyl)-6-(2-methoxyphenyl)-4-(trifluoromethyl)tetra 
hydropyrimidin-2(1H)-one (RK-1006) 
13C NMR (CDCl3): δ 195.67, 177.03, 163.68, 156.67, 129.96, 129.77, 129.11, 128.90, 
123.06, 120.15, 113.18, 110.65, 80.38, 54.96, 42.14 
IR (KBr Pellet): 3520cm-1(-OH), 3374cm-1(-NH), 2910-2949cm-1(C-H), 1668.84cm-1     (-
C=O) 1599 cm-1  (-CO-NH), 1498-1529 cm-1 (-NH Bend), 1219-1244 cm-1 (C-O-C),1140-
1210 cm-1 ( C-F) 
 
4-Hydroxy-5-(4-methoxybenzoyl)-6-(4-chlorophenyl)-4-(trifluoromethyl)tetra 
hydropyrimidin-2(1H)-one (RK-1007) 
1H-NMR (300 MHz, DMSO-d6): δ 3.76 (s, 3H),  4.37 (d, 1H, J=11.10 Hz), 4.93 (d, 1H, 
J=11.06 Hz), 6.85 (d, 2H, J=8.70 Hz), 7.10 (s, 1H), 7.23 (t, 3H, J=7.53 Hz), 7.40 (d, 2H, 
J=8.32 Hz), 7.71 (d, 3H, J=8.00 Hz) 
IR (KBr Pellet):      3462.31cm-1(-OH), 3345cm-1(-NH), 2902-2947cm-1(C-H), 1698cm-1 
(-C=O) 1662 cm-1  (-CO-NH), 1491-1511cm-1 (-NH Bend), 1211-1249 cm-1 (C-O-
C),1018-1104cm-1 ( C-F) 
 
4-Hydroxy-5-(4-methoxybenzoyl)-6-(3-hydroxyphenyl)-4-(trifluoromethyl)tetra 
hydropyrimidin-2(1H)-one (RK-1008) 
IR (KBr Pellet): 3466.32cm-1(-OH), 3356cm-1(-NH),  2921-2950cm-1(C-H), 1690cm-1    
(-C=O), 1662.6 cm-1 (-CO-NH), 1491-1502cm-1 (-NH Bend), 1206-1271 cm-1 (C-O-
C),1111-1271cm-1 ( C-F) 
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13C NMR (CDCl3): δ 196.61, 163.53, 159.92, 157.03, 154.23, 138.60, 130.12, 129.33, 
129.03, 117.65, 115.19, 114.16, 113.22, 81.30, 55.19, 55.01, 46.68 
 
4-Hydroxy-5-(4-methoxybenzoyl)-6-(3,4-dimethoxyphenyl)-4-(trifluoromethyl) 
tetrahydropyrimidin-2(1H)-one (RK-1009) 
1H-NMR (300 MHz, DMSO-d6):δ 3.58 (s, 3H), 3.67 (s, 3H), 3.76 (s, 3H), 4.48 (d, 1H, 
J=11.02 Hz), 4.83 (d, 1H, J=11.60 Hz), 6.72 (m, 2H, J=8.12 Hz), 6.85 (d, 2H, J=8.67 Hz), 
6.96 (s, 1H), 7.10 (d, 2H, J=7.12 Hz), 7.68 (s, 1H), 7.78 (d, 2H, J=8.73 Hz) 
IR (KBr Pellet): 3478cm-1(-OH), 3321cm-1(-NH),  2910-2950cm-1(C-H), 1699.98 cm-1        
(-C=O), 1674.12 cm-1 (-CO-NH), 1498-1522cm-1 (-NH Bend), 1211-1249 cm-1 (C-O-C), 
1107-1171cm-1 ( C-F) 
 
4-Hydroxy-5-(4-methoxybenzoyl)-6-(4-methylthiophenyl)-4-(trifluoromethyl) 
tetrahydropyrimidin-2(1H)-one (RK-1010) 
IR (KBr Pellet): 3450cm-1(-OH), 3340cm-1(-NH),  2912-2950cm-1(C-H), 1685 cm-1        
(-C=O), 1674.12 cm-1 (-CO-NH), 1490-1510cm-1 (-NH Bend), 1206-1248 cm-1 (C-O-C), 
1170-1204cm-1 ( C-F) 
 
4-Hydroxy-5-(4-methoxybenzoyl)-6-phenyl-4-(trifluoromethyl)tetrahydropyrimidin-
2(1H)-one (RK-1011) 
IR (KBr Pellet): 3440cm-1(-OH), 3329cm-1(-NH),  2930-2956cm-1(C-H), 1701 cm-1        
(-C=O), 1674.33cm-1 (-CO-NH), 1493-1530cm-1 (-NH Bend), 1190-1226 cm-1 (C-O-C), 
1090-1204cm-1 ( C-F) 
 
4-Hydroxy-5-(4-methoxybenzoyl)-6-(3-methoxyphenyl)-4-(trifluoromethyl) 
tetrahydropyrimidin-2(1H)-one (RK-1012) 
IR (KBr Pellet): 3470cm-1(-OH), 3350.11cm-1(-NH),  2921-2956cm-1(C-H), 1704 cm-1        
(-C=O), 1665.2cm-1 (-CO-NH), 1493-1522cm-1 (-NH Bend), 1185-1240 cm-1 (C-O-C), 
1089-1172cm-1 ( C-F) 
 
4-Hydroxy-5-(4-methoxybenzoyl)-6-(4-nitrophenyl)-4-(trifluoromethyl)tetra 
hydropyrimidin-2(1H)-one (RK-1013) 
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IR (KBr Pellet): 3452cm-1(-OH), 3349cm-1(-NH),  2911-2946cm-1(C-H), 1697.63 cm-1        
(-C=O), 1656.23 cm-1 (-CO-NH), 1580.12 cm-1 (-C-NO2), 1498-1520cm-1 (-NH Bend), 
1107-1199 cm-1 (C-O-C), 1107-1182cm-1 ( C-F) 
 
4-Hydroxy-5-(4-methoxybenzoyl)-6-(2-nitrophenyl)-4-(trifluoromethyl)tetra 
hydropyrimidin-2(1H)-one (RK-1014) 
IR (KBr Pellet): 3478cm-1(-OH), 3350cm-1(-NH),  2903-2922cm-1(C-H), 1710 cm-1        
(-C=O), 1662.35 cm-1 (-CO-NH), 1578 cm-1 (-C-NO2), 1510-1523cm-1 (-NH Bend), 1201-
1230cm-1 ( C-F)1112-1175 cm-1 (C-O-C)  
 
4-Hydroxy-5-(4-methoxybenzoyl)-6-(3-chlorophenyl)-4-(trifluoromethyl)tetra 
hydropyrimidin-2(1H)-one (RK-1015) 
IR (KBr Pellet): 3456cm-1(-OH), 3321cm-1(-NH), 2911-2976(C-H), 1678 cm-1(-C=O) 
1658 cm-1(-CO-NH), 1599 cm-1 (-NH Bend), 1170-1209 cm-1 (C-O-C),  1170-1181cm-1 
(C-F),  750-760 cm-1 (C-Cl) 
 
4-Hydroxy-5-(4-methoxybenzoyl)-6-(3-bromophenyl)-4-(trifluoromethyl)tetra 
hydropyrimidin-2(1H)-one (RK-1016) 
IR (KBr Pellet): 3441cm-1(-OH), 3309cm-1(-NH), 2905-2923(C-H), 1699.9 cm-1(-C=O) 
1674 cm-1(-CO-NH), 1599-1607 cm-1 (-NH Bend), 1170-1178 cm-1 (C-O-C),  1170-
1181cm-1 (C-F),  550-556 cm-1 (C-Br) 
 
4-Hydroxy-5-(4-methoxybenzoyl)-6-(3-phenoxyphenyl)-4-(trifluoromethyl)tetra 
hydropyrimidin-2(1H)-one (RK-1017) 
IR (KBr Pellet): 3445cm-1(-OH), 3326.65cm-1(-NH),  2910-2956cm-1(C-H), 1697 cm-1        
(-C=O), 1668.82cm-1 (-CO-NH), 1493-1520cm-1 (-NH Bend), 1190-1226 cm-1 (C-O-C), 
1050-1170cm-1 ( C-F) 
 
4-Hydroxy-5-(4-methoxybenzoyl)-6-(3,4,5-trimethoxyphenyl)-4-(trifluoromethyl) 
tetrahydropyrimidin-2(1H)-one (RK-1018) 
IR (KBr Pellet): 3482cm-1(-OH), 3311cm-1(-NH), 2908-2978(C-H), 1689 cm-1(-C=O) 
1668 cm-1(-CO-NH), 1499-1523 cm-1 (-NH Bend), 1161-1209 cm-1 (C-O-C),  1170-
1181cm-1 (C-F)   
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4-Hydroxy-5-(4-methoxybenzoyl)-6-napthyl-4-(trifluoromethyl)tetrahydro 
pyrimidin-2(1H)-one (RK-1019) 
13C NMR (CDCl3): δ 191.04, 162.25, 155.41, 132.78, 130.78, 130.15, 129.49, 128.75, 
128.63, 127.86, 126.50, 125..18, 124.56, 120.80, 112.49, 84.31, 54.72, 50.85, 48.87, 
43.15 
IR (KBr Pellet): 3462.34cm-1(-OH), 3219cm-1(-NH),  2902-2947cm-1(C-H), 1691 cm-1        
(-C=O), 1559 cm-1 (-CO-NH), 1506-1523cm-1 (-NH Bend), 1219-1244cm-1 ( C-F),1022-
1109 cm-1 (C-O-C)  
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Mass value of 4-hydroxy-5-(4-methoxybenzoyl)-6-substituted-
phenyl-4-(trifluoromethyl)tetrahydropyrimidin-2(1H)-ones 
Compound 
Code.No 
(m/z) 
Relative intensity 
RK-1001 428 (09%) 
RK-1002 439-18 (12%) 
RK-1003 424 (15%) 
RK-1004 410 (25%) 
RK-1005 412 (18%) 
RK-1006 424 (10%) 
RK-1007 428 (11%) 
RK-1008 410 (15%) 
RK-1009 454 (17%) 
RK-1010 440 (05%) 
RK-1011 394 (10%) 
RK-1012 424-18 (14%) 
RK-1013 439(15%) 
RK-1014 439 (20%) 
RK-1015 428 (12%) 
RK-1016 473-18 (14%) 
RK-1017 486 (18%) 
RK-1018 484-18 (20%) 
RK-1019 444.4(17%) 
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Spectra of the Representative compounds 
 
[a] 1H NMR Spectra of RK-1005 
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[b] 1H NMR Spectra of RK-1007 
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[c] 1H NMR Spectra of RK-1002 
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[d] 1H NMR Spectra of RK-1009 
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[e] 1H NMR Spectra of RK-1003 
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[f] 13C NMR of RK-1002 
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[g] 13C NMR of RK-1005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
H
NH
O
O O
F3C
HO
F
 
 
Synthesis and Characterization of trifluoro…… 49
[h] 13C NMR of RK-1008 
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[i] 13C NMR of RK-1006 
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[j] 13C NMR of RK-1018 
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[k] 13C NMR of RK-1019 
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[l] IR Spectra of RK-1001  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[m] IR Spectra of RK-1008  
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[n] IR Spectra of RK-1006 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[o] IR Spectra of RK-1019 
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[p] EI-MS of 1,3 DIKETONE 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
[q] EI-MS of RK-1010 
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Reaction Scheme 
 
Step-I 
 
 
 
 
 
 
 
 
Step-II 
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Experimental 
 
Step-1 
Preparation of 4,4,4-Trifluoro-1-(4-methoxyphenyl)Butane-1,3- 
dione 
 
In freshly prepared Sodium methoxide (1.7equivalent) in methanol, 4-methoxy 
acetophenone was added into it at 15-20 0C. It was stirred for 30 minutes at 20 0C. 1.2 
equivalent of trifluoroethyl acetate was added into it by dropping funnel within 30 
minutes at 20 0C, stirred for 12 hrs at 60OC. TLC was checked for completion of reaction. 
Reaction mixture was poured in to 10%HCl solution & stirred for 15 minutes. Product 
was precipitated; it was filtered & washed with twice by 100 ml water. Product was 
recrystallized in methanol: water (80:20). It was dried in vacuum at 30-40 0C  
Note: - The entire reaction was carried out under nitrogen atmosphere 
Yield: 78% 
TLC System: (Hexane: Ethyl acetate) 
                                9    :        1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[4-Hydroxy-6-substitutedphenyl-2-thioxo… 
 
58
Step-2 
 
Preparation of [4-Hydroxy-6 substituted-phenyl-2-thioxo-4-
(trifluoromethyl)hexahydropyrimidin-5-yl](4-methoxyphenyl) 
Methanones (General Method) 
  
1.5 equivalent thiourea was dissolved in to 15 ml methanol until clear solution was 
observed.1.0 equivalent of  1,3 diketone & 1.0 equivalent of Substituted Benzaldehyde 
was added in to stirred well, clear solution was observed. 2-3 drops of Conc.HCl was 
added in to it, stirred for 5-6 hours according to the reactivity of the substituted 
benzaldehyde. Reaction mixture was cooled at room temperature. TLC was checked for 
completion of reaction. Reaction mixture was cooled to room temperature , kept in a 
fridge until solid product was observed.15 ml Methanol was added in to it, heated to 
reflux temperature. Product was filtered through suction and washed twice by 20 ml of 
methanol. 
Product was dried in oven at 60 0C 
 
Yield: 65-70% 
 
TLC System: (Chloroform: Methanol) 
                                7           :        3 
 
The physical data are given in table No. 2 
 
 
 
 
 
 
  
Physical data of [4-hydroxy-6 substituted-phenyl-2-thioxo-4-
(trifluoromethyl)hexahydropyrimidin-5-yl](4-methoxyphenyl)methanones 
 
 
 
 
 
 
 
 
 
 
Table No: - 2 
 
C, H , N Analysis 
 Sr. No Code.No 
 
Substitution 
R 
M.F M.W M.POC 
C H N 
1 RK-2001 3,4-di OCH3 C21H21F3N2O5S  470.46 187-190 53.61 (53.59) 
4.50 
(4.53) 
5.95 
(5.92) 
2 RK-2002 4-F C19H16F4N2O3S  428.40 175-178 53.27 (53.24) 
3.76 
(3.78) 
6.54 
(6.55) 
3 RK-2003 3-Br C19H16BrF3N2O3S 489.31 156-158 46.64 (46.62) 
3.30 
(3.28) 
5.73 
(5.69) 
4 RK-2004 3-NO2 C19H16F3N3O5S  455.41 145-147 50.11 (50.08) 
3.54 
(3.54) 
9.23 
(9.22) 
5 RK-2005 2-OCH3 C20H19F3N2O4S  440.44 152-155 54.54 (54.51) 
4.35 
(4.31) 
6.36 
(6.30) 
6 RK-2006 3-OH C19H17F3N2O4S  426.41 191-192 53.52 (53.50) 
4.02 
(3.99) 
6.57 
(6.59) 
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Table No: - 2 
 
 
C, H , N Analysis 
 Sr. No Code.No 
 
Substitution 
R 
M.F M.W M.P 
C H N 
7 RK-2007 4-OCH3 C20H19F3N2O4S  440.44 156-157 54.54 (54.52) 
4.35 
(4.33) 
6.36 
(6.35) 
8 RK-2008 3-OCH3 C20H19F3N2O4S  440.44 165-168 54.54 (54.50) 
4.35 
(4.36) 
6.36 
(6.37) 
9 RK-2009 4-Cl C19H16ClF3N2O3S 444.86 159-160 51.30 (51.28) 
3.63 
(3.61) 
6.30 
(6.28) 
10 RK-2010 H C19H17F3N2O3S  410.41 148-150 55.60 (55.58) 
4.18 
(4.15) 
6.83 
(6.85) 
11 RK-2011 4-SCH3 C20H19F3N2O3S2  456.5 178-180 52.62 (52.59) 
4.20 
(4.21) 
6.14 
(6.15) 
12 RK-2012 3-Cl C19H16ClF3N2O3S 444.86 185-187 51.30 (51.28) 
3.63 
(3.61) 
6.30 
(6.28) 
13 RK-2013 2-Cl C19H16ClF3N2O3S 444.86 150-152 51.30 (51.27) 
3.63 
(3.66) 
6.30 
(6.31) 
14 RK-2014 4-NO2 C19H16F3N3O5S  455.41 163-164 50.11 (50.10) 
3.54 
(3.51) 
9.23 
(9.26) 
15 RK-2015 2-NO2 C19H16F3N3O5S  455.41 168-170 50.11 (50.07) 
3.54 
(3.51) 
9.23 
(9.26) 
16 RK-2016 
 
3-OPh C25H21F3N2O4S  502.51 175-178 59.75 (59.73) 
4.21 
(4.18) 
5.57 
(5.58) 
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Spectral discussion 
 
13C NMR spectral study  
13C NMR spectral discussion of [4-Hydroxy-6 substituted-phenyl-2-thioxo-4-
(trifluoromethyl)hexahydropyrimidin-5-yl](4-methoxyphenyl)methanone 
13C NMR spectra of [4-hydroxy-6 substituted-phenyl-2-thioxo-4-
(trifluoromethyl)hexahydropyrimidin-5-yl](4-methoxyphenyl)methanone were recorded 
on Bruker 400MHz instruments using DMSO and CHCl3 as the solvents with 
tetramethylsilane (TMS) as the respective internal standard. . In the spectrum, a quartet 
for the carbon atom connected with the trifluoromethyl substituent is located at 80-81 
ppm (3J(C-F) =32-34 Hz) which is typical for a quarternary carbon rather than a carbonyl 
carbon atom. Methoxy group attached to phenyl ring is located at 54-56 ppm. The –CH 
(asymmetric) group attached with different substituent    is appeared at 46-47 ppm  and –
CH (asymmetric) group attached with carbonyl is located at 54-56 ppm. The carbonyl 
carbon attached with phenyl ring and –CH group is located at 191-196 ppm and 
(C=S)carbon attached with –NH group  is 165-175 ppm. The pattern of phenyl ring 
depends up on the substitution; it is appeared between 110-160 ppm. 
 
PMR spectral study 
PMR spectral discussion of [4-Hydroxy-6 substituted-phenyl-2-thioxo-4-
(trifluoromethyl)hexahydropyrimidin-5-yl](4-methoxyphenyl)methanone 
1HNMR of the synthesized compounds were recorded on DPX-300MHz FT-NMR 
spectrophotometer (Bruker) instrument using TMS as an internal reference standard in 
DMSO-D6 solvent. 1HNMR spectra show the number of proton & chemical environment 
of each proton in each compound. The singlet observed for methoxy proton of  4-
methoxy phenyl in the range of δ 3.7-3.9. Methine (-CH) attached with –NH and 
substituted phenyl ring gives typical doublet at δ 4.2-4.6 with J Value 11.4 Hz and 
methine (-CH) group attached with carbonyl shows clear doublet at δ 4.7-5.0 with J Value 
11.3 Hz. Hydroxyl group (OH) attached to quaternary carbon represents singlet at δ 7.4-
7.6. The proton of the aromatic ring attached to the carbonyl group appeared at δ 6.6-7.5. 
The two protons of the different –NH shows peak at δ 8.7-9.0. In some case, it shows 
different singlet peak for each of –NH proton. The pattern of the 1HNMR spectra between 
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δ 6.8-8.0 clearly indicated that the benzene ring attached to the unsymmetrical carbon 
atom is meta or para substituted. 
Individual 1HNMR data of synthesized compounds is mentioned in spectral data. 
 
IR spectral study 
The infrared spectra of all compounds of this chapter were recorded on Shimadzu 8400 
FT-IR spectrophotometer by KBr pellet method. 
 The different frequencies of infrared spectrum of [4-hydroxy-6 substituted-phenyl-2-
thioxo-4-(trifluoromethyl)hexahydropyrimidin-5-yl](4-methoxyphenyl)methanone are 
discussed here. The Hydroxy group (-OH) appeared in the range of (3350-3400cm-1), 
typical thiocarbonyl frequencies appeared for this cyclic thiourea in the range of (1050-
1200cm-1). The carbonyl group of 4-methoxyphenyl appeared at (1670-1699cm-1). The 
secondary –NH frequencies appeared in all the compounds in the range of 3160-3540cm-
1. The –OCH3 functional group frequencies are also observed like 1205-1215cm-1 for C-
O-Ar stretching. The CF3 group stretching vibrations observed at 1000-1380cm-1 
Detail of each synthesized compounds IR spectra is depicted in spectral data. 
 
Mass spectral study 
The mass spectrums of the all compounds of this series were recorded by GCMS-QP2010 
spectrometer (EI method). The molecular ion peak (M+) values are in good match with 
molecular formula for synthesized compounds. In some cases, molecular ion peak (M+) 
peak does not appear due to the loss of H2O from the synthesized compounds, so it 
exhibit M-18 peak. Probable mass fragmentation of [4-hydroxy-6 substituted-phenyl-2-
thioxo-4-(trifluoromethyl)hexahydropyrimidin-5-yl](4-methoxyphenyl)methanones is 
written in spectral data for individual compounds separately. 
 
Elemental Analysis 
Elemental analysis of the compounds was carried out on Elementar Vario EL III Carlo 
Erba 1108 model at CDRI, Lucknow and the results are in agreement with the structures 
assigned.   
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SPECTRAL DATA 
[4-Hydroxy-6(3,4-dimethoxyphenyl)-2-thioxo-4-(trifluoromethyl)hexahydro 
pyrimidin-5-yl](4-methoxyphenyl)methanone (RK-2001) 
1H-NMR (300 MHz, DMSO-d6):δ 3.60 (s, 3H), 3.67 (s, 3H), 3.76 (s, 3H), 4.62 (d, 1H, 
J=11.44 Hz), 4.88 (d, 1H, J=11.41 Hz), 6.73 (m, 2H, J=8.23 Hz), 6.85 (d, 2H, J=8.63 
Hz), 7.11 (s, 1H), 7.47  (s, 1H), 7.83 (d, 2H, J=8.67 Hz), 8.92 (d, 2H, J=8.62 Hz) 
13C NMR (CDCl3): δ 195.65, 177.56, 163.77, 148.65, 148.37, 130.17, 128.96, 127.63, 
120.04, 113.25, 110.50, 110.15, 80.12, 56.06, 55.46, 55.20, 54.96, 44.90 
IR (KBr Pellet): 3478cm-1(-OH), 3321cm-1(-NH),  2910-2950cm-1(C-H), 1699.98 cm-1        
(-C=O), 1674.12 cm-1 (-CO-NH), 1498-1522cm-1 (-NH Bend), 1211-1249 cm-1 (C-O-C), 
1107-1171cm-1 ( C-F) 
 
[4-Hydroxy-6(4-fluorophenyl)-2-thioxo-4-(trifluoromethyl)hexahydropyrimidin-5-
yl](4-methoxyphenyl)methanone (RK-2002)  
13C NMR (CDCl3): δ 194.18, 177.33, 163.47, 163.01, 160.56, 132.25, 130.04, 129.59, 
129.51, 129.33, 80.20, 55.26, 55.00, 45.61 
IR (KBr Pellet): 3471.47cm-1(-OH), 3345cm-1(-NH),  2954cm-1 (C-H), 1699.98 cm-1        
(-C=O) 1659 cm-1(-CO-NH), 1498-1529 cm-1 (-NH Bend), 1243 cm-1 (C-O-C),  1140-
1210 cm-1 (CF3 & C-F) 
 
[4-Hydroxy-6(3-bromophenyl)-2-thioxo-4-(trifluoromethyl)hexahydropyrimidin-5-
yl](4-methoxyphenyl)methanone (RK-2003) 
IR (KBr Pellet): 3441cm-1(-OH), 3309cm-1(-NH), 2905-2923(C-H), 1699.9 cm-1(-C=O) 
1674 cm-1(-CO-NH), 1599-1607 cm-1 (-NH Bend), 1170-1178 cm-1 (C-O-C),  1170-
1181cm-1 (C-F),  550-556 cm-1 (C-Br) 
 
[4-Hydroxy-6(3-nitrophenyl)-2-thioxo-4-(trifluoromethyl)hexahydropyrimidin-5-
yl](4-methoxyphenyl)methanone (RK-2004) 
1H-NMR (300 MHz, DMSO-d6):δ 3.74 (s, 3H),  4.70 (d, 1H, J=11.40 Hz), 5.13 (d, 1H, 
J=11.39 Hz), 6.82 (d, 2H, J=8.70 Hz), 7.46 (t, 1H, J=7.94 Hz), 7.66 (s, 1H), 7.81 (m, 3H), 
7.99 (d, 1H, J=8.04 Hz), 8.83 (s, 1H), 9.15 (s, 1H), 9.26 (s, 1H) 
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IR (KBr Pellet): 3470cm-1(-OH), 3340cm-1(-NH), 2954(C-H), 1690 cm-1(-C=O) 1659 
cm-1(-CO-NH), 1576 cm-1 (-NH Bend), 1570 cm-1 (-C-NO2), 1243 cm-1 (C-O-C),  1140 
cm-1 (C-F) 
 
[4-Hydroxy-6(2-methoxyphenyl)-2-thioxo-4-(trifluoromethyl)hexahydropyrimidin-5-
yl](4-methoxyphenyl)methanone (RK-2005) 
IR (KBr Pellet): 3520cm-1(-OH), 3374cm-1(-NH), 2910-2949cm-1(C-H), 1668.84cm-1     (-
C=O) 1599 cm-1  (-CO-NH), 1498-1529 cm-1 (-NH Bend), 1219-1244 cm-1 (C-O-C),1140-
1210 cm-1 ( C-F) 
 
[4-Hydroxy-6(3-hydroxyphenyl)-2-thioxo-4-(trifluoromethyl)hexahydropyrimidin-5-
yl](4-methoxyphenyl)methanone (RK-2006) 
IR (KBr Pellet): 3466.32cm-1(-OH), 3356cm-1(-NH),  2921-2950cm-1(C-H), 1690cm-1    
(-C=O), 1662.6 cm-1 (-CO-NH), 1480-1520cm-1 (-NH Bend), 1206-1271 cm-1 (C-O-
C),1111-1271cm-1 ( C-F) 
 
[4-Hydroxy-6(4-methoxyphenyl)-2-thioxo-4-(trifluoromethyl)hexahydropyrimidin-5-
yl](4-methoxyphenyl)methanone (RK-2007) 
1H-NMR (300 MHz, DMSO-d6): δ 3.61 (s, 3H), 3.76 (s, 3H),  4.45 (d, 1H, J=11.46 Hz), 
4.90 (d, 1H, J=11.44 Hz), 6.72 (d, 2H, J=8.44 Hz), 6.85 (d, 2H, J=8.70 Hz), 7.29 (d, 2H, 
8.44 Hz), 7.52 (s, 1H), 7.75 (d, 2H, J=8.71 Hz), 8.94 (d, 2H, J=8.62 Hz) 
IR (KBr Pellet): 3466cm-1 (-OH), 3321cm-1 (-NH),  2920-2959cm-1  (C-H), 1690 cm-1 
(-C=O) 1662.69 cm-1(-CO-NH), 1576 cm-1 (-NH Bend), 1271 cm-1 (C-O-C), 1190 cm-1 
(C-F) 
 
[4-Hydroxy-6(3-methoxyphenyl)-2-thioxo-4-(trifluoromethyl)hexahydropyrimidin-5-
yl](4-methoxyphenyl)methanone (RK-2008) 
1H-NMR (300 MHz, DMSO-d6): δ 3.52 (s, 3H), 3.65 (s, 3H),  4.53 (d, 1H, J=11.40 Hz), 
4.92 (d, 1H, J=11.39 Hz), 6.68 (d, 1H, J=8.04 Hz), 6.86 (t, 3H, J=8.29 Hz), 6.98 (s, 1H), 
7.06 (t, 1H, J=7.80 Hz), 7.53 (s, 1H), 7.78 (d, 2H, J=8.68 Hz), 8.96 (s, 1H), 9.03 (s, 1H) 
13C NMR (CDCl3): δ 194.45, 177.29, 163.42, 158.94, 137.65, 130.06, 129.40, 129.03, 
119.76, 113.89, 113.22, 112.99, 80.19, 55.96, 54.99, 54.73, 45.34 
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IR (KBr Pellet): 3470cm-1(-OH), 3350.11cm-1(-NH),  2921-2956cm-1(C-H), 1704 cm-1        
(-C=O), 1665.2cm-1 (-CO-NH), 1493-1522cm-1 (-NH Bend), 1185-1240 cm-1 (C-O-C), 
1089-1172cm-1 ( C-F) 
 
[4-Hydroxy-6(4-chlorophenyl)-2-thioxo-4-(trifluoromethyl)hexahydropyrimidin-5-
yl](4-methoxyphenyl)methanone (RK-2009) 
1H-NMR (300 MHz, CDCl3):δ 3.83 (s, 3H), 4.15 (d, 1H, J=11.32 Hz), 4.98 (d, 1H, 
J=11.29 Hz), 6.31 (s, 1H), 6.78 (d, 3H, J=8.94 Hz), 7.07 (s, 1H), 7.17-7.26 (m, 5H), 7.53 
(s, 1H), 7.56 (s, 1H) 
IR (KBr Pellet):  3462.3 cm-1(-OH), 3345cm-1(-NH), 2902-2947cm-1(C-H), 1698cm-1    
(-C=O) 1662 cm-1 (-CO-NH), 1491-1511cm-1 (-NH Bend), 1211-1249 cm-1 (C-O-
C),1018-1104cm-1 ( C-F) 
 
[4-Hydroxy-6-phenyl-2-thioxo-4-(trifluoromethyl)hexahydropyrimidin-5-yl](4-
methoxyphenyl)methanone (RK-2010) 
1H-NMR (300 MHz, CDCl3): δ 3.80 (s, 3H), 4.17 (d, 1H, J=11.28 Hz), 4.99 (d, 1H, 
J=11.28 Hz), 6.42 (s, 1H), 6.73 (d, 2H, J=8.97 Hz), 6.79 (s, 1H), 7.05 (s, 1H), 7.22 (m, 
4H), 7.50 (d, 2H, J=8.68 Hz) 
13C NMR (CDCl3): δ 194.03, 177.36, 163.54, 135.03, 133.46, 130.06, 129.30, 129.20, 
128.03, 113.36, 80.34, 55.33, 55.01, 45.50 
IR (KBr Pellet): 3440cm-1(-OH), 3329cm-1(-NH),  2930-2956cm-1(C-H), 1701 cm-1        
(-C=O), 1674.33cm-1 (-CO-NH), 1493-1530cm-1 (-NH Bend), 1190-1226 cm-1 (C-O-C), 
1090-1204cm-1 ( C-F) 
 
[4-Hydroxy-6(4-thiomethylphenyl)-2-thioxo-4-(trifluoromethyl)hexahydropyrimidi-
n-5-yl](4-methoxyphenyl)methanone (RK-2011) 
13C NMR (CDCl3): δ 196.21, 163.56, 154.07, 138.41, 133.82, 130.13, 129.22, 127.65, 
125.59, 113.25, 81.43, 55.00, 54.78, 46.67, 14.74 
IR (KBr Pellet): 3450cm-1(-OH), 3340cm-1(-NH),  2912-2950cm-1(C-H), 1685 cm-1        
(-C=O), 1674.12 cm-1 (-CO-NH), 1490-1510cm-1 (-NH Bend), 1206-1248 cm-1 (C-O-C), 
1170-1204cm-1 ( C-F) 
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[4-Hydroxy-6(3-chlorophenyl)-2-thioxo-4-(trifluoromethyl)hexahydropyrimidin-5-
yl](4-methoxyphenyl)methanone (RK-2012) 
IR (KBr Pellet): 3456cm-1(-OH), 3321cm-1(-NH), 2911-2976(C-H), 1678 cm-1(-C=O) 
1658 cm-1(-CO-NH), 1599 cm-1 (-NH Bend), 1170-1209 cm-1 (C-O-C),  1170-1181cm-1 
(C-F),  750-760 cm-1 (C-Cl) 
 
[4-Hydroxy-6(2-chlorophenyl)-2-thioxo-4-(trifluoromethyl)hexahydropyrimidin-5-
yl](4-methoxyphenyl)methanone (RK-2013) 
IR (KBr Pellet): 3435cm-1(-OH), 3320cm-1(-NH), 2976.26(C-H), 1670 cm-1(-C=O) 1659 
cm-1(-CO-NH), 1599 cm-1 (-NH Bend), 1223-1275 cm-1 (C-O-C),  1170 cm-1 (C-F),  750 
cm-1 (C-Cl) 
 
[4-Hydroxy-6(4-nitrophenyl)-2-thioxo-4-(trifluoromethyl)hexahydropyrimidin-5-
yl](4-methoxyphenyl)methanone (RK-2014) 
13C NMR (CDCl3): δ 182.32, 169.64, 165.85, 162.60, 146.52, 146.03, 145.30, 129.29, 
127.56, 125.72, 122.88, 113.97, 113.56, 107.12, 59.98, 54.93, 54.71 
IR (KBr Pellet): 3452cm-1(-OH), 3349cm-1(-NH),  2911-2946cm-1(C-H), 1697.63 cm-1        
(-C=O), 1656.23 cm-1 (-CO-NH), 1580.12 cm-1 (-C-NO2), 1498-1520cm-1 (-NH Bend), 
1107-1199 cm-1 (C-O-C), 1107-1182cm-1 ( C-F) 
 
[4-Hydroxy-6(2-nitrophenyl)-2-thioxo-4-(trifluoromethyl)hexahydropyrimidin-5-
yl](4-methoxyphenyl)methanone (RK-2015) 
IR (KBr Pellet): 3478cm-1(-OH), 3350cm-1(-NH),  2903-2922cm-1(C-H), 1710 cm-1        
(-C=O), 1662.35 cm-1 (-CO-NH), 1578 cm-1 (-C-NO2), 1510-1523cm-1 (-NH Bend), 1201-
1230cm-1 ( C-F)1112-1175 cm-1 (C-O-C)  
 
[4-Hydroxy-6(3-phenoxyphenyl)-2-thioxo-4-(trifluoromethyl)hexahydropyrimidin-5-
yl](4-methoxyphenyl)methanone (RK-2016) 
IR (KBr Pellet): 3445cm-1(-OH), 3326.65cm-1(-NH),  2910-2956cm-1(C-H), 1697 cm-1        
(-C=O), 1668.82cm-1 (-CO-NH), 1493-1520cm-1 (-NH Bend), 1190-1226 cm-1 (C-O-C), 
1050-1170cm-1 ( C-F) 
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Mass value of [4-Hydroxy-6 substituted-phenyl-2-thioxo-4-
(trifluoromethyl)hexahydropyrimidin-5-yl](4-methoxyphenyl) 
methanones 
Compound 
Code.No 
(m/z) 
Relative intensity 
RK-2001 470 (8 %) 
RK-2002 428-18 (9 %) 
RK-2003 489 (6 %) 
RK-2004 455 (11 %) 
RK-2005 440 (7 %) 
RK-2006 426 (8 %) 
RK-2007 440 (4 %) 
RK-2008 440 (5 %) 
RK-2009 444-18 (5 %) 
RK-2010 410 (7 %) 
RK-2011 456 (7 %) 
RK-2012 444 (5 %) 
RK-2013 444 (4 %) 
RK-2014 455 (10 %) 
RK-2015 455 (7 %) 
RK-2016 502 (8 %)  
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Spectra of the Representative compounds 
 
[a] 1H NMR Spectra of RK-2010 
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[b] 1H NMR Spectra of RK-2001 
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[c] 1H NMR Spectra of RK-2008 
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[d] 1H NMR Spectra of RK-2004 
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[e] 1H NMR Spectra of RK-2007 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
H
NH
O
O S
F3C
HO
OCH3
 
 
[4-Hydroxy-6-substitutedphenyl-2-thioxo… 
 
73
[f] 13C NMR of RK-2001 
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[g] 13C NMR of RK-2014 
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[h] 13C NMR of RK-2008 
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[i] 13C NMR of RK-2002 
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[j]     13C NMR of RK-2016 
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[k] 13C NMR of RK-2011 
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[l] IR Spectra of RK-2007 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[m] IR Spectra of RK-2015 
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[n] IR Spectra of RK-2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[o] IR Spectra of RK-2002 
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[p] EI-MS of RK-2009 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[q] EI-MS of RK-2010 
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Conclusion  
In the present work, the Biginelli type cyclocondensation of a fluorine containing 1, 3 
diketone have been studied. In analogy to the reaction of 1,3-diketone with different 
substituted benzaldehyde and urea, we find hexahydropyrimidine. These reactions were 
conventionally carried out in methanol in the presence of the catalytical amount of Conc. 
HCl for 5-6 hours providing hexahydropyrimidine products in moderate to good yields. In 
principle, one has to consider two isomeric structures for these condensation products, 
namely hexahydropyrimidine structure of type A or the isomeric acyclic ureidopropionate 
structure of keto and enol tautomers. 
It has to be mentioned that an earlier report on the condensation of 1,3-diketone with urea 
and benzaldehyde postulated the formation of the corresponding ureidopropionate B (R= 
CF3, R= 4-methoxyphehyl , X=O, S) under essentially similar reaction conditions. Based 
on comparison of melting points and spectral data, we assume that the identical material 
has been isolated. However, we assign the structure B of the corresponding 
hexahydropyrimidine of type A to this product based on the detailed spectroscopic 
characterization that we have carried out. 
 
N
H
NH
Ph
HO
R
R'
O
X
R
O O
R'
H
NHCXNH2Ph
HOr
A B  
 
 
The IR spectra of products are characterized by the absence of two narrow absorption 
bands corresponding to the asymmetric and symmetric vibration of the amino groups in 
structures B. However, sharp and intense signals for the hydroxy functionality in structure 
A are present in all cases. 
 In the 1H NMR spectra of compounds, the most characteristic signals are two doublets 
corresponding to the two trans-axial methine protons in A. The observed coupling 
constants (J=11.0-11.8 Hz) agree very well with the values previously found for our 
reference compound A. (R= CF3, R= 4-methoxyphehyl, X=O, S). It is therefore 
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reasonable to assume that the same relative stereochemistry as shown in A and ring 
orientation is observed in all cases 
In addition, the cyclic nature of compound was confirmed by 13C NMR spectroscopy. In 
the spectrum, a quartet for the carbon atom connected with the trifluoromethyl substituent 
is located at 79-81 ppm (3J(C-F) =31.1 Hz) which is typical for a quarternary carbon 
rather than a carbonyl carbon atom. Therefore, all the spectroscopic data clearly confirm 
the cyclic structure of type A for the products obtained. 
Non-symmetrical 1,3-diketones are employed in the above Biginelli-type 
cyclocondensation process two isomeric products may possibly be formed. Cyclization of 
the pyrimidine nucleus may occur on the carbonyl group at the fluorinated substituent or 
the carbonyl group connected with the non-fluorinated substituent to form the 
corresponding heterocycles C or D, respectively, or a mixture of both isomers. Literature 
data indicate that condensation of amines with non-symmetrical 1,3-diketones having one 
fluorinated substituent preferably occurs at the carbonyl group attached to the non-
fluorinated radical. 
N
H
NH
Ph
HO
R
R'
O
X
DR= CF3
R'=4-methoxy phenyl
X= O, S
C
N
H
NH
Ph
HO
R'
R
O
X
 
 
In the NMR spectra of compounds, signals for only one isomer are observable. The 
distinction between structures C and D was easily made on the basis of 13C NMR 
spectroscopic data, as the quartet signal of the carbon atom attached to the trifluoromethyl 
group (3JC-F=30-34 Hz) is located at 80.69 ppm, which is typical for a quarternary 
carbon atom (structure C,O-C-N) rather than carbonyl carbon in structure D. Thus, the 
above cyclocondensation occurs regioselectively on the carbonyl group at the fluorinated 
substituent. 
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In conclusion, we have synthesized a family of novel fluoroalkyl substituted 
hexahydropyrimidines by Biginelli-type three-component cyclocondensation reaction of 
fluorinated 1,3-dicarbonyl compounds with benzaldehyde and (thio)urea.  
 
The antimicrobial activities of these compounds are investigated against eight different 
bacterial strains. The results are shown in tabular form. Some of the shown in Tabular 
form. Some of the compounds show moderate activity but not comparable to Linezolid, a 
standard drug 
The other biological properties of these substances are currently under investigation. 
 
Antimicrobial Activity 
 
Background for antibacterial screening 
 
Antibiotic resistance is a serious concern worldwide as it would result in strains against 
which currently available antibacterial agents will be ineffective. In general, bacterial 
pathogens may be classified as either gram-positive or gram-negative pathogens. 
Antibiotics compounds with effective activity against both gram-positive and gram-
negative pathogens are generally regarded as having a broad spectrum of activity. The 
synthesized compounds were preliminary screened against gram-positive and gram-
negative pathogens.  
 
Gram-positive pathogens, for example Staphylococci, Entprococci, Streptococci and 
Micobacteria bacteria, are particularly because of the development of resistant strain 
which are difficult to eradicate from the hospital environment once established. Example 
of such strains are methicillin resistance staphylococcus (MRSA), methicillin resistance 
coagulase negative staphylococci (MRCNS), penicilline resistance streptococcus 
pnumoniae and multiplied resistance enterococcus faecium, community acquired 
pathogens (CAP), and so on. 
 
Quinolones as a class of antibacterial agents are well known and are being used 
extensively throughout the world. They are potent inhibitor of gram-positive and gram-
negative pathogens and may be administered orally or intravenously. A wide range of 
quinoline antibacterial has been introduced in the last decades which includes 
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norfloxacin, ciprofloxacin, ofloxacin and recently launched gutifloxacin and 
moxifloxacin.  
 
However, some of quinoline antibacterials have been associated with significant side 
effects. (J. Antimicrob. Chemother. 1994, 33, 685) and some of them have been 
discontinoued at different stage of development. (eg. Trovafloxacin)  
 
However, due to increase in antibacterial resistance and also otherwise there is a continue 
need for other compounds which are more effective against resistance bacteria, have 
improved intestinal absorption, metabolic stability and exhibit less toxicology.  
 
Protocol for antibacterial activity 
 
The minimum inhibitory concentrations (MIC) of the compounds for the microorganisms 
were determined by preparing working solution for each compound of concentration of 
128 µg/ml after dissolving it in DMSO. Two fold serial dilution of above solution was 
prepared in duplicate using Muller Hinton Borth, in well Tissue culture plate with cover 
flat bottom wells to give a final volume of 150 and concentration of compound ranging 
from 64 µg/ml -0.12 µg/ml. 30 µg/ml of Standard suspension of each organism which was 
prepared with turbidity equivalent to the 1:10 diluted 0.5 McFarland standard with 
density 107 CFU/ml. These 96-well tissue culture plate containing the test samples and 
positive and negative controls, were incubated at 37oC for 16-18 hours. The wells were 
visually inspected for growth and were also read at 630 nm by Automated Micropalte 
Reader [(EL800) Trinity Biotech] and the MICs were recorded as the lowest 
concentration of drug which inhibits the growth of bacteria. The compounds inhibited the 
growth of these bacteria with MICs in a range of about 0.25 to about 64 
 
Abbreviations  
Bp : Bacillus pumilus MTCC 1607 
S.e. : Staphylococcus epidermidis MTCC 155 
S.p. : Staphylococcus pyogenes MTCC 442 
S.a.1. : Staphylococcus aureus MTCC 96 
S.a.2. : Staphylococcus aureus ATCC 14154 
S.a.3. : Staphylococcus aureus ATCC 25923 
 
 
Synthesis, Characterization and Anti… 
 
86
S.a.4. : Staphylococcus aureus ATCC 29213 
E.f.1 : Enterococcus faecalis MTCC 439 
E.f.2 : Enterococcus faecalis ATCC 14506 
 
 
Table   MIC [minimum inhibitory concentration in vitro activity µg/ml] 
values of synthesized compounds in various Gram positive and Gram 
negative bacteria. 
 
Code Bp Se Sp Sa1 Sa2 Sa3 Sa4 Ef1 Ef2 
RK-1001 0.5 1 4 8 8 16 >8 64 2 
RK-1002 2 0.5 2 16 16 8 16 32 4 
RK-1003 4 4 1 32 16 32 >64 >32 2 
RK-1004 2 0.5 >16 >16 ND 16 32 16 8 
RK-1005 2 2 8 4 32 4 2 >8 >16 
RK-1006 4 1 2 ND ND ND ND 4 32 
RK-1007 2 4 1 >8 >32 >32 4 32 16 
RK-1008 2 0.5 4 >32 4 8 16 >8 8 
RK-1009 1 2 16 16 2 16 >16 4 4 
RK-1010 2 8 32 8 0.5 ND ND ND ND 
RK-1011 4 8 >32 ND ND 8 8 8 4 
RK-1012 2 4 64 >64 16 >8 16 8 8 
Linezolid 1 2 0.5 4 4 4 4 2 4 
 
 
Code Bp Se Sp Sa1 Sa2 Sa3 Sa4 Ef1 Ef2 
RK-2001 2 4 1 8 4 16 64 4 16 
RK-2002 1 8 4 8 8 32 16 8 8 
RK-2003 0.5 >16 2 16 16 64 >8 16 8 
RK-2004 4 8 8 ND ND 16 ND ND 8 
RK-2005 8 8 4 >32 16 4 >16 8 >32 
RK-2006 2 2 2 64 8 ND 32 8 64 
RK-2007 2 ND 2 ND ND 8 8 4 4 
RK-2008 4 4 2 8 64 16 16 16 16 
RK-2009 >8 2 4 4 32 ND ND >32 >64 
RK-2010 16 >16 8 8 16 32 8 8 32 
Linezolid 1 2 0.5 4 4 4 4 2 4 
 
 
Note:- ND = not done 
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Introduction 
Pyrimidine is a six membered heterocyclic compound consisting of two nitrogen atoms at 
1 and 3 positions of heterocyclic ring. 
 
 
 
Pyrimidines have been isolated from the nucleic acid hydrolysates. Pyrimidine ring 
carrying various substituents may be built up from two or three aliphatic fragments by the 
principle synthesis or by a variety of other syntheses, which are complimentary rather 
than alternative to it. An alternative method of synthesis is the isomerisation or break 
down of another heterocycles such as hydration of purine, but such methods are rarely 
used. Pyrimidine is best considered as a resonance hybrid to which the uncharged 
equivalent Kekule. In present chapter, pyrimidine derivatives such as 2-hydroxy-
substituted-pyrimidines are studied.     
Pyrimidines are among those molecules that make life possible, have been present in 
some of the building blocks of DNA and RNA. 
 Several analogues of pyrimidines have been used as compounds that interfere with the 
synthesis and functioning of nucleic acids e.g. fluorouracil, which has been used in cancer 
treatment. Also there are some thiouracil derivatives, which produce adverse reduction in 
susceptible patients and found more potent and less likely to produce side effects and is 
being widely used [1]. There are several other important groups of pyrimidines with 
medicinal uses. 
Structures 1, 2 and charged structures 3 and 8 contributes. The self consistent (pπ),  
electron densities required for the ground state of pyrimidine are 0.776, 0.825 and 1.103 
for positions 2, 4 and 5 respectively[2]. Despite considerable localization of (pπ) electrons 
at nitrogen atoms of pyrimidines, the ring system is still sufficiently aromatic to possess 
substantial stability. This has a great advantage in the primary synthesis of pyrimidines. 
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The first primary synthesis from aliphatic fragments was carried out by Frankland et al. in 
1848. Since then many distinct primary synthetic methods have been devised [3-12].  It is 
also possible to prepare pyrimidines from other     heterocyclic compounds such as 
pyrrole[13], imidazole[14], isoxazole and oxazole[15,16], pyridine[17], pyrazine[18], 
1,3,5-triazine[19], oxazine[20], thiazine[21] by different processes. 
 
Synthetic Methods for Pyrimidines 
Various methods for synthesis of pyrimidines which are reported in the literature are as 
follows. 
(a) By the condensation of urea and malonic acid led to formation of pyrimidine [22]. 
(b) By the condensation of malonic ester and urea led to formation of pyrimidine [23]. 
(c) By the condensation of formamide with phenylazomalononitrile led to 
 formation of 4,5,6-triamino pyrimidine [24].  
(d)      By the condensation of aromatic aldehydes, ß-ketoester or substituted ß- 
 ketoester with urea or thiourea led to formation of pyrimidines [25].  
(e)   By the condensation of thiourea and substituted ß-ketoester in presence of  sodium 
ethoxide led to formation of 2-mercapto pyrimidines [26] 
(f)        By the condensation of chalcones with dicyandiamide in presence of          
 piperidine led to formation of pyrimidines [27].        
(g)       By thermal or microwave irradiation of thiourea and substituted β-ketoester 
 in presence of dimethylformamide led to formation of substituted tetra         
 hydro pyrimidines. [28] 
(h) One pot synthesis of substituted dihydropyrimidin-2-ones catalyzed by CuCl2. 
[29] 
(i) Synthesis of 3,4-dihydropyrimidin-2-(1H)-ones/thiones under microwave 
 irradiation.[30] 
(j) One pot efficient and novel synthesis of dihydropyrimidin-2-(1H)-ones 
 catalyzed by Tin (II) chloride (SnCl2). [31] 
(k) By microwave induced eco-friendly solvent free Biginelli reaction catalysed 
 by calcium chloride. [32] 
Pyrimidines have found their applications as herbicidal [33] and pesticidal [34,35] agents. 
Yoshida et al., [36] have synthesized 4-amino-5-formyl-2-mercapto pyrimidines as 
agrochemical intermediates.  Srivastava C. et al., [37] have synthesized new substituted 
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pyrimidines (3) as potential insecticides. N. Yasushi et al.,[38] synthesized 6-(1-fluoro 
ethyl)-5-iodo-4-alkylamino pyrimidines (4) as pesticides for agriculture and horticulture. 
Besides such a great biological importance of pyrimidines, they also contribute to an 
important class of dye viz. trichloro pyrimidine [39] dye which is a reactive dye. 
Pyrimidines also have     applications in liquid crystal composition.[40] Many synthetic 
members of pyrimidines are important as vulcanizing accelerator agents and  photography 
stabilizer.[41]  
 
Pharmacological Importance of Pyrimidines 
 Numerous pyrimidines are well known drugs for variety of diseases. They may be placed 
in four categories viz. barbiturates, sulfonamides, antimicrobials and antitumor agents. 
Uracil, thymine, alloxan, vicine and divicine, cytosine, chroticacid, willardiline, 
tetradotoxine, becimethrian (A), blasticidine (B), cougerotin, amicetin, bamicetin and 
plicacetin, phleomicine, blemycin and related families (C). 
 
 
 
 
 
 
 
 
 
 
 
 
Pyrimidine derivatives have wide varieties of usages. Pyrimidine ring   system is also 
present in Vitamin B2 and folic acid. Pyrimidine ring system having a mercapto group 
occupy a unique position in medicinal chemistry.[42] These types of derivatives play a 
vital role in biological processes[43-45] as well as synthetic drugs.[46] 
 
Some of the therapeutic activities of pyrimidine derivatives can be summarized as 
follows. 
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Antithyroid [47,48]        Antitumor [49-51] 
Antihypertensive[52-54]                     Antiinflammatory [55-57]  
Diuretic [58]                      Antimalarial [59-61] 
           Antispasmodic [62]        Anticonvulsant [63] 
           Antineoplastic[64,65]        Anthelmintic [66] 
           Antimicrobial [67-92]        Cardiovascular [93-95] 
           Antiviral [96-99]            Platelet aggregation inhibitor [100-01] 
           Antihistamine[102,103]        Anti-HIV[104,105] 
           Antitubercular[106] 
 
The basis of any rational drug discovery programme is fundamently, the Medicinal 
Chemistry. Although the synthesis of modified nucleic acids has been a subject of interest 
for some time, the intense focus on the medicinal chemistry of oligonucleotides dates 
perhaps to not more than five years. As a result of this, the scope of medicinal chemistry 
has recently been expanded enormously, but the biological data of supporting the 
conclusions about synthetic strategies have just begun to emerge.  
Modifications in the base, sugar and phosphate moeities of oligonucleotides and 
oligonucleotide conjugates have been reported. The subjects of medicinal chemistry 
programmes include approaches to create enhanced affinity and more selective affinity 
for RNA or duplex structures, the ability to cleave nucleic acid targets, enhanced nuclease 
stability, cellular uptake and distribution, in vivo tissue distribution, metabolism and 
clearance. Although substantial progress in the medicinal chemistry of oligonucleotides 
has been made in the past three years, it is not yet possible to reach the conclusion about 
the therapeutic ability of the novel modifications. Preliminary data on      effects on 
nuclease stability and hybridization properties for a few modifications and activity in 
vitro suggest that the next generation of oligonucleotides may display substantially 
improved potencies and selectivity. 
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Pyrimidine Modifications (Nucleotide) 
A relatively large number of modified pyrimidines have been synthesized and now 
incorporated into oligonucleotides and evaluated. The principle sites of modification are   
C2, C4, C5 and C6. These and other nucleoside analogues have recently been thoroughly 
reviewed. [107]  
 
 
 
 
 
 
In as much as the C2 position is involved in Watson-Crick hybridization, oligonucleotides 
containing C2 alkyl modified pyrimidines have shown unattractive hybridization 
characters. However, an oligonucleotide containing 2-thio thymidine(D) was found to 
hybridize well to DNA and, in fact even better to RNA with a thermal melting 
temperature (DTm) value of 1.5°C/modification. In a different study, oligoribonucleotides 
with 2’-O-methyl-2-thiouridine(E) exhibited a thermal melting temperature (DTm) value 
of +5.5°C/modification when hybridized against RNA resulting from a highly 
preorganized RNA-like C3’-endo conformation (attributed to the combination of 2-thio 
modification and 2’-O-Me substituent). Oligonucleotides with this modification also 
exhibit better hybridization discrimination for the uracil-guanosine (U-G) base pair 
formation compared to the normal uracil-adenine (U-A) base pair. This selectivity is a 
result of weaker hydrogen bonding and increased steric bulk of 2-thiocarbonyl group. 
[108] 
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In contrast, the pyrimidine modifications in 4-position with interesting properties have 
been reported. 4-Thiopyrimidines(F,G) have been incorporated into oligonucleotides with 
no significant negative effect on hybridization. However, recent studies have shown 
destabilization in the normal uracil-adenine (U-A) base pair formation and stabilization of 
the wobble uracil-guanosine (U-G) base pair for 4-thiouridine. A bicyclic and an 4-
methoxy analog of cytosine were shown to hybridize with both purine bases in DNA with 
thermal melting temperature (Tm) values approximately equal to that of natural base 
pairs.  Additionally, a fluorescent base has been incorporated into oligonucleotides and 
shown to enhance DNA-DNA duplex stability. [109] 
 
 
 
 
 
 
 
 
The pyrimidine modifications at C5 position including halogenated nucleosides have been 
reported. Although the stability of duplexes may be enhanced by incorporation 5-
halogenated uracil containing nucleosides, the occasional mispairing with guanidine and 
the potential that the oligonucleotide might degrade and release toxic nucleosides analogs 
cause concern. Oligonucleotides containing 5-propynylpyrimidine (I, J) modification 
have been shown to enhance the duplex stability thermal melting temperature (DTm = 
1.6°C/modification ), and support RNase H activity. The 5-heteroaryl-pyrimidines were 
also shown to  increase the stability of duplexes . A more dramatic influence was reported 
for the tricyclic 2’-deoxycytidine analoges, termed phenoxazine, exhibiting an 
enhancement of 2-5°C/modification, depending on the positioning of the modified bases. 
[110] 
 
 
 
 
 
NH
N
S
O
O
O
O
NH
N
S
O
O
O
O OH
(G)(F)
 
 
Synthesis and Characterization of N-cyclo…. 
 
100
 
 
 
 
 
 
 
 
 
 
As expected, modifications in the C6 position of pyrimidines are highly destabilizing. 
Oligonucleotides containing 6-azapyrimidines(K) have been shown not only to reduce the  
thermal melting temperature (Tm) value by 1-2°C per modification, but also to enhance 
the nuclease stability of oligonucleotides and to support E. coli RNase H-induced 
degradation of RNA targets.[111] 
The increasing interest in the early 1970s in properties and use of interferon (IFN) 
together with the difficulty in producing useful amounts of interferon (IFN) led to the 
search for agents that would induce IFN in the host. Precedenced at that time for 
interferon (IFN) inducers included viruses and bacterial wall constituents and entities of 
large molecular weight such as the polynucleotides. There were also several examples of 
low molecular weight substances such as certain antibiotics and the antiviral agent, 
tilorone.[112-113] In 1976, it was reported that 6-methyl pyrimidinone (2-amino-5-
bromo-6-methyl-4-(3H)pyrimidinone, ABMP) induced circulating levels of interferon 
(IFN) in several animal specis upon oral or intraperitoneal administration.[114] 
Subsequent structure-activity studies yielded a more potent and less toxic 6-phenyl 
ananlog called ABPP or bropirimine (2-amino-5-bromo-6-phenyl-4-(3H)pyrimidinone) 
(figure 1 and Table 1).[115,116] Bropirimine and related 6-aryl analogs were examined 
extensively for efficacy in virus and tumor models, along with their immunomodulatory 
properties and overall pharmacological effects.[117] 
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Preliminary SAR of antiviral activity of pyrimidinones 
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Anti viral  activity spectrum of pyrimidines 
 
Monosubstituted Disubstituted Heterocyclic 
Active 
2-F,OMe, Me, 3-
F,OMe, 2-Cl, NO2, 
Me, CF3, 
MeCH2CH2O, Br, 
I, 4-F, 4-Cl 
3,5-OMe, 2,5-Cl2, 
3,5-OMe, 3,4-Cl2, 
3,5-Cl2 
1-Naphthyl, 2-Furyl, 
2,3-pyridyl, 
2-Pyrazyl 
 
 
Inactive 
4-Me, CN, Butyl, 
OH,OCH2ph, OMe 
2,3-OMe 
2-Napthyl, 1-Furyl, 
4-Pyridyl, 
2-Quinoline 
        
As with the polynucleotides, the pyrimidinones exhibited significant activity against 
interferon (IFN) sensitive viruses such as Semliki Forest virus in vivo. However, in 
addition, they exhibited prophylactic and therapeutic activity upon either local or 
systemic administration to rodents infected with a variety of DNA viruses, such as the 
herpes viruses (HSV-1, HSV-2 , CMV and pseudorabies), and when administered 
intranasally for upper respiratory infections, such as infectious bovine rhinortacheites, 
influenza A and para-influenza-3. Particularly interesting activity was noted with 
bropirimine on intravaginal administration in protection against HSV-2 intravaginal 
infection in guinea pigs, an important model for genital herpes in humans. [118] 
Bropirimine also exhibited activity when given either intraperitoneally or orally to mice 
infected with Listera monocytogenes. The efficacy in this model was not abrogated by the 
addition of anti-interferon (IFN) antibody. [119] 
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Pyrimidines as Antifolates 
During a preliminary clinical trial designed to establish safety and suitability for use in 
the treatment of cancer, Farber found the folic acid derivatives pteroyldiglutamic acid (1) 
and pteroyltriglutamic acid (2) were accelerating the growth of malignant cells in the 
bone marrow of patients with acute leukemia. He obtained the newly synthesized 
antifolate pteroylaspartic acid from a natural product, from which encouraging results 
were obtained in children with acute leukemia. Better responses were observed with the 
aminopterin (3) and methotrexate(4). Injections of methotrexate induced temporary 
remissions in 30% of children, but Farber and his colleagues later combined it with drugs 
such as cortisone and mercaptopurine to achieve results which paved the way towards the 
currentposition where most children can be cured of the disease if given the appropriate 
treatment. The precise model of action of the antifolates became apparent in 1952. This 
was the inhibition of dihydrofolate reductase, the enzymes that catalyzed the 
transformation of folic acid so that it could be utilized for the synthesis of thymine for 
incorporation into DNA. Surprisingly, no other antifolate has emerged to rival 
methotrexate in the treatment of either acute leukemia or cancers.  
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5-Azacytidine ( Azacitidine; 5) the most active of the azapyrimidines, shows substantial 
activity in the treatment of murine and human leukemia, but little useful activity against 
solid tumours.[120] It is phosphorylated in vivo to the mono-,di- and tri- phosphate levels, 
and inhibits nucleic acid synthesis and function. In calf thymus nuclei, the synthesis of 
mRNA is inhibited, while the incorporation of 5-azacytidine into tRNA decreases amino 
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acid acceptor activity for most of the amino acids, further suppressing protein synthesis. 
[121] 
5-Azauracil (6) and 5-azaorotic acid (7) are competitive inhibitors of orotate 
phosphoribosyltransferase [122] and show activity against adenocarcinoma 755, but not 
against LI210 leukemia. 
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6-Azauridine (8) was formerly used to treat chronic myelogenous and acute leukemia 
[123], as well as psoriasis and mycosal infection. For the latter conditions, it was applied 
as its prodrug 2’,3’,5’-tri-O-acetyl-6-azauridine ( Azaribine; 9) which has been withdrawn 
from the market. 6-Azauridine is phosphorylated in vivo to it’s 5’-monophosphate, which 
inhibits orotidylic acid   metabolism, is primarily responsible for it’s cytotoxic effects. 
Halogenated Pyrimidines & Their Reactivity 
Of the various halogenated pyrimidines which have been prepared, only the fluorinated 
pyrimidines and nucleosides have useful antitumor activity, and of these, the most 
significant are 5-fluorouracil (FU) and it’s 2’-deoxyribo- nucleside (FUdR; Floxuridine). 
Both of these drugs have found wide uses in patients suffering from metastatic cancer, 
and have been administered both singly and in combination therapy. 
The presence of fluorine, which cannot be abstracted by base, halts the process. In 
contrast, the 5’-monophosphate of 5- chloro-, 5- bromo- and 5-iodo-2’-deoxyuridine, in 
which the halogen atom is bulkier and less electronegative, have little or no useful 
inhibitory activity for the enzyme. The drugs of fluorouracil (FU) showing good 
antitumour activity includes it’s 1-t-butylcarbamoyl[124],1-hexylcarbamoyl [125] and 1-
methoxycarbonylmethylcarbamoyl[126]derivatives, 5’-deoxy-5-fluorouridine[127] and 
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methyl-1-(5-fluoro-(1H)-2-oxopyrimidin -4-yl)-B-D-glucopyranuronate (26).[128] All of 
these contain in essence the fluorouracil (FU) moiety, ready via oxidative or hydrolytic 
means. 5-Fluoropyrimidin-4(1H)-one, with activity against tumors in experimental 
animals, is a different type of prodrug, being oxidized to 5-fluorouracil (FU) by xanthine 
oxidase.[129] 
A number of prodrugs of (FUdR; Floxuridine) have also been prepared a notably potent 
member being 5-bromo-6-methoxydihydro-5-fluro-2’-deoxyuridine (10).[130]  finally, a 
different species of fluoro-pyrimidine derivative, which as its 5’-monophosphate inhibits 
thymixylate synthetase is 5-trifluoromethyl-2’-deoxyuridine ( Trifluridine ; 11,12) it 
possesses a higher therapeutic index against adenocarcinoma 755 in mice than 2’-
deoxyribo-nucleoside (FUdR; Floxuridine).[131]  
 
 
  
 
 
 
 
 
 
                      (10)    (11)           (12) 
 
Pyrimidines as Antitumor Agents 
A number of other pyrimidine antagonists displaying antitumor activity, in which the base 
is conjugated to a modified sugar ring have been reported. Although D-Arabinofuranosyl 
uridine (ara-uridine) shows no useful acitivity,  and 5-bromo-and 5-iodo-D-
arabinofuranosyl uridine inhibit the growth of  sarcoma 180 and L1210 cells in 
culture.[132] Other thymidine analogues with similar activity include 5-azidomethyl-,5-
aminomethyl and 5-hydroxymethyl-2’-deoxyuridine[133].3’-Amino-3’-deoxy 
thymidine[134] and 3’-amino-2’,3’-dideoxycytidine[135] also posses strong activity 
against L1210 leukaemia 2’-Deoxy-2’-fluoro-5-methyl-1-B-D-arabinofuranosyluracil 
(FMAU; 29) is highly active against arabinofuranosyl cytidine (ara-C) resistant L1210 
and P815 cell lines both in vitro and in vivo.[136] 2-B-D-Ribofuranosylthiazole-4-
carboxamide (Tiazofurin; 30) has aroused much interest recently for its activity against 
solid tumor such as lung carcinoma. It is metabolized to an analogue of NAD in which 
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the thiazole-4-carboxamide moiety replaces the nicotinamide ring. However, it also 
depresses the synthesis of DNA and RNA, and thus merits inclusion as an antagonist of 
normal purine and pyrimidine metabolism. [137] 
 
Target for Antiviral Chemotherapy 
Viral chemotherapy presents a quite different problem from tumor chemotherapy. A virus 
[138] consists of a core of nuclear material, DNA or RNA, containing specific viral 
genes, which may be associated with ‘core proteins’, and which is surrounded by a 
protective protein coat. The coat may have functional protein appendages, and there may 
be present an ‘envelope’, rich in lipoprotein and glycoprotein. The virus possesses no 
energy-producing or protein-synthesizing machinery of its own. In order to reproduce, it 
must therefore become adsorbed to a host cell, be transported across the cell membrane, 
and uncoat in order that its viral genes may be expressed. The genome may require to be 
transported to the cytoplasm or the nucleus. The nuclear material must then be replicated, 
and the viral genes also transcribed into RNA (assuming that we are dealing with a DNA 
virus) and translated into virally specified protein. In addition to the coat protein, viral 
enzymes will be produced in this process, and these are vital for suborning the host cell’s 
internal biochemistry to serve the requirements of the virus. Before the viral proteins can 
be made, a process of maturation of the viral mRNA molecules, involving guanylylation 
and methylation to produce a ‘cap’ structure containing 7-methylguanosine 5’-phosphate 
in a 5’- 5’-pyrophosphate structure at the 5’- end of the mRNA, must occur. Once the 
synthesis of the    components needed to make fresh viral particles has been completed, 
maturation occurs, in which the nucleic acid and protein components are assembled to 
from the complete viral particle or virion, and finally this is released from the cell as a 
new , infective virus. RNA viruses require that their nucleic acid be replicated also, in 
order that new viral particles can form. Some RNA viruses code for an enzyme 
‘transcriptase’ or ‘replicase’ (RNA-directed RNA polymerase), which  replicates RNA 
strands directly without involving DNA[139] while others encode an enzyme ‘reverse 
transcriptase’ (RNA -directed DNA polymerase), which transcribes the RNA sequence 
into DNA-the reverse of the usual sequence which can subsequently become integrated 
into the host cell chromosome and is transcribed to from copies of the viral RNA.[140] 
Purine and pyrimidine antimetabolites which are active against viruses are thus most 
likely to be effective by inhibiting specifically the viral enzymes which are required to 
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replicate the viral nucleic  acids, or inhibiting the viral enzymes responsible for 
transcription and capping of mRNA, without  inhibiting the corresponding enzymes of the 
host cell.  
Alternatively, incorporation of an antimetabolite into a viral nucleic acid causing the 
cessation of strand synthesis, or otherwise disturbing the normal function of the nucleic 
acid in replication or in directing protein synthesis, offers another way of preventing the 
replication of functional virus.[141] Again, it is important that the integrity of the nuclear 
material of the host cell should not be compromised. One therefore seeks to exploit the 
differences between the viral enzymes to the discomfiture of the virus. 
5’- Amino-5-iodo-2’,5’-dideoxyuridine(Aminoidoxuridine; 16) displays good antiherpes 
activity and is less cytotoxic than (15).[142,143] The phosphorylation of 
Aminoidoxuridine(16) is catalyzed specifically by virus-induced thymidine kinase, and 
thus Aminoidoxuridine(16) is only potentiated in virus-infected cells. It inhibits the 
synthesis of DNA in infected cells. The 5-bromo-, 5-chloro- and 5-trifluoro-methyl 
derivatives of 5’-amino-2’,5’-dideoxyuridine also exhibit antiviral      activity[144]. 5-
Iodo-2’-deoxcytidine (17) and 5-bromo-2’-deoxycytidine (18) also show useful activity 
against herpes viruses and vaccinia with less cytotoxicity than the uridine compounds and 
more selective inhibition of virus replication. 
 
 
 
 
 
 
 
 
Pyrimidines as Anti-HIV Agents 
The strategy of designing nucleoside analogs that are selective for viral DNA 
polymerases is the most well-studied and successful approach to viral chemotherapy, and 
has led to the discovery of several clinically useful antiviral drugs. This strategy, 
however, has inherent limitations. Human DNA polymerases also required dNTP’s and 
the chemical mechanisms of polymerization by the viral and human enzymes are similar. 
Nucleoside analogs often have significant host toxicity that is probably related to 
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inhibition of host cell DNA synthesis. These compounds constitute the major class of 
antiviral drugs, and this approach is likely to yield additional active compounds in the 
near future. For the long term, however, other strategies may ultimately lead more 
selective agent within lower toxicity. 
Obviously, the key to design analogue with a lower affinity for the host enzyme than the 
viral enzyme, which requires that there be structural differences between the enzyme 
active sites. For reverse transcriptase, the most well studied inhibitor is 3’-azido-3’-
deoxythymidine (AZT; 19), which is currently used clinically to treat AIDS. [145,146] 
 
 
      
 
 
 
 
3’-azido-3’-deoxythymidine (AZT) inhibits HIV reverse transcriptase with an IC50 of 
40nM[147], but is 100-300 times less active against mammalian DNA polymerase a and 
DNA polymerase g. The reason for this selectivity is not clear since 3’-azido-3’-
deoxythymidine (AZT) is a chain terminator for mammalian DNA polymerases and 
inhibits normal cellular DNA synthesis.[148] Several other dideoxynucleoside analogs 
have been shown to be potent inhibitors of HIV replication in vitro.[149,150] In general, 
these compounds have the same mechanism of action as 3’-azido-3’-deoxythymidine 
(AZT), that is, intracellular conversion to the triphosphate derivative and subsequent 
inhibition of HIV reverse transcriptase. Some of these compounds are simply analogs of 
the natural 2’-deoxy- nucleoside in which the 3’-OH group has been replaced with a 
hydrogen, such as 2’,3’-dideoxycytidine(20), 2’,3’-dideoxyadenosine(21) and 2’,3’-
dideoxy thymidine(22). Other analogs contain a 2’-3’ double bond, such as 2’3’-
didehydro-2’,3’-dideoxythymidine (23). Several related analogs with other modifications 
to the ribose ring or the heterocyclic base moiety have also been reported to have activity 
against HIV or HIV reverse transcriptase.[151,152]   
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Recently, P. Khalili et al.[153] have carried out biochemical and pharmacokinetic 
evaluation of a novel nitric oxide donor pyrimidine nucleoside hybrid drug as a potential 
anticancer / antiviral agent. Rostom et al.[154] have synthesized and screened certain 2-
(benzoxazol-2-yl-amino)-3H-4-oxopyrimidines for in vitro anti-HIV activity. 
A family of trisubstituted pyrimidines has been described as selective COX-2 inhibitors. 
To explore the usefulness of pyrimidine derivatives as potential NSAIDs. Aurelio Orjales 
et al [155] have synthesized novel pyrimidine derivatives 40 and 41. In vitro biological 
evaluation of these compounds has provided information to determine the structural 
features necessary for COX-2 inhibitory activity.   
 
 
 
 
 
 
 
George L. Trainor et al synthesized & reported cyclic urea derivatives as a HIV protease 
inhibitors. They describe the potency, efficacy, bioavailability, structure activity 
relationship of cyclic urea derivatives. Some of the cylic urea compounds depicted below, 
active against HIV protease inhibitors [156] 
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Pyrimidines as a Melanin-Concentrating Hormone 1 Receptor 
 
Mohammad R. Marzabadi et al synthesized and carry out SAR Investigations for Novel 
Melanin-Concentrating Hormone 1 Receptor (MCH1) Antagonists. Melanin-
concentrating hormone (MCH) is a cyclic peptide originally isolated from salmonid 
pituitaries, where it was named for its ability to cause aggregation of melanin within skin 
melanophores, resulting in skin lightening.[157] Mammals, MCH is a cyclic 19-amino 
acid neuropeptide that is produced predominantly by neurons in the lateral hypothalamus 
and zonaincerta, which project broadly throughout the brain.[158]Mammalian MCH is 
highly conserved between rat, mouse, and human species, exhibiting 100% amino acid 
identity.2 The biological function of MCH is mediated by two receptors, MCH1 receptor 
and MCH2 receptor, which have been identified in several species, including human, 
rhesus monkey, ferret, and dog; [159] however, functional MCH2 receptor has not been 
found in rat, mouse, hamster, guinea pig, or rabbit.[160] Recent reports have suggested 
that the MCH peptide plays a major role in regulation of food intake and stress in 
rodents.[161] For example, the central administration of MCH stimulates food intake, 
while fasting results in an increase in MCH expression.[162] Furthermore, mice lacking 
the gene encoding MCH are lean, hypophagic and maintain elevated metabolic 
rates.[163] In contrast, mice over expressing the MCH gene are susceptible to obesity and 
insulin resistance.[164] In addition, MCH seems to be an activator of the HPA stress 
axis.[165] These findings suggest that small-molecule antagonists of the MCH1 receptor 
can potentially be used in the treatment of obesity and mood disorders.[161] The high-
throughput screening of Lund beck GPCR-directed compound collection identified 
dihydropyrimidines  as a high affinity and selective MCH1 receptor antagonist. The in 
vitro and in vivo properties of dihydropyrimidines were described recently.[166] 
However, experience with dihydropyrimidines as a highly metabolized and hydrolyzed 
analog resulting in low bioavailability, as well as experience with previously described 
dihydropyrimidinone substituted compounds,[167] prompted a search for alternative 
templates to circumvent hydrolysis and metabolism issues. 
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Pyrimidine as a HIV Reverse Transcriptase and Integrase 
 
Robert Vince et al synthesized Dual Inhibitors of HIV Reverse Transcriptase and 
Integrase. Inhibitors of HIV RT and protease (PR) constitute the core of chemotherapy for 
AIDS treatment.[168] The therapeutic effect of nucleoside RT inhibitors (NRTIs) is 
greatly hampered by their intrinsic toxicity,[169, 170] whereas the less toxic protease 
inhibitors (PIs) and non-nucleoside RT inhibitors (NNRTIs) are severely compromised by 
the quick emergence of resistant viral strains.[171, 172] In general, disease resistant to a 
single-target therapy can be mitigated by developing multitarget therapies. In the case of 
AIDS, highly active antiretroviral therapy (HAART)[173] combines NRTIs with NNRTIs 
or PIs and successfully suppresses HIV viral load to an undetectable level, dramatically 
improving the life quality of AIDS patients.[174] 
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Silvana Raic´-Malic et al synthesized 5-Substituted Pyrimidine Furo[2,3-d]pyrimidine 
4,5-Didehydro-L-ascorbic acid derivatives  and carried out antiviral and cytostatic 
evaluations.[175] 
 
 
 
 
 
 
 
C. Erec Stebbins et al carried out Multiple Conformational Virtual Screening for the 
Discovery of Yersinia Protein Kinase A Inhibitors. Yersinia spp. is currently an antibiotic 
resistance concern and a re-emerging disease. The essential virulence factor Yersinia 
protein kinase A (YpkA) contains a Ser/Thr kinase domain whose activity modulates 
pathogenicity.[176] 
 
 
 
 
 
 
 
 
 
Mycobacterium tuberculosis (M. tuberculosisa), Mycobacterium avium (M. avium), and 
Mycobacterium bovis (M. bovis) are clinically significant species of the genus 
Mycobacterium that are causative agents of tuberculosis (TB), killing over 2-3 million 
people annually worldwide.[177] TB bacilli are highly contagious, airborne, slow-
growing, gram-positive, aerobic, acidfast mycobacteria. The World Health Organization 
(WHO) estimates that between 1 and 2 billion people are latently infected with TB 
bacilli.[178-180] Approximately 8 million people develop active disease each year.[181] 
TB is the world’s second most common cause of death from infectious disease, after 
acquired immuno deficiency syndrome (AIDS).[182] TB and human immunodeficiency 
virus (HIV) have formed a new and deadly combination. There is resurgence in the 
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incidence of TB in developed and developing countries with high rates of HIV-TB 
coinfection. The increase in TB incidence is strongly associated with the prevalence of 
HIV infection.[183] M. tuberculosis and M. avium pose a significant challenge to the 
clinical management of tuberculosis in HIV-infected patients and are often responsible 
for their death.[184] For both TB and HIV, misdiagnosis and noncompliance with 
treatment regimens further compound the problem and facilitate the development of drug 
resistance.[183, 185] A number of pyrimidine nucleoside derivatives in which the 2'-
hydroxyl group has the opposite configuration (1-β-D-2'- arabinofuranosyl) to that of a 
ribonucleoside, exhibit potent antiviral, and anticancer properties.[186, 187] 
 
 
 
 
 
 
Peter Wipf et al generated focused library of 30 tetrahydropyrimidinone amides was 
prepared. The design was based on the structure of an Hsp70 modulator. This small 
library demonstrates the utility of tandem multi-component reactions in structure–activity 
relationship studies of biological lead molecules. The tandem Biginelli–Ugi multi 
component reaction facilitated the effective variation of four different substituents and 
allowed the synthesis of the library members in a sequence of only two one-pot 
reactions.[188] 
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06 
Reaction Scheme 
Step-I 
 
 
 
 
 
Step-II 
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Experimental procedure 
Step-I 
Preparation of N-Cyclohexyl-4-methyl-3-oxopentanamide 
3.0 ml concentrated KOH solution in water was added into 23.6 ml (0.206mol) 
cyclohexylamine and stirred well until the clear solution was observed. 25 ml (0.175mol) 
methyl-4-methyl-3-oxo pentanoate was added into it, stirred for five minutes, 
exothermicity was observed. 150 ml   toluene was added into it and refluxed for 6-7 
hours, TLC was checked for the completion of the reaction, slight starting materials 
remain unreacted. Reaction mixture was cooled to room temperature, it was added into 
250 ml 5% HCl solution, it was transferred into separating funnel, and toluene layer was 
collected. Toluene layer was again washed with 100 ml 5% HCl solution and twice with 
100 ml of water and 50 ml Brine solution. Organic layer was collected, dried over 
anhydrous sodium sulphate. Solvent was distilled out by using rotavapor at 40oC, Oily 
residue was observed. 50 ml Pet. Ether was added into it and kept in refrigerator, stirred 
well for 30 minutes at 20oC. Pet. Ether was decanted. Again 50 ml Pet. Ether was added 
and scratched out at 20oC. Solid product was separated; it was dried in an oven. 
TLC System: (Hexane: Ethyl acetate) 
                                8    :        2 
Yield: 65%    MP:-130-132OC 
 
 
Step-II 
Preparation of N-Cyclohexyl-1,2,3,4-tetrahydro-6-isopropyl-2-oxo-4-(Substituted) 
phenyl pyrimidine-5-carboxamide (General Method) 
In 100 ml RBF 1.5 equivalent Urea and 15 ml of methanol was added and heated until 
clear solution was observed. It was cooled to room temperature. 1.0 equivalent of N-
cyclohexyl-4-methyl-3-oxopentanamide and an aldehyde and 1-2 drops of Con. HCl was 
added into above solution and stirred for 6-7 hours at reflux temperature. In some cases 
solid products were obtained. It was filtered and washed twice with 20 ml of methanol. It 
was again purified by methanol at reflux temperature if needed. If solid product is not 
obtained, then reaction mixture was kept in a refrigerator for 5-6 hours. Solid product was 
separated 10 ml methanol was added into it and heated for 5 minutes. It was filtered and 
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washed twice with 10 ml of methanol. It was again purified by methanol at reflux 
temperature, if needed. 
TLC System: (Chloroform: Methanol) 
                                       7    :    3 
Yield: 57-72% 
The physical data are given in table No. 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Physical constants of N-cyclohexyl-1,2,3,4-tetrahydro-6-isopropyl-2-oxo-4-
substitued phenylpyrimidine-5-carboxamides 
 
 
 
 
 
 
 
Table No. 3 
C, H , N Analysis 
 Sr. No Code.No 
 
Substitution 
R 
M.F M.W M.P 
C H N 
1 RK-4001 H C20H27N3O2  341.45 141-143 65.61 (65.64) 
6.29 
(6.21) 
21.86 
(21.80) 
2 RK-4002 4-SCH3 C21H29N3O2S  387.53 145 59.58 (59.50) 
6.00 
(5.92) 
18.53 
(18.42) 
3 RK-4003 4-OCH3 C21H29N3O3  371.47 137-139 62.92 (62.81) 
6.34 
(6.30) 
19.57 
(19.51) 
4 RK-4004 2-Cl C20H26ClN3O2  375.89 151-152 57.83 (57.71) 
5.20 
(5.40) 
19.27 
(19.11) 
5 RK-4005 3-Br C20H26BrN3O2  420.34 158-159 50.16 (50.11) 
4.51 
(4.56) 
16.71 
(16.69) 
6 RK-4006 2-NO2 C20H26N4O4  386.44 143-145 55.81 (55.78) 
5.02 
(4.99) 
23.24 
(23.19) 
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Table No. 3 
C, H , N Analysis 
 Sr. No Code.No 
 
Substitution 
R 
M.F M.W M.P 
C H N 
7 RK-4007 4-NO2 C20H26N4O4  386.44 158-160 55.81 (55.78) 
5.02 
(5.05) 
23.24 
(23.18) 
8 RK-4008 3-Cl C20H26ClN3O2  375.89 131-133 57.83 (57.80) 
5.20 
(5.18) 
19.27 
(19.25) 
9 RK-4009 3-NO2 C20H26N4O4  386.44 166-068 55.81 (55.78) 
5.02 
(5.07) 
23.24 
(23.19) 
10 RK-4010 2-OCH3 C21H29N3O3  371.47 135-137 62.92 (62.90) 
6.34 
(6.31) 
19.57 
(19.52) 
11 RK-4011 4-Cl C20H26ClN3O2  375.89 143-145 57.83 (57.80) 
5.20 
(5.24) 
19.27 
(19.25) 
12 RK-4012 3-OCH3 C21H29N3O3  371.47 139-141 62.92 (62.94) 
6.34 
(6.31) 
19.57 
(19.59) 
13 RK-4013 3,4-di OCH3 C16H20N4O3  316.35 157-159 60.75 (60.71) 
6.37 
(6.41) 
17.71 
(17.72) 
14 RK-4014 3,4,5-tri OCH3 C17H22N4O4  346.38 165-166 58.95 (58.92) 
6.40 
(6.42) 
16.17 
(16.20) 
15 RK-4015 3-OPh C20H20N4O2  348.4 178-179 68.95 (68.93) 
5.79 
(5.83) 
16.08 
(16.11) 
16 RK-4016 2-OH C14H16N4O2  272.3 150-152 61.75 (61.72) 
5.92 
(5.90) 
20.58 
(20.61) 
17 RK-4017 3,4 di OH C14H16N4O3  288.3 169-171 58.32 (58.30) 
5.59 
(5.57) 
19.43 
(19.48) 
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Spectral discussion  
 
 
1H NMR spectral study 
 
1HNMR of the synthesized N-Cyclohexyl-1,2,3,4-tetrahydro-6-isopropyl-2-oxo-4-
substitued phenylpyrimidine-5-carboxamides were recorded on DPX-300MHz FT-NMR 
spectrophotometer (Bruker) instrument using TMS (Tetramethyl silane) as an internal 
reference standard in DMSO-D6 solvent. Numbers of proton identified from NMR 
spectrum and their chemical shift (δ ppm) were in agreement of structure of molecule. 
Isopropyl methine (-CH) proton gave a multiplet at 2.9-3.4 δ ppm. Both methyl groups of 
isopropyl chain protons gave a multiplet at 0.8-1.6 δ ppm and merge with cyclohexyl’s 
methelyne protons as cyclohexyl proton gave a multiplet in the range of 0.8-1.6 δ ppm. 
The proton on C4 carbon atom gave a singlet in range of 5.12-5.80 δ ppm. Aromatic 
protons were observed between 6.7-7.8 δ ppm. J values were calculated to identify ortho 
and meta coupling. In some typical cases, aromatic protons were obtained as multiplet. 
Singlet observed for the (–NH) proton attached to cyclohexyl ring & both cyclic (–NH) 
were gave a in the aromatic ring at 6.8-7.8 δ ppm. (For further details see individual 
compound Spectral data and 1H NMR Spectrum)   
 
13 C NMR Spectral study 
13C NMR spectra of synthesized N-Cyclohexyl-1,2,3,4-tetrahydro-6-isopropyl-2-oxo-4-
substitued phenylpyrimidine-5-carboxamides were recorded on Bruker 400MHz 
instrument using DMSO-d6 as the solvent with tetramethylsilane (TMS) as the respective 
internal standard. The chemical shifts were recorded in ppm. Numbers of carbon present 
in the parent molecules investigate are comparable with the experimental and 13C spectral 
evidences. The carbon C4(Asymmetric) of  pyrimidine ring appear around 45-50 and 
carbon of the cyclohexyl ring which attached to the –NH is appears around 43-70 δ ppm. 
The both methyl group of isopropyl chain show around 18-23 δ ppm. In such cases, two 
the methyl group show single peak, instead of two different peaks. Quaternary carbon 
atom of the pyrimidine nucleolus appears between 100-105 δ ppm. The aromatic carbon 
atoms of the phenyl ring appear around 124-145 δ ppm. The carbonyl carbon of the cyclic 
ketone appears at 148-153 δ ppm and ketone of the amide linkage is 159-165 δ ppm.  
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DEPT 135 
The presence of all five methylene groups, two methyl groups and methine are also 
confirmed by DEPT-135 experiment of the selected compounds.  
Mass spectral study 
 
Mass spectra were recorded on Shimadzu GC-MS-QP-2010 model using Direct Injection 
Probe Technique. The molecular ion peak was found in agreement with molecular weight 
of the respective compound. DHPMs having chlorine atom showed characteristic M+2 
peak. Characteristic M+2 ion peaks with one-third intensity of molecular ion peak were 
observed in case of compounds having chlorine atom. In some cases M-14, M-28, M-42 
peaks were observed due to the cleavage of the cyclohexyl ring present in parent DHPMs. 
Fragmentation pattern and mass values are for each compound summarized below. 
1. Cleave of C-N bond (adjacent bond to C=O bond at carbamoyl side chain at C-5 
position) gave intense peak in each spectrum.  
2. Cleavage of methyl group at C-6 position from above fragment gave characteristic 
peak at m/e value less than 15.  
3. Cleavage at chiral carbon of DHPMs, which gives substituted phenyl derivatives 
peak. 
4. In some cases bond breaking between C=O and C-5 position of the DHPMs gave 
peak at M-112. 
 IR spectral study  
 
Different functional groups present in the molecule were identified by distinguishing 
frequency obtained by their functional groups. Presence of two carbonyl groups is 
confirmed by IR spectra as two different carbonyl stretching frequencies were observed. 
Cyclic C=O group peak was observed between 1680-1710 cm-1 while another C=O group 
due to amide linkage (NH-CO-) was observed between 1650-1680 cm-1. Two N-H groups 
gave peaks between 3210-3380 cm-1. Cyclohexyl –CH2 appeared as per their 
characteristics between 2860-2945 cm-1. Substitution at the phenyl ring i.e. nitro, 
hydroxyl, chloro, methoxy, fluoro etc. gave bands characteristic as per their characteristic. 
(For further details see individual Spectral data)   
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Elemental analysis  
 
Elemental analysis of the synthesized compounds was carried out Elementar Vario EL III 
Carlo Erba 1108 model at CDRI, Lucknow and result calculated for percentage values of 
carbon, hydrogen and nitrogen in support of structure of synthesized compounds. The 
spectral and elemental analysis data are given in Physical data table of individual 
compounds.  
 
Spectral Data 
N-Cyclohexyl-1,2,3,4-tetrahydro-6-isopropyl-2-oxo-4-phenylpyrimidine-5- carbox- 
amide (RK-4001) 
IR (KBr Disc): 3355.25cm-1(-NH), 3271cm-1(-NH), 2936-2966(C-H, alkyl), 1450-
1550cm-1(-C=C) 1708.99 cm-1(-CO-NH, cyclic), 1647cm-1 ((-CO-NH) 
 
N-Cyclohexyl-1,2,3,4-tetrahydro-6-isopropyl-4-(4-(methylthio)phenyl)-2-oxopyrimi- 
dine-5-carboxamide (RK-4002) 
13C NMR (400 MHz, CDCl3): δ 165.16, 155.01, 137.14, 136.56, 135.08, 129.94, 127.93, 
125.67, 124.72, 71.33, 57.73, 51.51, 47.45, 46.21, 31.16, 24.92, 24.08, 19.58, 16.48, 
15.54, 14.81 
IR (KBr Disc): 3344.68cm-1(-NH), 2854-2931(C-H), 1710.92 cm-1(-C=O) 1675cm-1 
(-CO-NH), 1599 cm-1 (-NH Bend), 1450-1550 cm-1 (C=C)1170-1211 cm-1 (C-S-C),   
 
N-Cyclohexyl-1,2,3,4-tetrahydro-6-isopropyl-4-(4-methoxyphenyl)-2-oxopyrimidi-  
ne-5 –carboxamide (RK-4003) 
IR (KBr Disc): 3350.46cm-1(-NH), 2854-2933(C-H), 1708 cm-1(-C=O, cylic) 1643.41 
cm-1(-CO-NH), 1450-1550 cm-1 (C=C), 1247cm-1 (C-O-C) 
 
4-(2-Chlorophenyl)-N-cyclohexyl-1,2,3,4-tetrahydro-6-isopropyl-2-oxopyrimidine-    
-5-carboxamide (RK-4004) 
1H-NMR (300 MHz, DMSO-d6):δ 0.9-1.3 (m, 11H,  J=10.84 Hz{Average}), 1.4-1.56 
(m, 6H), 2.9-3.09 (m, 1H), 5.59 (s, 1H), 7.00 (s, 1H), 7.14-7.65 (m, 5H), 8.14 (s, 1H) 
IR (KBr Disc): 3421.83cm-1(-NH), 2862-2935(C-H), 1691.63 cm-1(-C=O, cylic) 1668 
cm-1(-CO-NH), 1450-1550 cm-1 (C=C), 758.05 cm-1 (C-Cl) 
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4-(3-Bromophenyl)-N-cyclohexyl-1,2,3,4-tetrahydro-6-isopropyl-2-oxopyrimidine-5-
carboxamide (RK-4005) 
13C NMR (400 MHz, CDCl3): δ 165.43, 153.04, 145.53, 143.14, 130.00, 129.73, 129.15, 
124.84, 121.82, 103.84, 55.59, 47.47, 32.05, 31.94, 27.87, 24.81, 24.23, 19.28, 19.09 
1H-NMR (300 MHz, DMSO-d6): δ 0.87-1.10 (m, 11H), 1.2-1.4 (m, 3H), 1.49-1.59 (m, 
3H),  3.45 (Broad Peak, 1H), 5.18 (s, 1H), 7.2-7.3 (m, 2H), 7.37-7.41 (m, 4H), 8.18 (s, 1H) 
IR (KBr Disc): 3284.88cm-1(-NH), 2864-2933(C-H), 1693.56 cm-1(-C=O) 1666 cm-1 
(-CO-NH), 1558-1600 cm-1 (-NH Bend), 550-556 cm-1 (C-Br) 
 
N-Cyclohexyl-1,2,3,4-tetrahydro-6-isopropyl-4-(2-nitrophenyl)-2-oxopyrimidine-5-
carboxamide (RK-4006) 
1H-NMR (300 MHz, DMSO-d6): δ 0.98-1.15 (m{Broad Peak}, 11H), 1.45-1.60 (m, 
6H), 3.02 (m, 1H), 5.78 (s, 1H), 7.07 (s, 1H),  7.19 (d, 1H, J=13.91 Hz), 7.49 (t, 1H) 7.60 
(d, 1H, J=6.47 Hz) 7.70 (t, 1H), 7.85 (d, 1H, J=7.30 Hz), 8.27 (s, 1H) 
IR (KBr Disc): 3279.10cm-1(-NH), 1693.56cm-1(-C=O) 1647.27 cm-1(-CO-NH), 1599 
cm-1 (-NH Bend), 1448-1480 cm-1(C=C), 1150 cm-1(C-NO2), 650 cm-1(-NO2 bend) 
 
N-Cyclohexyl-1,2,3,4-tetrahydro-6-isopropyl-4-(4-nitrophenyl)-2-oxopyrimidine-5-
carboxamide (RK-4007)  
IR (KBr Disc): 3261.74cm-1(-NH), 2856-2933 cm-1(C-H), 1708.94 cm-1(-C=O) 1646cm-
1(-CO-NH), 1545 cm-1 (-NH Bend), 1150 cm-1(C-NO2), 650 cm-1(-NO2 bend) 
 
4-(3-Chlorophenyl)-N-cyclohexyl-1,2,3,4-tetrahydro-6-isopropyl-2-oxopyrimidine-5-
carboxamide (RK-4008) 
13C NMR (400 MHz, CDCl3): δ 165.46, 153.08, 145.19, 143.12, 133.57, 129.44, 127.15, 
126.26, 124.39, 103.97, 55.08, 47.48, 32.05, 31.96, 27.90, 24.81, 24.22, 19.29, 19.12 
 IR (KBr Disc): 3281.02cm-1(-NH), 2854-2946(C-H), 1693 cm-1(-C=O) 1666.51 cm-1(-
CO-NH),  750 cm-1 (C-Cl) 
 
N-Cyclohexyl-1,2,3,4-tetrahydro-6-isopropyl-4-(3-nitrophenyl)-2-oxopyrimidine-5-
carboxamide (RK-4009) 
13C NMR (400 MHz, CDCl3): δ 166.84, 165.38, 153.19, 147.67, 145.31, 144.27, 143.95, 
132.65, 131.71, 129.02, 121.88, 121.72, 121.26, 120.03, 112.28, 103.56 
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IR (KBr Disc): 3399.83cm-1(-NH), 2856-2933 cm-1(C-H), 1718 cm-1(-C=O, cyclic) 
1672cm-1(-CO-NH), 1545 cm-1 (-NH Bend), 1136 cm-1(C-NO2), 590 cm-1(-NO2 bend) 
 
N-Cyclohexyl-1,2,3,4-tetrahydro-6-isopropyl-4-(2-methoxyphenyl)-2-oxopyrimidine-
5-carboxamide (RK-4010) 
IR (KBr Disc): 3270cm-1(-NH), 2862-2937(C-H), 1697.77 cm-1(-C=O, cylic) 1688.48 
cm-1(-CO-NH), 1450-1550 cm-1 (C=C), 1125cm-1 (C-O-C) 
 
4-(4-Chlorophenyl)-N-cyclohexyl-1,2,3,4-tetrahydro-6-isopropyl-2-oxopyrimidine -5-
carboxamide (RK-4011) 
IR (KBr Disc): 3271cm-1(-NH), 2884-2933(C-H), 1708.99 cm-1(-C=O) 1647 cm-1(-CO-
NH), 1545 cm-1 (-NH Bend), 705 cm-1 (C-Cl) 
 
N-Cyclohexyl-1,2,3,4-tetrahydro-6-isopropyl-4-(3-methoxyphenyl)-2-oxopyrimidine-
5-carboxamide (RK-4012) 
IR (KBr Disc): 3450.48cm-1(-NH), 2823-2945(C-H), 1711 cm-1(-C=O, cylic) 1676.52 
cm-1(-CO-NH), 1450-1550 cm-1 (C=C), 1186.21cm-1 (C-O-C) 
 
N-Cyclohexyl-1,2,3,4-tetrahydro-6-isopropyl-4-(3,4-dimethoxyphenyl)-2-oxopyri-
midine-5-carboxamide (RK-4013) 
IR (KBr Disc): 3350.24cm-1(-NH), 2870-2978(C-H), 1705.23 cm-1(-C=O,cylic) 1674.52 
cm-1(-CO-NH), 1440-1580 cm-1 (C=C), 1158-1185cm-1 (C-O-C) 
 
N-Cyclohexyl-1,2,3,4-tetrahydro-6-isopropyl-4-(3,4,5-trimethoxyphenyl)-2-oxopy 
rimidine-5-carboxamide (RK-4014) 
IR (KBr Disc): 3325cm-1(-NH), 2823-2945(C-H), 1699.98 cm-1(-C=O, cylic) 1666.3 cm-
1(-CO-NH), 1450-1550 cm-1 (C=C), 1140-1186.21cm-1 (C-O-C) 
 
N-Cyclohexyl-1,2,3,4-tetrahydro-6-isopropyl-2-oxo-4-(3-phenoxyphenyl)pyrimidine-
5-carboxamide (RK-4015) 
IR (KBr Disc): 3339.48cm-1(-NH), 2810-2943(C-H), 1701.08 cm-1(-C=O, cylic) 1676.52 
cm-1(-CO-NH), 1443-1552 cm-1 (C=C), 1086-1120cm-1 (C-O-C) 
N-Cyclohexyl-1,2,3,4-tetrahydro-4-(2-hydroxyphenyl)-6-isopropyl-2-oxopyrimidine-
5-carboxamide (RK-4016) 
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IR (KBr Disc): 3438cm-1(-OH), 3340cm-1(-NH), 2825-2945(C-H), 1698 cm-1(-C=O) 
1663.36 cm-1(-CO-NH), 1540-1559 cm-1 (-NH Bend) 
 
N-Cyclohexyl-1,2,3,4-tetrahydro-4-(3,4-dihydroxyphenyl)-6-isopropyl-2-oxopyri 
-midine-5-carboxamide (RK-4017) 
IR (KBr Disc): 3522cm-1(-OH), 3339cm-1(-NH), 2830-2977(C-H), 1687 cm-1(-C=O) 
1678 cm-1(-CO-NH), 1529 cm-1 (-NH Bend) 
 
m/z Mass values of N-Cyclohexyl-1,2,3,4-tetrahydro-6-isopropyl-2-
oxo-4-substitued phenylpyrimidine-5-carboxamides 
 
Compound  
Code. No 
(m/z) 
Relative intensity 
RK-4001 341 (15%) 
RK-4002 387 (08%) 
RK-4003 371-28 (10%) 
RK-4004 375 (09%) 
RK-4005 420-42 (05%) 
RK-4006 386 (06%) 
RK-4007 386 (13%) 
RK-4008 375 (12%) 
RK-4009 386 (11%) 
RK-4010 371 (07%) 
RK-4011 375 (10%) 
RK-4012 371 (13%) 
RK-4013 316-14 (28%) 
RK-4014 346 (12%) 
RK-4015 348 (11%) 
RK-4016 272 (09%) 
RK-4017 288 (08%)  
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Spectra of the Representative compounds 
[a] 1H NMR Spectra of RK-4004 
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[b] 1H NMR Spectra of RK-4005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
H
NHN
H
O
O
Br
 
 
Synthesis and Characterization of N-cyclo…. 
 
126
[c] 1H NMR Spectra of RK-4006 
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[d] 13C NMR of RK-4002 
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[e] 13C DEPT at 135 of RK-4002 for identification of methylene proton 
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[f] 13C NMR of RK-4005 
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[g] 13C DEPT at 135 of RK-4005 for identification of methylene proton 
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[h] 13C NMR of RK-4008 
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[i] 13C NMR of RK-4008 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[j] 13C DEPT at 135 of RK-4008 for identification of methylene proton 
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[k] 13C NMR of RK-4009 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[l] 13C DEPT at 135 of RK-4009 for identification of methylene proton 
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[m] EI-MS Spectra of RK-4006 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[n] EI-MS Spectra of RK-4011 
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[o] EI-MS Spectra of RK-4009 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[p] EI-MS Spectra of RK-4005 
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[q] IR Spectra of RK-4001 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
[r] IR Spectra of RK-4002 
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[s] IR Spectra of RK-4007 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[t] IR Spectra of RK-4011 
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Conclusion 
 
Our interest in dihydropyrimidinones stems from numerous pharmacologically activity 
and their presence as marine natural products. 
In the present work, the Biginelli type cyclocondensation(MCRs) of acetoacetanilide 
bearing a cyclohexyl ring have been studied. In correlation to the reaction of 
acetoacetanilide bearing a cyclohexyl ring with different substituted benzaldehyde and 
urea, we obtained a Dihydropyrimines posture at C5 position with cyclohexyl carbamoyl 
functional group. These reactions were conventionally carried out in methanol in the 
presence of the catalytical amount of Conc. HCl for 5-6 hours providing 
Dihydropyriminones in moderate to good yields. 
In continuation of this work, a replacement of phenyl ring by cyclohexyl group and 
methyl group by isopropyl group by Biginelli-type three-component cyclocondensation 
reaction with slight modification in acetoacetanilide. It shows that slight change in the 
building blocks can create a new diversity and ultimately a small library of novel 
dihydropyrimidinones is obtained.  
All the novel compounds are well characterized by spectral investigation as reported in 
earlier pages. 
In the IR spectra of compounds, the most characteristic sharp absorption bands of the 
secondary –NH group were obtained. 
In the 1H NMR spectra of compounds, the characteristic signals for the cyclohexyl 
protons are observed at 0.8-1.5 δppm. Isopropryl group protons agree very well with the 
standard values. All 13C NMR shows each of carbon atom. 13CNMR experiment-DEPT 
for the identification of the methylene carbon for cyclohexyl ring & methine carbon was 
carried out and its values agree with standard values. 
The biological properties of these substances are currently under investigation.  
 
 
 
 
 
 
 
 
 
 
Synthesis and Characterization of N-cyclo…. 
 
139
REFERENCES 
 
[1] Mc Gavack, T.H.J.; Chevalley, S.; Keni-gsberg, S. Bull N. Y. Med. Coll. 1953, 16, 58.  
[2]   Miller, L.;  Schmeising, M. J. Am. Chem. Soc. 1962, 84, 4623. 
[3] Rinkes, I. J. Recl. Trav. Cairn Pays-Bas. 1927, 46, 268. 
[4] Howard, G.A.; Lythgoe, B.; Todd, A.R. J. Chem. Soc. 1944, 476. 
[5] Whitehead, C.W.; Traversol, J.J. J. Am. Chem. Soc. 1958, 80, 2185. 
[6] Bredereck, H.; Effenberger, F.; Treiber, H.J. Chem. Ber.  1963, 96, 1505. 
[7] Brown,  D. J. Chem. Heterocyc. Compd., 1970, 20, 16-51. 
[8] Inoue, S.;  Saggimoto,  A.J.; Nodiff,  E.A. J. Org. Chem. 1961, 26, 4504 . 
[9] Van Allan,  J.A. Org. Synth.  1952, 32, 45. 
[10] Taylor, E.C.; Morriosn,   R.W. J. Org. Chem., 1967, 32, 2379. 
[11] Russell, P.B.; Hitchings, G.H. J. Am. Chem. Soc. 1952, 74, 3443. 
[12] Krohnke, P.; Schmidt, E.; Zoecher, W.Chem. Ber. 1964, 97, 1163. 
[13] Ajello, T. Gazz. Chem. Ital. 1940, 70, 504. 
[14]  Mitchell, H K.; Nyo, J.F. J. Am. Chem. Soc. 1947, 69, 674. 
[15]  Shaw, G.; Saugowdz, G. J. Chem. Soc. 1954, 665. 
[16] Dorhow, A.; Hell, J. Chem. Ber. 1960, 93, 1998. 
[17] Streef,  J.W.; Denhertog, H.J. Rec. Trav. Chem. Pays-Bas. 1969, 88, 1391. 
[18]  Crow W.D.; Wentrup, C. Tetrahedron Lett. 1969, 7, 3115  
[19] Schaefer, F.C.; Huffman, K.R.; Peters, G.A. J. Org. Chem. 1962, 27, 548. 
[20]  Eiden , F.; Nagar, B.S. Naturwissen Schaften, 1963, 50, 403. 
[21]  Warrer, R.N.; Cairn,  E.N.  Aust. J. Chem. 1971, 24, 785. 
[22]  Acheson,"An Introduction to the chemistry of Heterocyclic compounds", Inter Science (1969). 
[23] Vogel, A.I. "Vogel's Text book of Practical Organic Chemistry", 5th Ed., (1994) 
[24]  Badger "Chemistry of Heterocyclic Compounds", Academic Press (1961). 
[25]  Biginelli, Gazz Chem. Ital. 1983, 23, 360;  Atti. Accad. Lincei, 1894, (5)3, 195. 
[26] Elkholy, Y.M.; Elassar,  A.H.; Elnagdi, M.H. Hetero. Commun., 1997, 3 (2),151. 
[27]  Sharma, P.; Hussain, K.F.; Sukhwal, S.; Kothari, S. Ind. J. Chem. 1999, 35(B),966-968.  
[28] Kumar, B.; Kaur, B.; Kaur, J.; Parmar, A.; Anand, R.D.; Kumar,  H. Ind. J.Chem. 2002, 
41(B), 1526-1530. 
[29] Yan-Feng, L.; Li-Jan, L.; Ji-Tai, L.  Chemistry; An Indian Journal, 2004, 1(9), 628. 
[30] Afzal, Md. P.; Jayshankara, V. P. Ind. J. Hetero Chem. 2005, 14, 261. 
[31] Kumar, S.; Saini, A.; Sandha, J. S. Ind. J. Chem. 2004, 43B, 1485. 
 
 
Synthesis and Characterization of N-cyclo…. 
 
140
[32] Mishra, A.; Agnihotri, G.; Mudhusudar, S. K. Ind. J. Chem., 43B, 2018 (2004). 
[33]  Kreutzberger, A.; Gillessen,  J. J. Fluorine Chem. 1985, 29(4), 385-97 (Ger.) 
[34] Schulze, B.; Groksch, S.; Weber, L.; Muehistuedt,  M. Ger. D.D. 1987, 244, 342. 
[35] Kawamura, S.; Sato, J.; Hamada, T.; Sakaki,  M.; Sanemitsn. J. Agri.Food.Chem.  
 1993, 41, 288. 
[36] Yoshida, Hiroshi, Saito, Koiji, Watanable Masayuki.  Jpn. Kokai Tokkyo Koho,     
 Chem. Abstr. 1986, 105, 208917y. 
[37]  Srivastava, C.; Ahluwalia, V.K.; Goyal, B.; Das, U.; Agarwal, R. Ind. J.Chem. 1996, 
35(B), 976-979. 
[38]   Yasushi, N.; Katsutoshi, F. (Takeda Chemical Industries, Ltd., Japan) PCT Int. Appl. 
WO 02 38,550, 2002 (Cl. C07D239/26).  
[39]  Chatwal, G.R. "Synthetic Organic Chernistry", 1990, 272. 
[40] Nobumass, K.; Tesuye. Yashito, F.;  Naoyki, Y. Chiso Corp. Jap. Pat., 1984, 47466914. 
 [41]  Williams,  J.; Vandernberghe, V.Chem. Abstr. 1960, 54, 22657. 
[42] Nigam, S.C.; Saharia, G.S.; Sharma, H.R. J. Ind. Chem. Soc. 1983, 60, 583. 
[43]  Baddiley, J.; Lythgoe, B.; Todd, A.R. J. Chem. Soc.  1944, 318. 
[44]  Kenner, G.W.; Lythgoe,  B.; Todd, A.R.  J. Chem. Soc. 1944, 652. 
[45]  Baddiley, J.; Kenner, G.W.; Lythgoe,   B.; Todd, A.R. J. Chem. Soc. 1944, 657.  
[46]   Centolella,  A.P.; Nelson,  J.W.; Kolloff,  H.G. J. Am. Chem. Soc. 1943,65, 209.  
[47] Matteson, D.S.; Bleenbaum, M.S.; Bechtold, R.A.; Willsek, R.J. J. Org. Chem. 1978, 43, 
950. 
[48]  Katritzky, A.R.; Rees, C.W. 'Comprehensive Heterocyclic Chemistry', 1982, 3, 152. 
[49]  Heidelberger, C.C.; Chaudhari, N.C.; Dannberg, P.; Mooren, D.; Griesgach, L.; 
Duchinsky, R.;  Schnitzer, R.I.; Pleven,  E. Scheiner Nature, 1957, 179, 663. 
[50]  Okada, Hirochi, Kato, Masanari, Koyanagi. Chem. Pharm. Bull. 1999, 47(3), 430, (Eng). 
[51]  Safonova, T.V.; Keremov, A.F. Khim. Farm. Zn. 1998, 32(12), 11. (Eng). 
[52]    Vio,  L.; Mamolo,  M.G. Farmaco; Ed. Sce. 1983, 38(4), 255; Chem. Abstr. 1983, 99, 
88139e. 
[53]  Press, J.B.; Rushell, R.K. U.S. Pat. 4, 1987, 670, 560;  Chem. Abstr. 1987, 107, 115604v. 
[54] Rushell, R.K.; Press, J.B.; Rampnlla, R.A.; Mancnally, J.J.; Falotiko, R. J.Med. Chem.
 1988, 31, 1786. 
[55]  Hepworth, W.; Thompson, T.W. Chem Abstr. 1968, 69, 7724. 
 
 
Synthesis and Characterization of N-cyclo…. 
 
141
[56]  Nakaguti, O.; Shimazaki, N.; Shimazaki, M.; Nakatuka, M. Eur. Pat. Appl. Ep-1986, 
168, 005; Chem. Abstr. 1986, 105, 191118p. 
[57] Max, W.; Murty, B.; Peter, E.; Klaur, W. Novartis Pharma. Switz; PCT Int. WO 03, 
2003, 63, 871 (Cl.A61K31/505); Chem. Abstr. 2003, 139, 164802c  
[58] Papesch, V.; Schroeder; E.F. US Pat. 1956, 2724559; Chem. Abstr. 1956, 50, 1370. 
[59]  Tokutake, N. Brit. Pat. 146836B,  Chem. Abstr.  1977, 87, 102370j. 
[60]  Steilbuck, P.; Baltzly, R.; Hood,  H.M. J. Org. Chem. 1963, 28, 1983. 
[61]   Hood, H.M. Brit. Pat. 1964, 957, 797  
[62]  Chappel,  C.J.;  VanSeemann,  C. Prog. Med. Chem. 1963, 3, 89. 
[63]  Gupta, K.P.; Gupta,  R.C.; Bhargava, K.P. Eur. J. Med. Chem. 1982, 17(5), 448-52. 
[64]   Kotva,  R.; Krepelka,  J. Cellect. Czech. Chem. Commun., 1983, 48(l), 1, 137-43. 
[65]  Jean-Damien, C.; David, B.; Ronald, K.; Julian, G.; Pan, Li.; Robert,  D. Vertex           
Pharmaceuticals Incorporated, USA; PCT Int. Appl. WO 02 22, 2002, 608 
(Cl.C07D403/12). 
[66]  De'Souza, B.; Galay, J.J. Eur. Pat. 1984, 105, 029; Chem. Abstr. 1984, 101, 72748b. 
[67]  Anderson, G.W.; Halverstadt, I.F.; Miller, W.H.; Rohlin, R.O.; J. Am. Chem.Soc.  1945, 
67, 2197. 
[68]   Calas, Michele, Pages, Cecile and Barhier, Alain.  Eur. J. Med. Chem. Chem. Ther. 1983, 
18(1)  
[69]  Chem. Abstr. 1983, 99, 70673r. 
[70]  Stuart, A.; Paterson, T.; Roth, B. J. Med. Chem. 1983, 26(5), 667-73. 
[71] Kotva, R.; Krepelka, J. Czech. C.S. 1984, 224, 239; Chem. Abstr. 1985, 102, 45974m. 
[72]  Ahuwalia, V.K.; Sharma  H.R.; Tyagi, R. Ind. J. Chem. 1987, 26-B(7), 697-699.  
[73]  Parmar, J.M.; Modha, J.J.; Parikh, A.R. Ind. J. Chem. 1999, 38-B, 440-444. 
[74]  Fathlla, O.A. Ind. J. Chem. 2001, 40(B), 37-42. 
[75] Patil, L.R.; Ingle, V.S.; Bondge, S.P.; Bhingolikar, V.E. Ind. J. Het. Chem. 2001, 11, 131. 
[76] Parmar, J.M.; Modha, J.J.; Parikh, A.R. J. Inst. Chemist (India) 2001, 73(1). 
[77]  Nagar, D.N.; Sikotra, K.H.; Shah, V.H. J. Inst. Chemist (India) 2001, 73(3), 93.  
[78] Nagar, D.N.; Sikotra K.H.;, Shah, V.H. J. Inst. Chemist (India) 2001,73(4), 132. 
[79]      Patel, H.S.; Patel, V.K.; Dixit, B.C. Oriental J. Chem.  2001, 17(3), 411-414.  
[80] Datta, N.J.; Khunt,  R.C.; Parikh, A.R. Oriental J. Chem. 2001, 18(1), 131-134. 
[81]  Andotra, C.S.; Kaur, S.; Khajuria, J. Ind. J. Het. Chem. 2002, 12(1), 77-78. 
[82] Devi, E.S.; Prakash, E.O.; Rao, J.T. J. Inst. Chemist (India).  2002, 74(5), 167. 
[83] Kaspar, B.; Sorana, G.P.; Khalid, I. Chem. Abstra. 2002, 136, 151176q. 
 
 
Synthesis and Characterization of N-cyclo…. 
 
142
[84] Madkour, H.M.F.; Salem, M.A.I.; Soliman, E.A.; Mahmoud, N.F.H. Phosphorus Sulfur 
and Silicon and the Related Elements, 2002, 170, 15-27. Chem. Abstra.  2002, 136, 183780y. 
[85] Tsuneyuki, S.; Toshihide, H.; Toru, M.; Tsutomu, K.; Shinsuke, H. Ono Pharmaceutic 
Co.Ltd., Japan PCT Int. Appl. WO 02 51, 2002, 815, (Cl.C07D239/47);  Chem. Abstr. 
2002, 137, 78963h. 
[86]  Martin, E.; Hugo, Z.; Fredrik, C.; Peter, A. Syngenta participations A. G. Switz. PCT Int. 
Appl. WO 0253, 560, 2002 (Cl. C07D401/04); Chem. Abstra. 2002, 137, 169533j. 
[87] Chengxin, Z.; Zheng-Yu, L.; George, W.; Neal, B.; Serge, L. Motorina, Irina (usa) U.S. 
Pat. US 114, 445 (2003);  Chem. Abstra. 2003, 137, 53032g. 
[88]  Patil, L.R.; Mandhare, P.N.; Bondge, S.P.; Munde, S.B.; Mane, R.A. Ind. J. Het. Chem. 
2003, 12(3), 245-248. 
[89]  Karale, B.K.; Gill, C.H.; Shinagare M.S., Ind. J. Het. Chem. 2003, 12(3), 267-270. 
[90]  Swamy, S.N.; Murthy, A.K.; Rajanendar; E. Ind. J. Het. Chem., 2003, 12(4), 357-360  
[91]  Kumar, A.; Sharma, P.; Sharma, R.; Mohan, P. Ind. J. Chem. 2003, 42-B, 416-420. 
[92] Padhy, A.K. Ind. J. Chem. 2003, 42-B, 910-915. 
[93] Kurono, M. Jp 62, 1987, 267, 272 ; Chem. Abstr. 1988, 109, 37382t .94.K.Atwal; US 4, 
1988, 769, 371; Chem. Abstr. 1989, 110, 114853a. 
[95]  Chotto,  Mizuno, A. Eur. Pat. Ep. 1988, 195, 374; Chem. Abstr. 1989, 110, 231653w. 
[96]  A.; Kreutzberger, M. Sellheim, Che. Zig. 1984, 108, 253-5.;  Chem. Abstr. 1985, 102, 
24572p. 
[97]  Jaen, Ju an C; Tularik Inc. usa  PCT Int. Appl. WO 0264, 096, 2002 (Cl. A61K);      
 Chem. Abstr. 2002, 137, 185498g. 
[98]  Chamberlain, S.D.; Gudmundsson, K.;. Johns,  B.A Chem. Abstr.  2002, 137, 33316h. 
[99]  Khalili, G.; Shariri, R. Ind. J. Chem. 2002, 41-B, 1526-1530. 
[100] Narr,  B.; Woitun, E. Ger. Offen 2, 1973, 200, 764.;  Chem. Abstr., 1973, 79, 922, 798. 
[101] Kikugawa,  K.; Ichino, M. Chem. Pharm. Bull. 1973, 21, 1151. 
[102] Janssens, F.E.; Kennis, L.E.J.; Hens, J.E.; Torremans,  J.L.G.; Van, G.S.M. Eur 
Pat.Appl. Ep. 1985, 151, 826.  Chem. Abstr. 1986, 104, 68861c.  
[103]  Smith Kline and French Lab. Ltd. Chem. Abstr. 1985, 103, 22613z.  
[104]  Okabe, M.; Sun, R.C.; Zenehoff G.B. J. Org. Chem. 1991, 56, 4393. 
[105] K.; Noriyuki, M.; Hitoshi, Shionogi & Co. Ltd., Japan PCT Int. Appl. WO 03 47, 564 
(Cl. A61K31/343) 2002;  Chem. Abstr. 2003, 139, 36532c. 
[106] Jani, M.K.; Shah, B.R.; Undavia, N.K.; Trivedi, P.B. Chem. Abstr. 1994, 121,  35513p. 
 
 
Synthesis and Characterization of N-cyclo…. 
 
143
[107]  Sanghvi, Y.S.; Crooke,  S.T.; Lebleu, B. Antisense Research and Applications, CRC Press, 
Boca Raton, Fla, 1993, 273. 
[108] Ishikawa, T.; Yoneda, F.; et al. Biorg. & Med. Chem. Letts. 1991, 1, 523. 
[109] Nikiforov, T. T.; Connolly, B.A. Tetrahedron Letteres. 1991, 32, 3851. 
[110] Inoue, H.; Ohtsuka, E. Nucleic Acids Res. 1985, 13, 7119. 
[111] Sanghvi, Y.S.; Hoke, G.D.; Freier, S.M.; Zounes, M.C.; Gonzalez, C.; Cummins, L.; 
H.; Sasmor, P.D. Cook, Nucleic Acids Res., 21, 3197 (1993). 
[112] Wierenga, W.; Hess, H.J. in ‘Annual Reports of Medicinal Chemistry’ Academic 
Press, New York, 1982, 17 ,151. 
[114] Mayer, G. D. Pharmacol Ther. 1980, 8, 173. 
[115] Nicholas, F. R.; Weed, S. D.; Underwood, G. E. Antimicrob. Agents Chemother. 1976, 9, 
433. 
[116] Stringfellow, D. A.; Vanderberg, H. C.; Weed, S. D. J. Interferon Res. 1980, 1, 1. 
[117] Wierenga, W.; Skulnick, H. I.; Stringfellow, D. A.; Weed, S. D.; Renis, H. E.; Eidson, 
E. E. J. Med. Chem. 1985, 23, 237, 1864. 
[118]   Wierenga, W. Pharmacol Ther. 1985, 30, 67. 
[119] Renis, H. E.; Eidson, E. E.; Court, B. A.; Gray, J. E. ‘22nd Interscience Conference on 
Antimicrobial Agents and Chemotherapy’, 1982, October 4-6,435. 
[120] Anthony, H. R.; Stevenson, M.M.; Skamene, E. Int. J. Immunopharmacol. 1984, 4, 260. 
[121] Livingston, R. B.; Carter, S. K. ‘Single Agents in Cancer Chemotherapy’, IFI/Plenum, 
New York, 1970. 
[122] Kalousek, F.; Raska, K.; Turovcik, J. M.; Sorm, F. Collect. Czech. Chem.Commun. 1966, 
31, 1421. 
[123] Handschumacher, R. E. Cancer Res. 1963, 23, 634. 
[124] Hernandez, K.; Pinkel, D.; Lee, S.; Leone, L. Cancer Chemothe., Re. 1969, 53, 203. 
[125] Hoshi, A.; Igo, M.; Nakamura, A.; Inomata, T.; Kuretani, K.Chem. Pharm. Bull. 1987, 
26, 161. 
[126] Tsuruo, T.; Ida, H.; Naganuma, K.; Tsukagoshi, S.; Sakurai, Y. Cancer Chemother. 
Pharmacol. 1980, 4, 83. 
[127] Igo, M.; Hoshi, A.; Inomata, M.; Audo, N.; Kuretani, K. J. Pharmacobio-Dyn, 1981, 4, 
203. 
[128] Bollag, W.; Hartmann H. R. Eur. J. Cancer. 1980, 16, 427. 
[129] Arakawa, M.; Shimizu, R.; Sasagawa, K.; Inomata T.;  Shinkai, K. Gann. 1981, 72, 220. 
 
 
Synthesis and Characterization of N-cyclo…. 
 
144
[130]  Johns, D. G.; Sartorelli, A. C.; Bertino, J. R.; Iannotti, A. T.; Booth, B. A.; Welch, A. 
D. Biochem. Pharmacol. 1966, 15, 400. 
[131]  Discjomslu, R.; Gabriel , T.; Tautz, W.; Nussbaum, A.; Hoffer, M.; Grunberg, E.; 
Burchenal,  J. H.; J.J. Fox, J. Med. Chem. 1967, 10, 47. 
[132] Reyes, P.; Heidelberger, C.  Mol. Pharmacol. 1965, 1, 14.  
[133] Prusoff, W. H.; Schinazi,  R. F.; Chem, M. S. J. Med, Chem. 1979, 22, 1273. 
[134] Shiau, G. T.; Schinazi, R. F.; Chem,  M. S.; Prusoff, W. H. J. Med. Chem. 1980 23, 127. 
[135] Lin, T. S.; Fischer, P. H.; Prusoff, W. H. Biochem. Pharmacol. 1980, 31, 125. 
[136] Lin, T. S.; Mancini, W. R. J. Med. Chem. 1983, 26, 544. 
[137] Burchenal, J. H.; Chou, T. C.; Lokys, L.; Smith, R. S.; Watanabe, K. A.; Su, T, L.; 
Fox, J. J. Cancer Res. 1982, 42, 2598. 
[138] Martin, S. J. ‘The Biochemistry of Viruses’, Cambridge University Press, Cambridge, 
1978. 
[139] Senear, A. W.; Steitz, J. A. J. Biol. Chem., 1976, 251, 1902. 
[140] Temin, H.; Baltimore, D. Adv. Virus Res., 1973, 17, 129; Cold Spring Harbor Symp. 
Quant.  Biol., 1974, 39. 
[141] Prusoff, W. H.; Lin, T.S.; Mancini, W. R.; Otto, M. J.; Siegel, S. A.;  Lee, J. J.;  
In ‘ Topics in Antiviral Chemotherapy’. ed. R. T. Walkar and E. De Clercq, Plenum Press, 
New York, 1984, p. 1. 
[142] Prusoff, W. H.; Chen, M. S.; Fisher, P. H.; Lin, T-S.; Shiau, G. T.; Schinazi,  
R. F.; Walker, J. Pharmacol. Ther., 1979, 7, 1. 
[143]  Sidwell, R. W.; Witkowski, J. T.  ‘ Burger’s Medicinal Chemistry’, 4th edn. 
(2) Wolff, M. E. Wiley, New York, 1979, 543. 
[144] Lin, T. S.;  Neenan, J.P.; Cheng, Y.C.; Prusoff, W. H.; Ward, D. C. J. Med Chem. 
1976,19 ,495. 
[145]  DeClercq, E. Trends Pharmacol. Sci. 1987, 8, 339. 
[146] Furman, P. A.;. Barry, D. W. Am. J. Med. 1988, 85(2A), 176. 
[147] Cheng,Y.; Dutschman, G. E.; bastow, K. F.; Sarngadharan, M. G.;  Ting, R. Y. C. J. 
Biol. Chem., 1987, 262, 2187. 
[148] DeClercq E; balzarini E.; Descamps, J.; Eckstein, F.; Biochem. Pharmacol. 1980 84, 
8239. 
[149] Mitsuya, H.; Broder, S.  Nature (London), 1987,325, 773. 
 
 
Synthesis and Characterization of N-cyclo…. 
 
145
[150] DeClercq, E.; in ‘ Antiviral Drug Development, A Multidisciplinary 
Approach’, ed. E. DeClercq .; R. T. Walker. NATO ASI Series, series A, Plenum 
Press. New York, 1988,143, 97. 
[151] C.H.  Kim.;V. E. Marquez.; S. Border.; H. Mitsuya.;  J. S. Driscoll. J. Med. Chem. 1987, 
30, 862. 
[152] Y.C. Cheng.; G. E. Dutschman.; K. F. Bastow.; R. Y. C. Ting. J. Biol. Chem., 1987, 
262, 2187. 
[153] P. Khalili, E. Naimi, W. Y. Sun, E. E. Knaus and L. I. Wiebe, Eur. J. Pharm. Sci. 2003, 
19, 305. 
[154] Rostom, S. A.; Fahmy, H. T.; Saudi, M. N. Scientia Phatmaceutica. 2003, 71(2), 57-74  
[155] Aurelio, Orjales.; Ramón, Mosquera.; Agustin Berisa, M.; Teresa, Núñez.; Beatriz, 
López.; Carmen, M. FAES FARMA S.A., Department of Research, Bilbao,Spain,(2004). 
[156] De Lucca, G. V.; Kim, U. T.; Liang, J.; Cordova, B.;  Klabe, R. M.; Garber, S.; 
Bacheler, L. T.; Lam, G. N.; Wright, M.; Trainor, G. L. J. Med. Chem. 1998, 41, 2411. 
[157]  Kawauchi, H.; Kawazoe, I.; Tsubokawa, M.; Kishida, M.; Baker,B.L. Nature  1983, 
305 (5932), 321. 
[158]  Bittencourt, J. C.; Presse, F.; Arias, C.; Peto, C.; Vaughan, J.; Nahon, J. L.; Vale, 
 W.; Sawchenko, P. E. J. Comp. Neurol. 1992, 319 (2), 218. 
[159]  (a) Bachner, D.; Kreienkamp, H.; Weise, C.; Buck, F.; Richter, D. FEBS Lett. 
 1999, 457 (3), 522. (b) Chambers, J.; Ames, R. S.; Bergsma, D.; Muir, A.; 
 Fitzgerald, L. R.; Hervieu, G.; Dytko, G. M.; Foley, J. J.; Martin, J.; Liu, W. S.; 
 Park, J.; Ellis, C.; Ganguly, S.; Konchar, S.; Cluderay, J.; Leslie, R.; Wilson, S.; 
 Sarau, H. M. Nature 1999, 400 (6741), 261-265. (c) Lembo, P. M.; Grazzini, E.; 
 Cao, J.; Hubatsch, D. A.; Pelletier, M.; Hoffert, C.; St-Onge, S.; Pou, C.; 
 Labrecque, J.; Groblewski, T.; O’Donnell, D.; Payza, K.; Ahmad, S.; Walker, P. 
 Nat. Cell Biol. 1999,  1(5), 267. (d) Saito, Y.; Nothacker, H. P.; Wang, Z.;  Lin, S.       
H.; Leslie, F.; Civelli, O. Nature 1999, 400 (6741), 265. (e) Shimomura, Y.; Mori, M.; 
Sugo, T.; Ishibashi, Y.; Abe, M.; Kurokawa, T.; Onda, H.; Nishimura, O.; Sumino, Y.; 
Fujino, M. Biochem. Biophys. Res. Commun.  1999, 261 (3), 622. 
[160]  (a) An, S. Z.; Cutler, G.; Zhao, J. J.; Huang, S. G.; Tian, H.; Li, W.; Liang, L.; 
 Rich, M.; Bakleh, A.; Du, J.; Chen, J. L.; Dai, K. Proc. Natl. Acad. Sci. U.S.A.  2001,  
98 (13), 7576. (b) Hill, J.; Duckworth, M.; Murdock, P.; Rennie, G.; Sabido- David, 
C.; Ames, R. S.; Szekeres, P.; Wilson, S.; Bergsma, D. J.; Gloger, I. S.; Levy, D. S.; 
 
 
Synthesis and Characterization of N-cyclo…. 
 
146
Chambers, J. K.; Muir, A. I. J. Biol. Chem. 2001, 276 (23), 20125. (c) Mori, M.; Harada, 
M.; Terao, Y.; Sugo, T.; Watanabe, T.;  Shimomura, Y.; Abe, M.; Shintani, Y.; Onda, 
H.; Nishimura, O.; Fujino, M.  Biochem. Biophys. Res. Commun. 2001, 283 (5), 1013-
1018. (d) Sailer, A. W.;  Sano, H.; Zeng, Z.; McDonald, T. P.; Pan, J.; Pong, S. S.; 
Feighner, S. D.; Tan, C. P.; Fukami, T.; Iwaasa, H.; Hreniuk, D. L.; Morin, N. R.; 
Sadowski, S. J.; Ito, M.; Ito, M.; Bansal, A.; Ky, B.; Figueroa, D. J.; Jiang, Q.; Austin, 
C. P.; MacNeil, D. J.; Ishihara, A.; Ihara, M.; Kanatani, A.; Van der Ploeg, L. H.; 
Howard, A. D.; Liu, Q. Proc. Natl. Acad. Sci. U.S.A. 2001, 98 (13), 7564. (e) Tan, C. P.; 
Sano, H.; Iwaasa, H.; Pan, J.; Sailer, A. W.; Hreniuk, D. L.; Feighner, S. D.; Palyha, O. 
C.; Pong, S. S.; Figueroa, D. J.; Austin, C. P.; Jiang, M. M.; Yu, H.;  Ito, J.; Ito, M.; 
Ito, M.; Guan, X. M.; MacNeil, D. J.; Kanatani, A.; Van der Ploeg, L. H.; Howard, A. 
D. Genomics 2002, 79 (6), 785. 
[161]  (a) Hervieu, G. Expert Opin. Ther. Targets 2003, 7 (4), 495. (b) Shi, Y. Peptides 2004, 25 
(10), 1605. 
[162]  Qu, D.; Ludwig, D. S.; Gammeltoft, S.; Piper, M.; Pelleymounter, M. A.; Cullen, 
 M. J.; Mathes, W. F.; Przypek, R.; Kanarek, R.; Maratos-Flier, E. A  Nature 1996, 
 380 (6571), 243. 
[163]  Shimada, M.; Tritos, N. A.; Lowell, B. B.; Flier, J. S.; Maratos-Flier, E. Nature 
 1998, 396, 670.  
[164] Ludwig, D. S.; Tritos, N. A.; Mastaitis, J. W.; Kulkarni, R.; Kokkotou, E. Elmquist, 
J.; Lowell, B.; Flier, J. S.; Maratos-Flier, E. J. Clin. InVest. 2001, 107 (3), 379. 
[165] Kennedy, A. R.; Todd, J. F.; Dhillo, W. S.; Seal, L. J.; Ghatei, M.A.; O’Toole, C. 
 P.; Jones, M.; Witty, D.; Winborne, K.; Riley, G.; Hervieu, G.; Wilson, S.; Bloom, 
 S. R. J. Neuroendocrinol. 2003, 15 (3), 268-272. 
[166] Borowsky, B.; Durkin, M. M.; Ogozalek, K.; Marzabadi, M. R.; DeLeon, J.; Lagu, B.; 
Heurich, R.; Lichtblau, H.; Shaposhnik, Z.; Daniewska, I.; Blackburn, T. P.; 
Branchek, T. A.; Gerald, C.; Vaysse, P. J.; Forray, C. Nat. Med. 2002, 8 (8), 825. 
[167]  Lagu, B.; Tian, D.; Chiu, G.; Nagarathnam, D.; Fang, J.; Shen, Q.; Forray, C.; 
 Ransom, R. W.; Chang, R. S.; Vyas, K. P.; Zhang, K.; Gluchowski, C. 
 Bioorg.Med. Chem. Lett. 2000, 10 (2), 175. 
[168]  http://www.fda.gov/oashi/aids/virals.html. 
[169]  Schinazi, R. F.; Hernandez-Santiago, B. I.; Hurwitz, S. J. AntiViral Res. 2006,  71, 322. 
[170] Fokunang, C. N.; Hitchcock, J.; Spence, F.; Tembe-Fokunang, E. A.; Burkhardt, 
 J.; Levy, L.; George, C. Int. J. Pharmacol. 2006, 2, 152. 
 
 
Synthesis and Characterization of N-cyclo…. 
 
147
[171]  Young, B.; Kuritzkes, D. R. Infect. Dis. Ther. 2002, 25, 257. 
[172] Bacheler, L. T. Drug Resist. Updates 1999, 2, 56. 
[173]  Yeni, P. J. Hepatol. 2006, 44, S100-S103. 
[174]  Palella, F. J. D. K.; Moorman, A. N. Engl. J. Med. 1998, 338, 853. 
[175] Gazivoda, T.; Raic´-Malic´, S. J. Med. Chem. 2007, 50 (26), ------------- 
[176] Hu, X.; Prehna, G.; Stebbins, E. C. J. Med. Chem. 2007 web release on august 07 
[177]  (a) Valadas, E.; Antunes, F. Eur. J. Radiol. 2005, 55, 154. (b) World Health 
Organization Information Resource Center.  HIV, Tuberculosis and Malaria  WHO 
Fact Sheet No. 104; WHO: Geneva, Switzerland, 2004. 
[178]  (a) Maher, D.; Raviglione, M. Clin. Chest.  2005, 26, 168-182. (b) Pilheu, J. A. 
 Int. J. Tuberc. Lung Dis. 1998, 2, 696. 
[179]  (a) World Health Organization. Global Tuberculosis Control: Sur-Veillance,Planning, 
Financing; WHO: Geneva, Switzerland, 2004; Report. (b) Raviglione,  M. C.; Snider, 
D. E.; Kochi, A. J. Am. Med. Assoc. 1995, 273, 220. 
[180] (a) Willcox, P. A. Curr. Opin. Pulm. Med. 2000, 6, 198. (b) Me´ndez, A. P.; Raviglione, 
M. C.; Laszlo, A.; Binkin, N.; Rieder,  H. L.; Bustreo, F.; Cohn, D.L.; Weezenbeek, 
C. S. B. L.-van.; Kim, S. J.; Chaulet, P.; Nunn, P.  N.  Engl. J. Med. 1998, 338, 1641. 
[181]  World Health Organization. Tuberculosis: WHO Report; WHO: Geneva, 
 Switzerland,  2002. 
[182] (a) Guerrin-Tran, E.; Thiolet, J.-M.; Rousseau, C.; Henry, S.; Poirier, C.; Che, D.; 
Vinas, J.-M.; Jarlier, V.; Robert J. Eur. J. Epidemiol. 2006, 21, 783-785. (b) Frieden, T. 
R.; Sterling, T. R.; Munsiff, S. S.; Watt, C. J.; Dye, C. Lancet 2003, 162, 887. 
[183] Cohen, J. Science  2006, 313, 1554. 
[184] Pozniak, A. J. HIV Ther.  2002, 7, 13-16. 
[185] (a) Zhang, Y. Ann. ReV. Pharmacol. Toxicol. 2005, 45, 529-564. (b) Nayyar,  A.;Jain, R.  
Curr. Med. Chem. 2005, 12, 1873. 
[186] (a) Beres, J.; Bentrude, W. G.; Balzarini, J.; De Clercq, E.; Otvos, L. J. Med.   Chem. 
1986, 29, 494-499. (b) Herdewijn, P. AntiViral Chem. Chemother. 1994, 5,  131-
146. (c) Vincent, P.; Beaucourt, J. P.; Pichat, L. Tetrahedron Lett. 1981,  22, 945-947. 
[187] Johar, M.; Manning, T.; Tse, C.; Desroches, N.; Agrawal, B.;  Kumar, R.  J.  Med. 
Chem. 2007, 50, 3696. 
[188] Werner, S.; Turner, D. M.;  Lyon, M. A.; Huryn, D. M.;  Wipf, P. SYNLET, 2006,14, 
2334.01 
 
 
PEG-400 mediated and Microwave…..  
 
 
148
Introduction 
Dihydropyridines (DHP) are the important class of organic compounds in view of its 
ample of application in the pharmaceuticals.[1,3] Arthur Hantzsch in 1882 [2] first 
reported the classical synthesis of 1,4-dihydropyridines(1,4-DHPs) which involves one 
pot three-component coupling reaction of 1 equivalent of alkyl or aryl aldehyde, 2 
equivalents of β-ketoester and 1 equivalent of ammonia at reflux temperature using either 
acetic acid or ethanol as a solvent. However, the yield of 1,4-DHPs are generally low. 
Hence numerous methodologies with improved reaction conditions have been 
documented.[3] Many of these still suffer some serious drawbacks such as unsatisfactory 
yields, tedious work-up procedure, occurrence of side reactions including aromatization, 
economically non-viable, long reaction rate, high reaction temperature etc. 
To overcome these problems, numerous modifications attempted including new Lewis 
acid catalyst, Zn[L-proline] [4] under microwave condition. The catalyst is also recycled 
up to five runs but it appreciably loss the catalytic activity for the next successive runs 
and ultimately yield loss were observed. 1,4-DHPs were also synthesized by using water-
ethanol solvent[5] system using MWI, but this process fails at high microwave power, 
because reaction mixture is rapidly heated at high microwave power leading to solvent 
evaporation and hence precipitation of the reaction mixture were observed. The synthesis 
of 1,4-DHPs is also reported in room temperature ionic liquids[6] but the rate of reaction 
is sluggish than the microwave counterparts. Of all these methodologies, the ionic liquid 
medium is the sole protocol which allows the recycling of the solvent. There is despite the 
fact that, unlike several of ‘neoteric solvent’ like ionic liquids(ILs) where toxicity and 
environmental burden data are for the most part unknown while complete toxicity profiles 
are available for a range of polyethylene glycol(PEG) molecular weights and indeed, 
many are already approved for internal consumption by US-FDA.[7] Moreover, the vapor 
density for low molecular weight PEG is greater than 1 and this is consistent with the 
industry standard for selection of alternative solvents to Volatile Organic Chemicals 
(VOCs).[8]   
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Biological profile of 1,4-dihydropyridine 
The DHP skeleton is common to numerous bioactive compounds which include various 
vasodilator, geroprotective, antihypertensive, bronchodilator, antiatherosclerotic, 
hepatoprotective, antitumor, antimutagenic and antidiabetic agents [9-14]. 
DHPs nucleolus has number of pharmacologically commercial utility as calcium channel 
blockers, as exemplified by therapeutic agents such as Nifedipine [15] Nitrendipine[16] 
and Nimodipine[17]. Second-generation calcium antagonists include DHP derivatives 
with improved bioavailability, tissue selectivity, and/or stability, such as the 
antihypertensive/antianginal drugs like Elgodipine[18], Furnidipine[19,20], 
Darodipine[21], Pranidipine[22], Lemildipine[23], Dexniguldipine[24], Lacidipine[25], 
and Benidipine[26]. Number of DHP calcium agonists has been introduced as potential 
drug candidates for treatment of congestive heart failure [27, 28]. 
The key characteristic of calcium channel blockers is their inhibition of entry of calcium 
ions via a subset of channels, thereby leading to impairment of contraction. There are 
three main groups of calcium channel blockers, i.e. dihydropyridines, phenylalkylamines 
and benzothiazepines, classic examples of which are nifedipine, verapamil and diltiazem, 
respectively [29-32]. Each has a specific receptor on the calcium channel and a different 
profile of pharmacological activity. Dihydropyridines have a less negative inotropic effect 
than phenylalkylamines and benzothiazepines but can sometimes cause reflex 
tachycardia. Dihydropyridines are able to reduce peripheral resistance, generally without 
clinically significant cardiodepression. 
Among DHPs with other types of bioactivity, Cerebrocrast[33] has been recently 
introduced as a neuroprotectant and cognition enhancer lacking neuronal-specific calcium 
antagonist properties. In addition, a number of DHPs with platelet antiaggregatory 
activity have also been discovered [34]. These recent examples highlight the level of 
ongoing interest toward new DHP derivatives and have prompted us to explore this 
pharmacophoric scaffold to develop a fertile source of bioactive molecules. 
 
Some representative Ca2+ antagonists of Dihydropyridine class are as shown below: 
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In particular, DHP-CA (calcium channel antagonist DHP) are extensively used for the 
treatment of hypertension,[35] subarachnoid hemorrhage,[36, 37] myocardial 
infarction[38-41]and stable[42, 43] and unstable angina[44,45] even though recently their 
therapeutic efficacy in myocardial infarction and angina has been questioned[46]. This 
class of compounds is also under clinical evaluation for the treatment of heart failure [47], 
ischemic brain damage [48] nephropathies, and atherosclerosis [49]. 
1,4- DHPs having  different pharmacological activities such as antitumor[50], 
vasodilator[51], coronary vasodilator and cardiopathic[52], antimayocardiac ischemic, 
antiulcer[53], antiallergic[54], antiinflammatory[55] and antiarrhythmic[56], PAF 
antagonist[57], Adenosine A3 receptor antagonist[58] and MDR reversal activity[59,60]. 
 
It is found recently that when the imidazolyl moiety is linked to the phenyl ring by means 
of a C-N bridge, the activity tends to decrease. Finally, the replacement of DHP itself by a 
pyridine ring gives an inactive compound [61]. 
 
 
 
 
 
 
 
 
 
Cozzi  et al56 have synthesized a series of 4-phenyl-1,4-dihydropyridines bearing 
imidazol-1-yl or pyridine-3-yl moieties on the phenyl ring, with the aim of combining 
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Ca2+ antagonism and thermboxane A2(TxA2) synthase inhibition in the same molecules. 
Some of the compounds showed significant combined activity in vitro, while other 
showed single activity. As far as Ca2+ antagonism is concerned, two points deserve 
comment. First, the SAR, in most cases, does not differ substantially from that reported 
for classic DHP-CA, even though the potency is lower than that found with the most 
potent drugs of this class as, for example, reference compound nifedipine. In fact, Ca2+ 
antagonism is dramatically reduced by (a) replacement of DHP by a pyridine ring, (b)    
substitution of DHP nitrogen N-1 by a methyl group, (c) para substitution on the phenyl 
ring, and (d) replacement of one ester function by a ketone or carboxy group. All these 
variations are also detrimental in classic DHP-CA.[62] 
Hernandez-Gallegos et al [63] have synthesized new 1,4-dihydropyridines and evaluated 
their relaxant ability (rat aorta), antihypertensive activity in spontaneously hypertensive 
rats and their microsomal oxidation rate (MOR) was determined. 
 
 
 
 
 
 
 
R = 3-NO2, 4-F, 3,5-di-F, 3-Br-4-F.
R1 = R2= Me, Et, -CH2-CF3, -CH2CH2-OPh, -(CH2)2-N(CH3)-CH3-Ph  
Christiaans and Timmerman [64] studied new molecules like CV-159 for possible 
variation at 3-position. 
 
 
 
 
 
 
 
Carlos et al [65] reported 1,4-DHPs derivatives with a 1,2-benzothiazol-3-one-1-
sulphoxide group, linked through an alkylene bridge to the C3 carboxylate of the DHP 
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ring, with both vasoconstricting and vasorelaxant properties were obtained. In blocking 
Ca2+ evoked contractions of K+ depolarized rabbit aortic strips. Many compounds were 10 
times more potent than nifedipine. Their vascular versus cardiac selectivity was very 
pronounced. 
 
 
 
 
 
 
Schramm and coworker [66] have proved that phenyl carbamoyl moiety in 
dihydorpyridine affords for cardiovascular selective activity. 
Reddy and coworkers[67] synthesized 4-aryl hetroaryl-2,6-dimethyl-3,5-bis-N-(2-methyl 
/ 2-chloro phenyl)carbamoyl-1,4-dihydropyridines through one-pot synthesis using 
appropriate aromatic aldehydes and liquid ammonia. Pharmacological screening of the 
new 1,4-dihyropyridines were also carried out for CNS depresant (anticonvulsant and 
analgesic) and cardiovascular (inotropic and blood pressure) activities by standard 
methods. 
 
 
 
 
 
Similarly Kelvin Cooper (Pfitzer , USA) et al[68] found that DHP can be highly selective 
as platlet activating factor (PAF) antagonist. They found potent compounds and prove 
that platlet aggregating activity (PAF) exhibits a wide spectrum of biological activities 
elicited either directly or via the release of other powerful mediator such as Thromboxane 
A2 or the Leukotrienes. In vitro PAF stimulates the movement and aggregation and the 
release there from of tissue damaging enzymes and oxygen radicals. Accordingly 
compounds like UK-74505, antagonize the action of PAF and consequently also prevent 
mediator release by PAF, will have clinical utilities in the treatment of the variety of the 
allergic, inflammatory and hypersecretory conditions such as asthama, arthritis, rhinitis, 
bronchitis and utricaria in future. [69] 
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Neamati and coworkers [70] reported that a 1,4-dihydorpyridine NCS-372643 came out 
with its anti-HIV activity, which has opened up the synthetic as well as pharmacological 
importance in antiviral area also. 
 
 
 
 
 
Sonja [71] and group have synthesized a new series of calcium channel agonists 
structurally related to Bay K8644, containing NO donor furoxans and the related furazans 
unable to release NO. The racemic mixtures were studied for their action on L-type Ca2+ 
channels expressed in cultured rat insulinoma RINm5F cells. All the products proved to 
be potent calcium channel agonists 
 
 
 
 
 
 
 
2-Heterosubstituted-4-aryl-l,4-dihydro-6-methyl-5-pyrimidinecarboxylic acid esters, 
which lack  the potential C3 symmetry of dihydropyridine calcium channel blockers, were  
evaluated for biological  activity. Biological assays using potassium-depolarized rabbit 
aorta and radioligand binding techniques showed that some of these compounds are 
potent mimics of dihydropyridine calcium channel blockers. The combination of a 
branched ester (e.g. isopropyl, sec-butyl) and an alkylthio group (e.g. SMe) was found to 
be optimal for biological activity[72].  
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Labedipinedilol-A, a novel dihydropyridine-type calcium antagonist, has been shown to 
induce hypotension and vasorelaxation. Liouand co-workers have studied to investigate 
the effect of labedipinedilol-A on vascular function of rat aortic rings and cultured human 
umbilical vein endothelial cells (HUVECs). [73] 
Recent reports show that efonidipine, a dihydropyridine Ca2+ antagonist, has blocking 
action on T-type Ca channels, which may produce favorable actions on cardiovascular 
systems. However, the effects of other dihydropyridine Ca antagonists on T-type Ca 
channels have not been investigated yet. Therefore, Furukawa and group [74] have 
examined the effects of dihydropyridine compounds clinically used for treatment of 
hypertension on a T-type Ca channel subtype, alpha1G, expressed in    Xenopus oocytes. 
Twelve DHPs (amlodipine, barnidipine, benidipine, clinidipine, efonidipine, 
felodipine, manidipine, nicardipine, nifedipine, nilvadipine, nimodipine, 
nitrendipine) mibefradil were tested. Cilnidipine, felodinpine, nifedipine, nilvadipine, 
minodipine and nitrendipine had little effect on the T-type channel. The blocks by drugs 
at 10 muM were less than 10% at a holding potential of -100 mV. The remaining 6 drugs 
had blocking action on the T-type channel comparable to that on the L-type channel. 
These results show that many dihydropyridine Ca2+ antagonists have blocking action on 
the T-type channel comparable to that on the L-type channel. These results show that 
many dihydropyridine Ca+2 antagonists have blocking action on the alpha1G channel 
subtype. Joanna Rzeszowska-Wolny et al reported that compounds of the 1,4-
dihydropyridine (1,4-DHP) series  have been shown to reduce spontaneous, alkylation- 
and radiation induced mutation rates in animal test systems. Studies using AV-153, the 
1,4-DHP derivative that showed the highestantimutagenic activity in those tests, to 
examine if it modulates DNA repair in human peripheral blood lymphocytes and in two 
human lymphoblastoid cell lines.[75] 
N
N
H
R2X
COOR3
N
H
R2X
COOEtEtOOC
NO2
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1,4-Dihydropyridines are now established as heterocycles having numerous applications 
and having widened scope for its pronounced drug activity like calcium channel 
antagonism and antihypertensive action. Many other activities are associated with such 
compounds and they can be presented in the structure as 2,6-dimethyl-3,5-diacetyl or 
dicarboxylate or dicarbamoyl or many other homoaryl or heteroaryl carbon chain having 
C2 to C8 1,4-dihydropyridines substituted at 4-position.[76-81] 
 
In continuation of earlier work on DHPs, an improved synthetic protocol is used to 
prepare several structurally diverse 1,4-dihydropyridines.  
In short, in viewing the benignity and superiority of PEG as a solvent over ionic liquids 
and other reported protocols for the synthesis of 1,4-DHPs as mentioned earlier, herein 
we disclose our findings by using PEG-400 as a solvent for the rapid microwave assisted 
multi component reaction (MCR)  
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Reaction Scheme 
 
Step-I 
 
 
 
 
 
 
 
 
 
Step-II 
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Experimental Protocol 
 
Step-I  Preparation of N-(3-(Trifluoromethyl)phenyl)-3-oxobutanamide 
3-trifluoromethyl aniline (0.3 mol) and 3 ml concentrated KOH solution in water was 
stirred well until the clear solution was observed. methyl acetoacetate (0.27 mol) was 
added into it, stirred for five minutes. 100 ml toluene was added into it and refluxed for 6-
7 hours, TLC was checked for the completion of the reaction, slight starting materials 
remain unreacted. Reaction mixture was cooled to room temperature and added 100 ml 
toluene.  It was added into 250 ml 5% HCl solution and transferred into separating funnel, 
and toluene layer was collected. Toluene layer was again washed with 100 ml 5% HCl 
solution, twice with 100 ml of water and 50 ml Brine solution. Organic layer was 
collected, dried over anhydrous sodium sulphate. Solvent was distilled out by using 
rotavapor at 40oC, Oily residue was observed. 50 ml Pet. Ether was added into it and kept 
in refrigerator, stirred well for 30 minutes at 20oC. Pet. Ether was decanted. Again 50 ml 
Pet. Ether was added and scratched out at 20oC. Solid product was separated; it was dried 
in an oven. 
TLC System: (Hexane: Ethyl acetate) 
                                8    :        2 
Yield: 65% 
 
 
Step-II Preparation of N3,N5-Bis(3-(trifluoromethyl)phenyl)-1,4-dihydro-
2,6-dimethyl-4-(Substituted phenyl)pyridine-3,5-dicarboxamide 
(General Method) 
In 150 ml microwave flask, 2.5 equivalent of ammonium acetate and 15 ml PEG was 
added and stirred until the clear solution was observed. 1.0 equivalent of acetoacetanilide 
and 1.0 equivalent of different substituted banzaldehyde was added. It was subjected to 
microwave irradiation (300 W) at 80oC temperature for 5-8 minutes. Remove microwave 
flask from microwave instrument, it was stand to room temperature until solid product 
was observed. It was filtered and recrystallized in methanol. 
In some cases, solid product was observed. It was filtered and recrystallized in Methanol.  
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Reaction time and yield are depicted in physical data table No. 4 
 
TLC System: (Chloroform: Ethyl Acetate) 
                                7    :        3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Physical data of N3,N5-bis(3-(trifluoromethyl)phenyl)-1,4-dihydro-2,6-dimethyl-4-
(Substituted phenyl)pyridine-3,5-dicarboxamide 
 
N
H
N
H
O
N
H
O
F3C CF3
R
 
Table. No: 4 
C, H , N Analysis Code.No Substitution R M.F M.W M.P
 OC Time (Min) 
Yield 
(%) C H N 
RKDHP-1 H C29H23F6N3O2  559.5 239-240 5 78 62.25 (62.20) 
4.14 
(4.17) 
7.51 
(7.48) 
RKDHP-2 -2-Cl C29H22ClF6N3O2  593.95 220-222 7 82 58.64 (58.61) 
3.73 
(3.78) 
7.07 
(7.10) 
RKDHP-3 -4-SCH3 C30H25F6N3O2S  605.59 258-260 6 85 59.50 (59.55) 
4.16 
(4.13) 
6.94 
(6.98) 
RKDHP-4 -4-OCH3 C30H25F6N3O3  589.53 225-226 5 74 61.12 (61.08) 
4.27 
(4.22) 
7.13 
(7.18) 
RKDHP-5 -2-OCH3 C30H25F6N3O3  589.53 250-251 5 82 61.12 (61.17) 
4.27 
(4.23) 
7.13 
(7.18) 
RKDHP-6 -3,4-diOCH3 C31H27F6N3O4  619.55 222-223 8 71 60.10 (60.07) 
4.39 
(4.36) 
6.78 
(6.80) 
RKDHP-7 -3-NO2 C29H22F6N4O4  604.5 242-244 7 76 57.62 (57.58) 
3.67 
(3.72) 
9.27 
(9.31) 
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Table. No: 4 
 
C, H , N Analysis Code.No Substitution R M.F M.W M.P
 OC Time (Min) 
Yield 
(%) C H N 
RKDHP-8 -4-Cl C29H22ClF6N3O2  593.95 220-222 6 83 58.64 (58.61) 
3.73 
(3.78) 
7.07 
(7.10) 
RKDHP-9 3-Br C29H22BrF6N3O2  638.4 178-180 6 79 54.56 (54.51) 
3.47 
(3.41) 
6.58 
(6.54) 
RKDHP-10 -4-NO2 C29H22F6N4O4  604.5 240-242 5 84 57.62 (57.57) 
3.67 
(3.65) 
9.27 
(9.22) 
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Spectral Discussion 
 
1H NMR spectral study 
1HNMR of the N3,N5-bis(3-(trifluoromethyl)phenyl)-1,4-dihydro-2,6-dimethyl-4-
(Substitutedphenyl)pyridine-3,5-dicarboxamide compounds were recorded on DPX-
300MHz FT-NMR spectrophotometer (Bruker) instrument using TMS as an internal 
reference standard in DMSO-D6 solvent. 1HNMR spectra show the number of proton & 
chemical environment of each proton in each compound. The singlet observed for both 
methyl (–CH3) of two and six position of dihydropyridine in the range of δ 1.8-2.2. 
Asymmetric Methine proton gives singlet in the range of δ 5.0-5.4.  The pattern of the 1-
HNMR spectra between δ 6.8-8.0 clearly indicated that the benzene ring attached to the 
unsymmetrical carbon atom is meta or para substituted.  Both carbamoyl (-CO-NH) 
protons gives singlet in the range of δ 9.0-9.2. dihydropyrimidine (-NH) gives singlet in 
the range of δ 8.0-8.3. Both  (-CH) attached between  –NH and  (C-CF3) gives singlet δ 
7.4-7.8.  
 
FT-IR spectral study 
IR spectra were recorded on Shimadzu FTIR-8400 using KBr Disc and DRS techniques. 
The percentage transmission is given in cm-1. The different frequencies of infrared 
spectrum of N3,N5-bis(3-(trifluoromethyl)phenyl)-1,4-dihydro-2,6-dimethyl-4-
(Substituted phenyl)pyridine-3,5-dicarboxamide are studied.  The carbonyl frequencies 
appeared for amide in the range of (1650-1690cm-1). The presence of secondary amine 
was confirmed at 3000-3400 cm-1. The CF3 group stretching vibrations observed at 1000-
1380cm-1.  
 
Mass spectral study 
The mass spectrums of the all compounds of this series were recorded by GCMS-QP2010 
spectrometer. (EI method) The molecular ion peak (M+) values are in good match with 
molecular formula for synthesized compound. Probable mass fragmentation of N3,N5-
bis(3-(trifluoromethyl)phenyl)-1,4-dihydro-2,6-dimethyl-4-(Substituted phenyl)pyridine-
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3,5-dicarboxamide is represented in subsequent pages. Different fragmentation pattern is 
also observed in all synthesized compounds.  
 
Elemental Analysis 
Elemental analysis of the synthesized compounds was carried out Elementar Vario EL III 
Carlo Erba 1108 model at CDRI, Lucknow and the results are in agreement with the 
structures assigned.  
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Spectral Data 
N3,N5-Bis(3-(trifluoromethyl)phenyl)-1,4-dihydro-2,6-dimethyl-4-phenylpyridine-
3,5-dicarboxamide (RKDHP-1) 
1H-NMR (300 MHz, DMSO-d6): δ 2.10 (s, 6H),  5.12 (s, 1H), 7.08 (m, 1H), 7.22 (t, 4H, 
J=3.048 Hz), 7.31 (d, 2H, J=7.386 Hz) 7.47 (m, 2H, J=7.85 Hz), 7.78 (d, 2H, J=7.965 
Hz), 8.06 (s, 2H), 8.21 (s, 2H), 9.65 (s, 2H) 
IR (KBr Disc): 3298-3408cm-1(-NH), 2850-2976cm-1 (C-H), 1672cm-1(-CO-NH), 1599 
cm-1 (-NH Bend),  1150-1170cm-1 (C-F)   
 
4-(2-Chlorophenyl)-N3,N5-bis(3-(trifluoromethyl)phenyl)-1,4-dihydro-2,6-dimethyl 
pyridine-3,5-dicarboxamide (RKDHP-2) 
1H-NMR (300 MHz, DMSO-d6): δ 2.09 (s, 6H),  5.44 (s, 1H), 7.15 (m, 2H), 7.30 (m, 3H, 
J=8.074 Hz), 7.45 (m, 3H, J=7.85 Hz) 7.74 (d, 2H, J=8.007 Hz), 8.06 (s, 2H), 8.31 (s, 
1H), 9.76 (s, 2H) 
IR (KBr Disc): ): 3294-3421cm-1(-NH), 2850-2976cm-1 (C-H), 1660 cm-1(-CO-NH), 
1602 cm-1 (-NH Bend),  1124-1165cm-1 (C-F), 750 cm-1 (C-Cl) 
 
N3,N5-Bis(3-(trifluoromethyl)phenyl)-1,4-dihydro-2,6-dimethyl-4-(4-(methylthio) 
phenyl)pyridine-3,5-dicarboxamide (RKDHP-3) 
1H-NMR (300 MHz, DMSO-d6): δ 2.10 (s, 6H), 2.26 (s, 3H),  5.08 (s, 1H), 7.13 (m, 4H, 
J=8.30 Hz), 7.31 (d, 2H, J=7.869 Hz), 7.47 (t, 2H, J=7.90 Hz) 7.79 (d, 2H, J=7.971 Hz), 
8.07 (s, 2H), 8.22 (s, 1H), 9.65 (s, 2H) 
IR (KBr Disc): ): 3199-3430cm-1(-NH), 2860-2985cm-1 (C-H), 1680cm-1(-CO-NH), 
1605 cm-1 (-NH Bend),  1135-1156cm-1 (C-F)   
 
N3,N5-Bis(3-(trifluoromethyl)phenyl)-1,4-dihydro-4-(4-methoxyphenyl)-2,6-
dimethylpyridine-3,5-dicarboxamide (RKDHP-4) 
1H-NMR (300 MHz, DMSO-d6): δ 2.09 (s, 6H), 3.64 (s, 3H),  5.07 (s, 1H), 6.76 (d, 2H, 
J=8.58 Hz), 7.14 (d, 2H, J=8.56 Hz), 7.30 (d, 2H, J=7.485 Hz), 7.47 (t, 2H, J=7.914 Hz), 
7.78 (d, 2H, J=8.076 Hz), 8.07 (s, 2H), 8.17 (s, 1H), 9.60 (s, 2H) 
IR (KBr Disc): 3288-3352cm-1(-NH), 2870-2960cm-1 (C-H), 1666.55cm-1(-CO-NH), 
1599 cm-1 (-NH Bend), 1228 cm-1 (C-O-C), 1118-1166cm-1 (C-F)   
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N3,N5-Bis(3-(trifluoromethyl)phenyl)-1,4-dihydro-4-(2-methoxyphenyl)-2,6-
dimethylpyridine-3,5-dicarboxamide (RKDHP-5) 
1H-NMR (300 MHz, DMSO-d6): δ 2.16 (s, 6H), 3.59 (s, 3H),  5.37 (s, 1H), 6.85 (m, 2H), 
7.07(t, 1H, J=4.365 Hz), 7.20 (d, 1H, J=6.06 Hz), 7.32 (d, 2H, J=7.41 Hz), 7.50 (t, 2H, 
J=7.89 Hz), 7.78 (d, 2H, J=7.95 Hz), 8.10 (s, 2H), 8.34 (s, 1H), 9.54 (s, 2H) 
IR (KBr Disc): 3308-3399cm-1(-NH), 2829-2952cm-1 (C-H), 1678.13cm-1(-CO-NH), 
1597.11 cm-1 (-NH Bend), 1238 cm-1 (C-O-C), 1124-1163cm-1 (C-F)   
 
N3,N5-Bis(3-(trifluoromethyl)phenyl)-1,4-dihydro-4-(3,4-dimethoxyphenyl)-2,6-
dimethylpyridine-3,5-dicarboxamide (RKDHP-6) 
IR (KBr Disc): 3360-3459cm-1(-NH), 2854-2976cm-1 (C-H), 1697.32cm-1(-CO-NH), 
1596.65 cm-1 (-NH Bend), 1238-1245 cm-1 (C-O-C), 1111-1176cm-1 (C-F)   
 
N3,N5-Bis(3-(trifluoromethyl)phenyl)-1,4-dihydro-2,6-dimethyl-4-(3-
nitrophenyl)pyridine-3,5-dicarboxamide (RKDHP-7) 
IR (KBr Disc): 3312-3345cm-1(-NH), 2829-2952cm-1 (C-H), 1678.13cm-1(-CO-NH), 
1597.11 cm-1 (-NH Bend), 1238 cm-1 (C-O-C), 1124-1163cm-1 (C-F)   
 
4-(4-Chlorophenyl)-N3,N5-bis(3-(trifluoromethyl)phenyl)-1,4-dihydro-2,6-
dimethylpyridine-3,5-dicarboxamide (RKDHP-8) 
IR (KBr Disc): 3258-3480cm-1(-NH), 2847-2951cm-1 (C-H), 1680.85cm-1(-CO-NH), 
1576.32 cm-1 (-NH Bend), 1235 cm-1 (C-O-C), 1124-1163cm-1 (C-F), 750 cm-1 (C-Cl) 
  
4-(3-Bromophenyl)-N3,N5-bis(3-(trifluoromethyl)phenyl)-1,4-dihydro-2,6-
dimethylpyridine-3,5-dicarboxamide (RKDHP-9) 
IR (KBr Disc): 3329-3431cm-1(-NH), 2827-2943cm-1 (C-H), 1678.13cm-1(-CO-NH), 
1578 cm-1 (-NH Bend), 1215-1236 cm-1 (C-O-C), 1144-1153cm-1 (C-F),   
 
N3,N5-Bis(3-(trifluoromethyl)phenyl)-1,4-dihydro-2,6-dimethyl-4-(4-
nitrophenyl)pyridine-3,5-dicarboxamide (RKDHP-10) 
IR (KBr Disc): 3340-3480cm-1(-NH), 2870-2957cm-1 (C-H), 1690.52cm-1(-CO-NH), 
1576 cm-1 (-NH Bend), 1224-1234 cm-1 (C-O-C), 1120-1135cm-1 (C-F)  
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Mass value of N3,N5-bis(3-(trifluoromethyl)phenyl)-1,4-
dihydro-2,6-dimethyl-4-(Substitutedphenyl)pyridine-3,5-
dicarboxamide 
 
 
Compound 
Code.No 
(m/z) 
Relative intensity 
RKDHP-1 559.5 (35%) 
RKDHP-2 593.95 (40%) 
RKDHP-3 605.59 (42%) 
RKDHP-4 589.53 (45%) 
RKDHP-5 589.53 (37%) 
RKDHP-6 619.55 (32%) 
RKDHP-7 604.5 (30%) 
RKDHP-8 593.95 (30%) 
RKDHP-9 638.4 (30%) 
RKDHP-10 604.5 (30%) 
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Spectra of the representative compounds 
 
[a] 1H NMR Spectrum of RKDHP-1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[b] 1H NMR Spectrum of RKDHP-2 
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[c] 1H NMR Spectrum of RKDHP-3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[d] 1H NMR Spectrum of RKDHP-4 
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[e] 1H NMR Spectrum of RKDHP-5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[f] 1H NMR Spectrum of RKDHP-6 
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[g] Mass Spectrum of RKDHP-4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[h] Mass Spectrum of RKDHP-2 
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[i] Mass Spectrum of RKDHP-3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[j] Mass Spectrum of RKDHP-5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
H
N
H
O
N
H
O
F3C CF3
SCH3
N
H
N
H
O
N
H
O
F3C CF3
OCH3
 
PEG-400 mediated and Microwave…..  
 
 
171
[k] Spectrum of RKDHP-1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[l] Spectrum of RKDHP-2 
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[m] Spectrum of RKDHP-5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[n] IR Spectrum of RKDHP-4 
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Conclusion 
 
In the present work, the Hantzch-pyridine type cyclocondensation(MCRs) of 
acetoacetanilide bearing a 3-Trifluoromethyl group have been studied.  In order to reduce 
the reaction time, increase the yield and clean process, reaction of acetoacetanilide with 
different substituted benzaldehyde and ammonium acetate in PEG-400 at 80oC 
temperature under influence of microwave (300W) was afforded, Dihydropyridines at 
carbon C3 and C5 with 3-Trifluoromethyl Phenyl carbamoyl functional group were 
prepared.  
In current work replacement of ester group with (3-triflouromethyl) phenyl ring by 
Hantzch-pyridine three-component cyclocondensation reaction with slight modification in 
acetoacetanilide was successfully employed with dual support of PEG mediated and 
microwave supported synthetic method. It shows that slight change in the building blocks 
can create a new diversity and ultimately several novel dihydropyridines are obtained. 
The biological properties of these substances are currently under investigation.  
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Introduction 
 
SYNTHETIC APPROACH 
Several methods have been reported for the different isomer of the Pyrazolo pyrimidines. 
Several synthetic outlines from the literature survey are depicted below.  
 
SCHEME 1 [1] 
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NHR1
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Reagents and condition 
Acetic acid, reflux (30min) 
SCHEME 2 [2]  
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N OCHO
d, e f
g, h
1
2 3
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5
6
Reagents and condition 
(a) H2 (1 atm), 10% Pd/C, EtOH (95%); (b) NaNO2, HCl/H2O, 0oC; then ethyl 
cyanoacetate, NaOAc, MeOH/H2O, 0oC (55%); (c) BrCH2CO2Me, K2CO3, DMF, 90oC 
(10– 20%); (d) NaNO2, TFA, 0oC; then NaN3 (80%); (e) LiOH, THF/H2O (90%); (f) 
(COCl)2, CH2Cl2; then 4, DMAP, CH2Cl2 (70%); (g) SnCl2ÆH2O, MeOH, 65oC; (h) 95% 
HCO2H, reflux (70% for two steps); (i) AcNHOH, K2CO3, DMF; (j) K2CO3, EtOH, 65oC 
(45% for two steps); (k) PBr3, CH2Cl2; (l) pyrrolidine, CH3CN, (50% for two steps). 
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SCHEME 3 [3] 
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Reagents and condition 
(a) PPh3/Br2 (b) ArNCO (c) K2CO3 
SCHEME 4 [4] 
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Reagents and condition 
(a) i-Pr2NEt, Toluene, 1h, reflux (b) Cl3CCl3, PPh3, EDC, i-Pr2NEt, (c) R-NH2, CHCl3, 
reflux 
SCHEME 6 [6] 
N
O
OH
O
a N
O
OH
O
I
N
O
N
H
O
I
N
N
NH2O
Nb
c
N
O
N
H
N
I
N
N
O
N
1 2 3
4  
 
Reagents and condition 
(a) NIS (N-Iodo succinimide), TFA (Trifluoro acetic acid) , TFAA (Trifluoro acetic 
anhydride, reflux (b) (COCl)2, MDC, DMF, 0oC to RT, then 4-amino-5-ethyl-1-(2-
pyridinylmethyl)-1H-pyrazole-3-carboxamide, Pyridine, MDC, rt (c) KHDMS, n-
propanol, reflux 
SCHEME 7 [7] 
 
NC
S S
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O
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O S
R1  
 
Reagents and condition 
(a) R1 NHNH2, MeOH, reflux (b) CH3CONH2, Heat (c) CH3CO2Et, NaOEt, EtOH 
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Biological Activity Displayed by Pyrazolo pyrimidines 
 
The biological activity of pyrazolo pyrimidines is enlisted as below. 
 
1. CDK-inhibitors 
2. Phosphodiesterase 5 inhibitors (PDE5 inhibitors) 
3. Activity against Thromboembolic disease 
4. Herbicidal activity 
5. Antiproliferative activity 
6. p38 Kinase inhibitors 
 
1. CDK-inhibitors 
Controlling the cell cycle by inhibition of the proteins that regulate its progression is an 
attractive strategy for addressing cancer and other diseases associated with abnormal 
cellular proliferation. [8] One family of such proteins, the cyclin-dependent kinases 
(CDKs), is made up of at least nine highly homologous enzymes that in association with 
specific regulatory subunits (cyclins) control progression of the cell cycle. [9] 
CDK/cyclin activity oscillates with cyclin expression/degradation and is further regulated 
by the action of several families of protein kinases and phosphatases. [10, 11] A series of 
checkpoints serves to ensure the viability of progeny cells by preventing progression of 
cells with damaged DNA, an inappropriate chromosome count, or for which necessary 
structural features or conditions of nourishment do not exist. Passage through an initial 
G1 restriction point occurs upon release by the retinoblastoma protein (pRb) of the 
transcription factor E2F. [12] This is triggered by phosphorylation of several S/T residues 
on pRb, the primary substrate of CDK4/cyclin D. The fate of cells that enter G1 but 
which do not progress through the G1 or subsequent checkpoints is to undergo apoptosis. 
[13]  
Since tumour cells have misregulated cell cycles, it has been postulated that they may be 
especially sensitive to agents that restore checkpoint control. The importance of these 
kinase pathways is highlighted by the fact that the genes encoding CDKs, their cyclin 
partners, or their endogenous peptide inhibitors (CKIs) are mutated in a large proportion 
of human tumours. [14] One family of CKIs, the CIP/KIP class, is relatively 
promiscuous, having affinity for CDK2, CDK3, CDK4, and CDK6. [15] CKIs in the 
INK4 class, however, are highly selective for the closely related CDKs 4 and 6, 
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suggesting the possibility of selective inhibition by small molecule mimics. For these 
reasons, we sought to discover small-molecule protein kinase inhibitors that were 
selective for CDK/cyclin complexes, specifically CDK4/cyclin D1. Applicability of this 
approach to cancer chemotherapy is still an unresolved question. While a number of 
small-molecule CDK inhibitors have been disclosed, clinical experience is limited to the 
ATP-competitive agent flavopiridol. [16] Flavopiridol is relatively nonselective in its 
inhibition of the various CDKs; it also appears to inhibit other protein kinases. More 
recently, great strides have been made in the search for CDK-selective kinase inhibitors, 
including the discovery of a highly selective CDK4/cyclin D inhibitor by optimization of 
a nonselective lead. [17] Markwalder, J. A. et al [18] identified a lead compound 4,5-
dihydro-1H-pyrazolo[3,4-d]pyrimidine-4-one (1)  by high-throughput screening of a 
subset of ~160000 compounds.  The compound is active against CDK4/cyclin D1 was 
performed with a readout of percentage inhibition of pRb phosphorylation at 20µM. 
Discrete IC50 values were obtained for compounds that were active upon retest and 
appeared chemically attractive. This screening strategy identified several series of 
inhibitors with modest potency (IC50‹ 50µM) 
HN
N N
N
O S
CF3
Cl
Cl
1  
 
Recently Markwalder et al [19] have patented the following core structure 2 or it isomeric 
structure 3 as a potent CDK inhibitors. 
HN
N
O
R6
R1
R3
Where R1= Hydrogen, alkyl, cycloalkyl, aralkyl, etc.
            R3=Hydrogen or lower alkyl
            R6= Substituted or unsubstituted aralkyl or heteroaralkyl
2
N
N
OH
R6
R1
R3
3
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2. PDE5 inhibitors 
Phosphodiesterases (PDEs) are a superfamily of enzymes that degrade the intracellular 
second messengers cyclic AMP and cyclic GMP [20-22]. As essential regulators of cyclic 
nucleotide signaling with diverse physiological functions, PDEs are drug targets for the 
treatment of various diseases, including heart failure, depression, asthma, inflammation 
and erectile dysfunction [23-26]. Of the 12 PDE gene families, cGMP-specific PDE5 
carries out the principal cGMP-hydrolysing activity in human corpus cavernosum tissue. 
It is well known as the target of sildenafil citrate (Viagra) and other similar drugs for the 
treatment of erectile dysfunction. Despite the pressing need to develop selective PDE 
inhibitors as therapeutic drugs, only the cAMP-specific PDE4 structures are currently 
available [27-28]. 
 
HN
N
N
N
Et
O
N
N
O
O
S
N O
O
N
Et
PDE5 IC50 = 1.3nM
PDE6 IC50 = 386nM
F = 45% (man)
                  4
HN
N
N
N
O
N
N
O
O
PDE5 IC50 = 5.5nM
PDE6 IC50 = 840nM
Predicted F> 70% (Man)
                     5
 
The launch of sildenafil as the first oral treatment for male erectile dysfunction 
revolutionized the treatment of this disease. [29] 
Following the development of sildenafil, the PDE5 inhibitors with greater selectivity over 
phosphodiesterase type 6 (PDE6), since this enzyme is believed to be responsible for the 
low incidence of adverse visual events, such as abnormalities in color vision, associated 
with high doses of sildenafil. SAR describing how this selectivity was achieved through 
the discovery of the pyridyl methyl analogue 4 has already been published. [30] 
Compound 4 is a potent PDE5 inhibitor displaying approximately 300-fold selectivity 
over canine cone PDE6. [30] In clinical trials, compound 4 showed dose-dependent 
increases in Cmax and AUC over the dose range 1-800 mg and increases in these 
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parameters when coadministered with ketoconazole (a potent inhibitor of P-glycoprotein 
and CYP3A4).15 Further studies showed that compound 4 is a substrate for human P-
glycoprotein and CYP3A4, which explains the variations in pharmacokinetic data that 
arose when these species were either saturated or inhibited. As a consequence of these 
clinical data, we desired a PDE5 inhibitor with high and dose-independent oral 
bioavailability, since this would minimize the impact of any interactions with 
coadministered drugs in the clinic. [31] 
In order to identify a potent and selective PDE5 inhibitor with high and dose-independent 
oral bioavailability, to minimize the impact on Cmax of any interactions with 
coadministered drugs. In general, good solubility, high absorption across the intestinal 
wall, and low first-pass clearance are required for high oral bioavailability. [32] Focused 
was on reducing the first-pass clearance of soluble, rule-of-five compliant [33] PDE5 
inhibitors to achieve this objective. The piperazine sulfonamide group is the primary site 
of metabolism in the sildenafil series. [34] Consequently, finding of a more metabolically 
stable replacement for this functionality. This led to a novel series of potent and selective 
PDE5 inhibitors, with a methyl ketone at the 5’-position of the 5-(2-alkoxy-3-pyridinyl)-
2, 6-dihydro-7H-pyrazolo [4,3-d]pyrimidin-7-one 5 template. These compounds are 
relatively small (MW<500) with moderate lipophilicity, and this results in good oral 
absorption. In addition, they have low clearance (the predominant metabolite in human 
hepatocytes being the secondary alcohol) and a basic group attached at the N2 position, 
which provides good aqueous solubility via salt formation. The combination of these 
factors leads to high oral bioavailability in vivo. 
Pfizer Global Research and Development, United Kingdom team has carried out SAR of 
pyrazolo-pyrimidines for getting optimized structure of the PDE5 inhibitors. The clinical 
knowledge gained from the pioneering PDE5 inhibitor sildenafil and subsequent agents, 
has highlighted the potential of PDE5 inhibition for treatment of additional indications 
beyond male erectile dysfunction. Such indications would be best treated by highly 
selective agents suitable for chronic once daily oral dosing. This talk details the discovery 
and progression of a pyrazolopyrimidine PDE5 inhibitor series designed to display 
inherently good physicochemistry, and targeting a chronic once daily treatment goal. Key 
features can be summarized. 
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1. Rationalisation of SAR in the pyrazolopyrimidine series with emphasis on the C3 
substituent. Rationalisation includes the use of co-crystal structure information to guide 
design for potency and selectivity.  
2. An assessment of physical properties in the series with emphasis on optimising 
permeability and clearance to drive long half-life oral pharmacokinetics.  
3. In depth assessment of a PDE5 selective and physicochemically optimised lead with 
the potential for once daily dosing in man.[35] 
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3. Coagulation factor Xa 
Thromboembolic diseases remain the leading cause of death and disability in developed 
countries. This reality, combined with the limitations of current therapies, has led to 
extensive efforts to develop novel antithrombotic agents. [36] Factor Xa has become a 
major focus of pharmaceutical intervention in the past decade because of its central role 
in the blood coagulation cascade. [37] Extensive preclinical and clinical evidence has 
demonstrated that inhibition of factor Xa is efficacious in both venous and arterial 
thrombosis. [38, 39] Previously, it was demonstrated that a series of non-benzamidine N-
arylpyrazole carboxamides, represented by the 3-aminobenzisoxazole P1 analog 
razaxaban [40] were highly potent, selective, and orally bioavailable small molecule fXa 
inhibitors (Fig. 1). Razaxaban has been shown to be efficacious in phase II deep vein 
thrombosis (DVT) clinical trials. [41] Furthermore, it was demonstrated that the 4-
methoxyphenyl residue could be an effective P1 group when combined with an optimized 
pyrazole-P4 subunit, as in compound 7. [42] Recently, bicyclic core variants of 2, 
represented by the 1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one 8, [43] have been shown to 
retain potent binding affinity for fXa. These bicyclic variants were also expected to be 
less susceptible to in vivo amide hydrolysis, which in the case of N-arylpyrazole 
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carboxamides such as (6) and (7) would liberate a biarylaniline fragment. However, 
compound (8) was found to have only modest efficacy in a rabbit rteriovenous (A-V) 
shunt thrombosis model [44] relative to razaxaban. This was rationalized on the basis of 3 
being 5-fold less potent than razaxaban. [43]  
Li, Y. L. et al [45] have synthesized and screened a small library and screened for their 
coagulation factor Xa. Among the designed series compounds 9, 10 and 11 are not only 
potent fXa inhibitors, but they are also highly selective versus relevant serine protease. 
Compound has a favourable pharmacokinetic profile in dogs, with lower clearance and 
longer hald-life relative to Razaxaban. Furthermore, 9, 10 and 11 are highly efficacious in 
the rabbit A-V shunt thrombosis model, with activity comparable to the clinical 
candidate, razaxaban.  
FH
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4. Herbicidal activity 
Liu, Z. et al [46] have synthesized the small library of 6-(4-
alkoxycarbonylalkoxy)phenoxy-3-alkylthio(alkylsulphonyl)-1-phenyl-5-(substituted 
phenyl)pyrazole[3,4-d]pyrimidin-4-ones and screened for the herbicidal activity. The 
herbicidal activity of all the compounds were taken against brassica napus (rape) and 
echinochloa crus-galli (barnyard grass) has been investigated at the dosage of 100 and 
10mg/L using the reported procedure, compared with the distilled water and 2,4-
dichlorophenoxyl acetic acid (2,4-D), a commercially available herbicide in the market. 
The results of preliminary bioassay showed that some of them exhibit good herbicidal 
activities. Out of the designed series compounds 12, 13, 14, 15 and 16 showed more than 
90% inhibitory rate to root of rape and barnyard grass at 100mg/L. it is also interesting to 
note that ethyl ester showed higher herbicidal activity than the corresponding methyl ester 
and n-propyl ester in general. The reason may be the hydrolysis of the products. 
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5. Antiproliferative activity 
The understanding of the fundamental biology of cancer increased dramatically in recent 
years [47] and has strongly impacted on both experimental and gradually also on clinical 
tumour therapy. We now believe that the future of tumour therapy is in the development 
of molecularly targeted agents that specifically block key mechanisms involved in 
development and progression of specific types of cancer. [48] Due to their critical role in 
tumour development and progression, molecules capable of inhibiting protein kinases are 
of central interest in targeted cancer therapy. In particular, tyrosine kinases (TKs) are 
enzymes that catalyze the specific phosphorylation of tyrosine residues on proteins. 
Protein tyrosine kinases (PTKs) participate in a wide variety of cellular activities 
including proliferation, secretion, adhesion, and responses to mitogens and stress. [49, 50] 
The TK Src is the prototype member of the nonreceptor Src family of PTKs that include 
c-Yes, Fyn, c-Fgr, Lyn, Lck, Hck, Clk, Yrk, and c-Src. [51] In particular, the nonreceptor 
pp60c-Src PTK transduces signals that control the above cellular processes. [52-54] Src is 
activated following engagement of many different classes of cellular receptors and 
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participates as a convergence point in different signaling pathways. [49, 50, 55] In this 
regard, Src is a critical component of the signaling cascades initiated by tyrosine kinase-
linked receptors, such as the epidermal growth factor receptor (EGFR), and Gprotein 
coupled receptors and is directly associated with, and may regulate signaling via, the 
EGFR and HER-2/ neu receptor PTKs, [56, 57] both of which are involved in cancer. 
Finally, Src overexpression and activation has been correlated with a large number of 
growth-regulatory processes in which Src participates. In particular, the Src protein is 
overexpressed in many tumours such as colon, breast, gastric, and prostatic tumours and 
plays a key role in controlling their proliferation and invasiveness. [58, 59] On the basis 
of these considerations, inhibitors of Src phosphorylation process may stop uncontrolled 
tumour cell growth and play an important role as new therapeutic agents for the treatment 
of cancer. During the past decade, examples of pyrazolo[3,4-d]-pyrimidines active as TKs 
inhibitors have been reported in the literature by different authors. Many of these 
compounds were highly active, and some of them have been largely used as standard or 
reference compounds and as a tool to set up in vitro assays and to prove their 
functionality. However, only a few demonstrated in vivo activity. As an example, 
approaches aimed at identifying ATP-competitive small molecules led to the 
characterization of derivatives 1 as potent inhibitors of EGFR TK, (17) [60] while PP1 
and PP2 (10) were described as very strong and selective inhibitors of the c-Src family of 
kinases. [61] Unfortunately, attempts to improve the biological profile of the latter 
compounds have so far met little success. Following these studies, some other inhibitors, 
possessing different chemical structures and interesting c-Src inhibitory activity, have 
been recently reported. In particular, pyrrolo[2,3-d]pyrimidines have been described as 
selective and potent inhibitors of c-Src with inhibition potency of about 10nM and 20-
fold selectivity toward a panel of other TKs. [62] Other efforts directed to c-Src kinase 
inhibitors included substituted 5,10-dihydropyrimido[4,5-b]quinolines, showing an in 
vitro c-Src inhibition activity in the nanomolar range. [63] 
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Schenone et al [64] synthesized and screened 4-aminopyrazolo[3,4-d]pyrimidines bearing 
various substituents at position 1 and 6. The synthesized compounds were screened for 
their anti porliferative activity agintst A431 cell line. The compound 19 shows the better 
inhibitors of the Src phosphorylation than the reference compound PP2 (18). 
N
N N
N
HN
MeS Cl
n-Bu
19  
Schenone et al [65] have also synthesized a series of 4-aryl-4-amino-1H-pyrazolo[3,4-
d]pyrimidine and tested against tumour cell lines  A 431. Among the designed series the 
most potent having EC50 values 4.3 (20) and 1.4 (21). The values in the parenthesis 
denote the % inhibition of relative to the reference compound (AG1478) (22). 
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6.  p38 Kinase inhibitors 
 
Bristol-Myers Squibb Pharmaceutical Research institute reported that Pyrazolo-
pyrimidines as selective and potent p38 inhibitors. P38 kinase is a key enzyme involved in 
regulating the production and action of pro inflammatory cytokines such as tumour 
necrosis factor (TNF). Inhibitors of p38 kinase therefore may have utility in the treatment 
of multiple inflammatory diseases such as rheumatoid arthritis (RA). BMS team has 
recently discovered a novel series of pyrazolo-pyrimidines as highly potent and selective 
p38 inhibitors. The lead compound from this series possesses activity in an in vivo 
preclinical model of acute inflammation. Synthesis, SAR studies and an X-ray co-crystal 
structure of a prototypical analog bound to the enzyme will be presented. [66] 
N
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In current chapter, synthetic work carried out leading to the formation of pyrazolo[3,4-d]-
pyrimidinones by multicomponent single step reaction. The synthesis was initiated with 
the reaction of β-ketoester with hydrazine hydrate in catalytic amount of acetic acid to 
obtain pyrazolones, which further reacted with urea and substituted banzaldehyde in 
presence of HClO4-fuller’s earth and under the influence of the microwave irradiation to 
get the title compounds. 
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Reaction Scheme 
Step-I 
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Plausible mechanisms 
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Experimental protocol 
 
Preparation of Catalyst 
A 70% aqueous perchloric acid (1.8 g, 12.5 mmol) was added to a suspension of Fuller’s 
earth 23.7 g) in ether (50 ml). The mixture was concentrated and the residue was heated at 
100oC for 48 h under vacuum to give Fuller’s earth-HClO4 (0.5 mmol/g) as free flowing 
powder (50 mg = 0.025 mmol of HClO4). 
 
Step-I  Synthesis of 3-Isopropyl-1H-pyrazol-5(4H)-one 
1.0 equivalent of β-ketoester (methyl 4-methyl-3-oxopentanoate) and 2-3 drops of acetic 
acid was stirred at 20oC. 1.1 equivalent of hydrazine hydrate was added into it. It was 
stirred for 5-10 minutes at 15-20oC maintained temperature range. Solid product was 
precipitated, filtered by suction and washed twice with 20 ml of water. Then it was 
washed with methanol: water (50:50). It was dried at 40oC under vacuum for 2 hours. 
The structure of the product was confirmed by 1H NMR and 13C NMR. 
TLC System: (Hexane: Ethyl acetate) 
                                8    :        2 
Yield: 75%,  MP: - 185oC. 
 
Step-II  Synthesis of 4,5-Dihydro-3-isopropyl-4-(substituted phenyl)-1H- 
pyrazolo[3,4-d]-pyrimidine-6(7H)-ones by influence of microwave  
(General Method) 
1.5 equivalents of urea and 15 ml acetonitrile were taken in microwave flask, stirred until 
clear solution was observed. 1.0 equivalent of substituted benzaldehyde, pyrazolone and 
25mol% heterogeneous catalyst HClO4/Fuller’s earth was added into it. The reaction 
mixture was subjected to microwave irradiation at 300W power and 80oC for an 
appropriate time. Reaction was monitored by TLC, after completion of reaction as 
indicated by TLC, it was filtered at 60-65oC by suction and kept it in fridge for 2-3 hours. 
Solid product was obtained, filtered, and washed twice with 10 ml acetonitrile. It was 
dried at 50oC for 2 hours. The reaction time and percentage yields are depicted in the 
Physical Data Table. 
TLC System: (Chloroform: Methanol) +1-2 drops of acetic acid 
                               7    :        3 
 
 
 
Microwave-Accelerated and classical… 
 
197
Step-II  Synthesis of 4,5-Dihydro-3-isopropyl-4-(substituted phenyl)-1H- 
pyrazolo[3,4-d]-pyrimidine-6(7H)-ones by conventional method  
(General Method) 
The intimate mixture of banzaldehyde (1.0 equivalent), pyrazolone (1.0 equivalent) and 
urea (1.5 equivalents) was stirred in acetonitrile (20ml) until clear solution was observed. 
Conc. HCl (3-4 drops) was added as the catalyst. The reaction mixture was allowed to 
reflux for an appropriate time. After the completion of reaction, the reaction mixture was 
cooled. In some reaction, the solid product was found during the reflux. The product was 
filtered and washed with acetonitrile and dried in oven.  
The reaction time and percentage yields of the respective products are shown in the 
Physical Data Table No. 5 
 
 
 
 
 
 
 
 
 
 
 
 
Physical data of 4,5-dihydro-3-isopropyl-4-substitued phenyl-1H-pyrazolo 
[3,4-d]pyrimidine-6(7H)-ones 
 
 
 
 
 
 
Table. No: 5 
 
aConventional 
 heating 
Microwave  
irradiation 
C, H , N Analysis 
 Code.No 
 
Substitution 
R 
M.F Yields  
(%) 
Time 
(h) 
Yields 
(%) 
Time 
(min) 
M.W M.P OC 
C H N 
RK-5001 H C14H16N4O  70 5:30 92 3 256.3 ≥ 250 65.61 (65.34) 
6.24 
(6.11) 
21.86 
(21.70) 
RK-5002 -2-NO2 C14H15N5O3  78 6:00 90 4 301.3 ≥ 250 55.81 (55.75) 
5.02 
(4.89) 
23.24 
(23.50) 
RK-5003 -3-NO2 C14H15N5O3  69 6:00 92 3 301.3 ≥ 250 55.81 (55.75) 
5.02 
(4.89) 
23.24 
(23.50) 
RK-5004 -4-NO2 C14H15N5O3  78 5:30 88 5 301.3 ≥ 250 55.81 (55.75) 
5.02 
(4.89) 
23.24 
(23.50) 
RK-5005 -3-OC6H5 C20H20N4O2  75 8:00 93 2 348.4 ≥ 250 68.95 (68.50) 
5.79 
(5.63) 
16.08 
(16.21) 
RK-5006 3-Br C14H15BrN4O  72 7:00 85 3 335.2 ≥ 250 50.16 (50.11) 
4.51 
(4.53) 
23.84 
(23.70) 
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N
H
NH
N
N
H O
R
Table. No: 5 
 
RK-5007 3,4- di-OCH3 C16H20N4O3  73 6:30 90 4 316.35 ≥ 250 60.75 (60.60) 
6.37 
(6.40) 
17.71 
(17.52) 
RK-5008 3,4,5-tri-OCH3 C17H22N4O4  76 7:30 87 5 346.38 ≥ 250 58.95 (58.64) 
6.40 
(6.55) 
16.17 
(16.22) 
RK-5009 3- OCH3 C15H18N4O2  69 5:30 90 5 286.33 ≥ 250 62.92 (62.81) 
6.34 
(6.25) 
19.57 
(19.63) 
RK-5010 2- OCH3 C15H18N4O2  78 6:45 86 2 286.33 ≥ 250 62.92 (62.83) 
6.34 
(6.35) 
19.57 
(19.62) 
RK-5011 4- OCH3 C15H18N4O2  76 6:30 91 3 286.33 ≥ 250 62.92 (62.87) 
6.34 
(6.38) 
19.57 
(19.63) 
RK-5012 3-Cl C14H15ClN4O  65 6:00 90 3 290.75 ≥ 250 
57.83 
(57.63) 
5.20 
(5.15) 
19.27 
(19.21) 
RK-5013 4-Cl C14H15ClN4O  72 6:00 87 4 290.75 ≥ 250 
57.83 
(57.80) 
5.20 
(5.16) 
19.27 
(19.34) 
RK-5014 2-Cl C14H15ClN4O  71 7:15 95 2 290.75 ≥ 250 
57.83 
(57.56) 
5.20 
(5.31) 
19.27 
(19.36) 
RK-5015 2-OH C14H16N4O2  68 5:00 89 3 272.3 ≥ 250 61.75 (61.62) 
5.92 
(6.00) 
20.58 
(20.62) 
RK-5016 4-SCH3 C15H18N4OS  73 6:30 85 5 302.39 ≥ 250 59.58 (59.42) 
6.00 
(5.91) 
18.53 
(18.64) 
RK-5017 3,4 di-OH C14H16N4O3  82 5:30 92 2 288.3 ≥ 250 58.32 (58.37) 
5.59 
(5.50) 
19.43 
(19.39) 
RK-5018 4-F C14H15FN4O  75 6:30 87 3 274.29 ≥ 250 61.30 (61.27) 
5.51 
(5.48) 
20.43 
(20.38) 
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Spectral discussion 
FT-IR Spectra 
IR spectra were recorded on Shimadzu FTIR-8400 using KBr disc and DRS techniques. 
The percentage transmittance is given in cm-1. The presence of isopropyl group shows at 
~1395 and 1365 wave numbers as doublet. It strongly indicates the presence of isopropyl 
group. The presence of amine shows at ~3450 wave numbers. The absence of peak at 
~1680 wave number indicates the presence hydroxyl group instead of carbonyl 
functionality. The hydroxyl functional group gives a broad peak ~3350. The SP2 =C-H 
will show at ~3100 wave numbers, while C=C at ~1649 wave numbers. Rests of the 
informations are given in the spectra of the compounds. 
 
1H NMR Spectra 
Proton NMR spectra of synthesized 4,5-dihydro-3-isopropyl-4-(substituted phenyl)-1H- 
pyrazolo[3,4-d]-pyrimidine-6(7H)-ones were recorded on Bruker 300 and 
400MHz(Avance-II) instruments using DMSO and TFA as the solvents with 
tetramethylsilane (TMS) as the respective internal standard. Chemical shifts were 
recorded in (δ) and coupling constants were recorded in Hertz (J). Number of protons 
found in NMR is concomitant with the theoretical value. The compounds are hardly 
soluble in the solvent like DMSO or TFA even on heating. The solution becomes hazy on 
dissolution.  
 
EI-MS Spectra 
EI-MS spectra were recorded on Shimadzu GC-MS QP-2010 by Electron Impact method. 
In all the compounds, the molecular weights were found to be 43 m/z less than the 
molecular ion peak. No particular fragmentation pattern is observed from the spectra. 
 
Elemental Analysis 
Elemental analysis of the all synthesized compounds was carried out Elementar Vario EL 
III Carlo Erba 1108 model at CDRI, Lucknow and the results are in agreement with the 
structures assigned.  
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Spectral data 
4,5-Dihydro-3-isopropyl-4- phenyl-1H-pyrazolo[3,4-d]pyrimidine-6(7H)-one 
(RK-5001) 
IR (KBr Disc):   3722.34 cm-1(-OH enol form), 3362-3441 cm-1(-NH), 2920-2964 
cm-1(C-H), 1531-1589 cm-1 (-NH Bend) 
 
4,5-Dihydro-3-isopropyl-4-(2-nitrophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6(7H)-one 
(RK-5002) 
1H-NMR (300 MHz, DMSO-d6): δ 0.82-0.92 (Broad, 13H ), 1.21-1.25 (Broad, 29H),   
5.21 (m, 1H), 6.71 (m, 1H), 7.57 (m, 2H), 7.73 (m, 2H), 7.78 (m, 2H), 8.1 (d, 1H) 
 IR (KBr Disc):   3477.77 cm-1(-OH enol form), 3362-3441 cm-1(-NH), 2920-2966 
cm-1(C-H), 1521-1589 cm-1 (-NH Bend), 1589.4 cm-1 (-C-NO2) 
 
4,5-Dihydro-3-isopropyl-4-(3-nitrophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6(7H)-one 
(RK-5003) 
IR (KBr Disc):   3439.19 cm-1(-OH enol form), 3385 cm-1(-NH), 2872-2966 cm-1(C-H), 
1550-1577 cm-1 (-NH Bend), 1529 cm-1 (-C-NO2) 
 
4,5-Dihydro-3-isopropyl-4-(4-nitrophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6(7H)-one 
(RK-5004) 
IR (KBr Disc):   3527 cm-1(-OH enol form), 2968 cm-1(-NH), 2870-2928 cm-1(C-H), 
1518-1589 cm-1 (-NH Bend), 1518-1527cm-1 (-C-NO2) 
 
4,5-Dihydro-3-isopropyl-4-(3-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-6(7H)-
one (RK-5005) 
IR (KBr Disc): 3543cm-1(-OH enol form), 3462.34cm-1(-NH), 2870-2968cm-1(C-H), 
1543-1583 cm-1 (-NH Bend) 
 
4,5-Dihydro-3-isopropyl-4-(3-bromophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6(7H)-one 
(RK-5006) 
IR (KBr Disc): 3319 cm-1(-OH enol form), 3240 cm-1(-NH), 2920-2966cm-1(C-H), 1550-
1579 cm-1 (-NH Bend), 550-578 cm-1 (C-Br) 
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4,5-Dihydro-3-isopropyl-4-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-
6(7H)-one (RK-5007) 
1H-NMR (300 MHz, DMSO-d6): δ 0.83 (m, Broad, 6H ), 1.3 (m, 1H), 3.7-3.8 (d, 6H), 
5.23 (s Broad, 1H), 7.00 (d, 1H), 7.06 (m, 4H), 7.39 (s, 1H),  7.51 (m, 1H), 9.89 (s, 1H) 
IR (KBr Disc): 3441cm-1(-OH enol form), 3338.89cm-1(-NH), 2920-2966cm-1(C-H), 
1510-1589 cm-1 (-NH Bend), 1109-1166cm-1 (C-O-C) 
 
4,5-Dihydro-3-isopropyl-4-(3,4,5-trimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-
6(7H)-one(RK-5008) 
1H-NMR (300 MHz, DMSO-d6): δ 1.19-1.23 (Broad, 6H ), 1.29 (Broad, 1H), 3.09 (m, 
3H), 3.50 (m, 3H), 3.6-3.7 (m, 3H),  3.75-3.8 (d, 1H),  5.23 (m, 1H), 6.45 (m, 5H) 
IR (KBr Disc): 3441cm-1(-OH enol form), 3338.89cm-1(-NH), 2920-2966cm-1(C-H), 
1510-1589 cm-1 (-NH Bend), 1109-1166cm-1 (C-O-C) 
 
4,5-Dihydro-3-isopropyl-4-(3-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-6(7H)-
one (RK-5009) 
IR (KBr Disc): 3527cm-1(-OH enol form), 3338.89cm-1(-NH), 2914-2956cm-1(C-H), 
1510-1589 cm-1 (-NH Bend), 1109-1166cm-1 (C-O-C) 
 
4,5-Dihydro-3-isopropyl-4-(2-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-6(7H)-
one (RK-5010) 
IR (KBr Disc): 3520cm-1(-OH enol form), 3000cm-1(-NH), 2920-2966cm-1(C-H), 1536-
1578 cm-1 (-NH Bend), 1186-1290cm-1 (C-O-C) 
 
4,5-Dihydro-3-isopropyl-4-(4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-6(7H)-
one (RK-5011) 
IR (KBr Disc): 3441cm-1(-OH enol form), 3387.11cm-1(-NH), 2934-2966cm-1(C-H), 
1510-1525 cm-1 (-NH Bend), 1109-1174cm-1 (C-O-C) 
 
4,5-Dihydro-3-isopropyl-4-(3-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6(7H)-one 
(RK-5012) 
IR (KBr Disc): 3527cm-1(-OH enol form), 3466.20cm-1(-NH), 2926-2986cm-1(C-H), 
1527-1583 cm-1 (-NH Bend), 709-783 cm-1 (C-Cl) 
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4,5-Dihydro-3-isopropyl-4-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6(7H)-one 
(RK-5013) 
IR (KBr Disc): 3527.927cm-1(-OH enol form), 3460cm-1(-NH), 2889-2964cm-1(C-H), 
1517-1558 cm-1 (-NH Bend), 740-785 cm-1 (C-Cl) 
 
4,5-Dihydro-3-isopropyl-4-(2-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6(7H)-one 
(RK-5014) 
IR (KBr Disc): 3537cm-1(-OH enol form), 3462 cm-1(-NH), 2868-2966cm-1(C-H), 1527-
1583 cm-1 (-NH Bend), 720-748 cm-1 (C-Cl) 
 
4,5-Dihydro-3-isopropyl-4-(2-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-6(7H)-
one (RK-5015)  
1H-NMR (300 MHz, DMSO-d6): δ 1.1-1.3 (m, Broad, 6H ), 5.2-5.3 (Broad, 1H), 6.75 
(m, 3H), 6.85 (d, 1H), 6.99 (m, 1H), 7.31 (m, 1H), 7.37 (m, 1H), 9.11 (dd, 1H), 9.30 (s, 
1H) 
IR (KBr Disc): 3319 cm-1(-OH enol form), 3240cm-1(-NH), 2926-2968cm-1(C-H), 1529-
1575 cm-1 (-NH Bend) 
 
4,5-Dihydro-3-isopropyl-4-(4-(methylthio)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-
6(7H)-one (RK-5016) 
IR (KBr Disc): 3539cm-1(-OH enol form), 3462.20cm-1(-NH), 2950-2964cm-1(C-H), 
1533-1577 cm-1 (-NH Bend) 
 
4,5-Dihydro-3-isopropyl-4-(3,4-dihydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-
6(7H)-one (RK-5017) 
IR (KBr Disc):   3583 cm-1(-OH) , 3334-3360 cm-1(-NH), 2930-2966 cm-1(C-H), 1521-
1556 cm-1 (-NH Bend) 
 
4,5-Dihydro-3-isopropyl-4-(4-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6(7H)-one 
(RK-5018) 
IR (KBr Disc): 3527.927cm-1(-OH enol form), 3460cm-1(-NH), 2889-2964cm-1(C-H), 
1520-1568 cm-1 (-NH Bend) 
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Spectra of the representative compounds 
 
1H NMR Spectrum of 3-isopropyl-1H-pyrazol-5(4H)-one 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR Spectrum of 3-isopropyl-1H-pyrazol-5(4H)-one 
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1H NMR Spectrum of RK-5007 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR Spectrum of RK-5015 
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1H NMR Spectrum of RK-5015 
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1H NMR Spectrum of RK-5002 
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1H NMR Spectrum of RK-5008 
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IR Spectrum of RK-5001 
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IR Spectrum of RK-5002 
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IR Spectrum of RK-5005 
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IR Spectrum of RK-5014 
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EI-MS Spectrum of RK-5004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EI-MS Spectrum of RK-5001 
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EI-MS Spectrum of RK-5009 
 
 
IR Spectrum of RK-5015 
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Conclusion 
Here we reported catalytic green method for the synthesis of pyrazolone pyrimidine using 
HClO4-fuller’s earth as an efficient ecofriendly heterogeneous inorganic catalyst and 
carried out comparison of yield obtained by classical heating using Conc. HCl as the acid 
catalyst with this green and eco friendly approach. 
From the 13C NMR and 1H NMR spectrum of the starting material (Pyrazolone), we 
concluded that the starting material is stable in the enol form. 
This data of pyrazolone spared us to work out on it. So we used this heterocyclic ketone 
as a building block in Biginelli-type multi component reaction, ultimately we got a new 
and Diversed Heterocyclic Synthon in single step. 
Earlier literature survey shows that most of work carried out by using different 
symmetrical, unsymmetrical and cyclic 1,3-diketones and different β-keto esters. No one 
used the heterocyclic ketone that is stable in enol form.  
Various methodologies for the synthesis of pyrazolo pyrimidines were reported by 
different authors, represented in the synthetic approaches in the introduction part and also 
not single step process. Several step has been carried out for formation of this type of core 
structure Here we introduced a phenyl ring at C4 position of the pyrazolo pyrimidine by 
Conventional as well as Microwave assisted Organic synthesis (MAOS) through 
modification in building block of the Biginelli type Multi component reaction and 
eventually, we got a diversity in core structure of the pyrazolo pyrimidines 
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General Protocol 
 
 
 
1. 1H NMR and 13C NMR spectra were recorded on Bruker Avance II 300 and 
400 MHz NMR spectrometer using TMS as an internal reference.  
 
2. Mass spectra were recorded on GC-MS QP-2010 spectrometer. 
 
3. IR spectra were recorded on Schimadzu FR-IR-8400 spectrometer using 
KBr pellet or DRS method.  
 
4. Elemental analysis was carried out on Vario EL III Carlo Erba 1108. 
 
5. Thin layer chromatography was performed on Silica Gel (Merck 60 F254). 
 
6. The chemicals used for the synthesis of compounds were purchased from 
Spectrochem, Loba, Merck, Rankem, Thomas-baker and SD fine chemicals, 
India. 
 
7. Melting Points were taken in open capillary and are uncorrected. 
 
8. Microwave synthesizer (Questron Technologies Corporation, Canada) 
QPro-M model monomode open-vessel was used in the MAOS.  
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Summary 
The work represented in the Thesis entitled “Synthesis, Characterization and Screening of 
Pharmacologically Active Chemical Entities” can be summarized as below. 
 
Chapter 1.1 covers literature survey on mechanistic studies, various alternative synthetic 
methodologies in Multi component Biginelli reaction. Various natural products 
containing DHPMs viz. crambine, batzelladine display activity as potent HIV gp-120-
CD4 inhibitor. Several Synthetic DHPMs shows pharmacologically activity like orally 
active antihypertensive agents, α1a adrenoceptor-selective antagonists, calcium channel 
blockers, gastric inhibitory and fatty acid transporter FATP4 Inhibitors are recapitulated 
in this chapter. Fragment based approach for the core structure of Dihydropyrimidines 
also described.  Different synthetic approaches for the 1,3 Diketones  used in Multi 
component reaction are discussed. Various Catalysts for the rapid, mild and higher 
yielding protocols, several ionic liquids for the clean synthesis and modern chemistry are 
descried in detail. Various building blocks and diversity created by this advance and solid 
phase synthesis also described in introductory part of this chapter.  
 
In Chapter 1.2 contains design for the synthesis of starting material which has been used 
for Target Molecules (TMs), plausible mechanism of the hexahydropyrimidinones. The 
Biginelli type cyclocondensation of a fluorine containing 1, 3 diketone have been studied 
in this chapter. In analogy to the reaction of 1,3-diketone with different substituted 
benzaldehyde and urea. These reactions were conventionally carried out in methanol in 
the presence of the catalytical amount of Conc. HCl for 5-6 hours. Here, we consider that 
two isomeric structures for these condensation products, namely the hexahydropyrimidine 
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structure of type A or the isomeric acyclic ureidopropionate structure of keto and enol 
tautomers. 
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By the help of the IR spectra, 1H NMR, 13C NMR and Mass spectra of products, prove the 
correct structure is represented in this part. In all, total 19 compounds are synthesized in 
this chapter. 
 
Chapter 1.3 contains the synthetic details for the Trifluoromethyl bearing hexahydro 
thiopyrimidinones. The entire synthesized compounds are well characterized by 1H NMR, 
13C NMR, IR spectra. From the literature and studies of the spectral analysis, the cyclic 
nature of this compounds are illustrated in detail.  In all, total 17 compounds are 
synthesized in this chapter. 
The antimicrobial profile of representative chapters where studied and are given at 
the end of the chapter.  
 
Chapter 2 covers the various synthetic routes for the formation of the pyrimidines 
nucleolus. Some of the therapeutic activities of pyrimidine derivatives like antithyroid, 
antitumor, antihypertensive, diuretic, antiviral, antiinflammatory, platelet aggregation 
inhibitor, anticonvulsant, antitubercular, melanin-concentrating Hormone 1 Receptor, 
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HIV Reverse Transcriptase and Integrase and Preliminary SAR of antiviral activity of 
pyrimidinones are represented in detail. Synthetic approach for the targeted molecules 
(Dihydropyrimines at C5 position with cyclohexyl carbamoyl functional group) is 
discussed . All the synthesized compounds were well characterized by the 1H NMR, 13C 
NMR, IR spectra and Mass spectral investigations are represented on this chapter.     
 
Chapter 3 contains microwave assisted multi component synthesis for Trifluoromethyl 
containing dihydropyridines by using PEG-400 as a solvent. In the introductory part, the 
detail of the some serious drawbacks of the previously reported procedure such as 
unsatisfactory yields, tedious work-up procedure, occurrence of side reactions including 
aromatization, economically non-viable, long reaction rate, high reaction temperature etc 
and biological profile of the 1,4-Dihydropyridines are mentioned. This chapter covers 
experimental details, spectra of the new synthesized compounds. All compounds were 
well characterized by modern techniques like 1H NMR, IR and Mass.  In all, total 10 
compounds are synthesized in this chapter. 
 
Chapter 4 involves the conventional and non-conventional method for the synthesis of 
various Pyrazolo [4,3-d]Pyrimidines. Both the methods consist of the solution phase 
synthesis. The classical heating was carried out in acetonitrile and by using conc. HCl as 
the acid catalyst whilst the microwave assisted reaction was also carried out in 
acetonitrile but novel heterogeneous catalyst HClO4-Fuller’s earth was utilized for the 
reactions. The compounds are characterized by 1H NMR, IR and Mass spectral 
techniques. Fifteen compounds were synthesized in this series. The biological study of 
newly synthesized compounds for anti-HIV screening is underway. 
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